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Abstract 
Aims The method for the confirmation of drugs of abuse for addiction testing within 
King’s College Hospital prior to 2008 was a labour intensive thin layer 
chromatography method. To replace this with a faster method more suited to future 
requirements, the laboratory bought a liquid chromatography system with ion trap 
mass spectrometric detection. The development of the routine analytical method and 
the implementation of this method within the laboratory using on-line solid phase 
extraction and Turboflow® sample preparation will allow the laboratory to operate 
successfully in the field of clinical drugs of abuse testing in the future. 
Method Analyses are performed on an ion trap mass spectrometer with an 
electrospray ion source following reversed phase liquid chromatography, initially 
using on-line solid phase extraction with a Jasco XLC® series autosampler and pump 
and later a Thermo Turboflow® on-line extraction method with a CTC Combi-Pal® 
autosampler and Agilent 1100 series liquid chromatography system. Elution of drugs 
and metabolites is performed with a multi-step gradient of ammonium formate buffer 
and acetonitrile, followed by regeneration of the extraction and analytical columns to 
starting conditions. Detection is achieved with a Thermo LCQ Fleet ion trap mass 
spectrometer with a combination of full spectrum survey scans, dedicated product ion 
scans, neutral loss scans and data dependent product ion scans in two analysis 
segments. Total run time is only 20 minutes, allowing a throughput of around 65 
samples per day.  
Results The methods include the novel combination of the elimination of any 
hydrolysis step, on-line SPE or Turboflow extraction, detection of multiple drug 
groups, full spectrum analysis and library matching, the use of data dependent scans 
and ion trap mass spectrometry using MS3 and neutral loss scans. The methods 
developed were validated using a departmental method validation protocol and 
accepted for routine use. Simultaneous detection of over fifty analytes has been 
found possible in a range of clinically relevant drug groups, including opiates, 
amphetamines, methadone, propoxyphene, cocaine, ketamine and their metabolites. 
The use of neutral loss scans and product ion scans of phase 2 drug metabolites 
permits the addition of previously unidentified drugs and metabolites to the method, 
allowing the laboratory’s services to develop in line with requirements of the service. 
Quality is maintained through the use of standard operating procedures, staff 
training, quality control samples and external quality assessment.  
Conclusion Drugs of abuse testing is key for treatment and monitoring of drug 
addiction. The introduction of modern mass spectrometry techniques has reduced 
the turnaround time of routine analysis for a range of drugs and metabolites and 
increased the range of drugs that can be analysed. The methods introduced have 
revolutionised testing at King’s College Hospital and produced a method which is 
capable of evolving with the needs of the service to keep abreast of future 
requirements of the service. 
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1. Introduction 
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Drugs and medicines have been encountered, in one form or another, for many 
hundreds of years. Cannabis has been found buried with mummies from around 
2700 years ago (Russo, et al., 2008) and evidence of coca leaf chewing has been 
found in mummies dating back at least 2760 years (Rivera, Aufderheide, Cartmell, 
Torres and Langsjoen, 2005). These drugs were usually in their unpurified natural 
form and were often used socially or in religious ceremonies, as well as having 
medicinal uses. Opium in particular was used recreationally and the opium dens in 
London were notorious in the 18th century. Britain even went to war twice with China 
in the middle of the 19th century over the supply of opium, the opium wars. 
As chemistry advanced during the 19th century, it became possible to purify active 
ingredients of plants to produce concentrated drugs close to those we use today. 
Morphine was purified from opium in around 1804 by FWA Sertürner (Jurna, 2003) 
and the use became more widespread after the invention of the hypodermic syringe 
and needle in the 1850’s, leading to increased use in minor surgery and in 
anaesthesia (Brownstein, 1993). The use of these new, purified drugs led to 
dependence and more severe acute effects than either alcohol or opium (Rogers, 
2011). 
In an effort to reduce the addictive qualities of morphine, German chemists working 
for Bayer tried chemically modifying the morphine molecule. Previously they had 
success chemically modifying sodium salicylate, the analgesic found in willow bark 
that caused stomach problems and produced the less toxic acetylsalicylate, or 
aspirin, that is still in widespread use (Sneader, 2000, Mueller and Scheidt, 1994). 
With morphine they produced diacetylmorphine, but unfortunately this drug was 
found to be more addictive than the morphine it was designed to replace. 
German chemists continued work on alternative painkillers and in the mid-1940s 
developed methadone, a synthetic drug that targets the opiate receptors in the brain, 
giving the same kind of painkilling effect as morphine and heroin (Brownstein, 1993). 
Experiments in the early 1960s showed that methadone could be used as a 
pharmaceutical therapy to treat heroin addiction and since then methadone has 
become the preferred treatment for heroin addiction in the UK (Kreek, 2000). 
Cannabis use increased significantly in the 1960s and advances in technology led to 
the development of the Enzyme Multiplied Immunoassay Technique (EMIT) 
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immunoassays for drugs of abuse (Rodgers, et al., 1978). This was frequently 
partnered with another emerging technology, the gas chromatograph with mass 
spectrometric detection (GC-MS) (O'Connor and Rejent, 1981). In skilled hands, a 
GC-MS could identify a range of drugs with a high degree of confidence and this 
technique became the “gold standard” method (DuPont, 1990). Any pre-existing thin 
layer chromatography (TLC) and colour tests were crude by comparison and many 
legal guidelines now specify mass spectrometry for legally defensible quantitative 
results (European Workplace Drug Testing Society, 2002, GTFCh, 2009, Society of 
Forensic Toxicology / American Academy of Forensic Sciences, 2006).  
GC-MS analysis of drugs requires a high degree of skill and understanding, as well 
as expensive equipment and this might not be sustained in smaller laboratories, such 
as those testing for drugs for clinical use (Bryson, 1996). With a lower burden of 
proof, the quicker and cheaper TLC methods survived in these clinical laboratories, 
sometimes supplemented with high performance liquid chromatography (HPLC) and 
gas chromatography with a flame ionisation detector (GC-FID) (Nováková and 
Maresová, 1997, Center for Substance Abuse Treatment. , 2005) 
In 1989, the Electrospray Ionisation (ESI) source was developed (Fenn, Mann, Meng, 
Wong and Whitehouse, 1989), allowing an HPLC to be linked directly to mass 
spectrometry to give the Liquid Chromatograph – Mass Spectrometer (LC-MS). Since 
then, the cost and complexity of LC-MS systems has reduced, while the computing 
power and capability has significantly improved (Annesley, 2003) and LC-MS 
systems are now within the reach of clinical laboratories (Kang, 2012). With the 
introduction of a mass spectrometer to the laboratory at King’s College Hospital 
(KCH), a method needed to be developed that would be suitable for clinical drugs of 
abuse testing to replace the existing TLC method and allow the laboratory to develop 
for the future. 
1.1. Samples used for drug testing 
Almost any bodily fluid has been used for the detection of drugs for one application or 
another and in post mortem toxicology it is also common to test for drugs in different 
organs. For clinical toxicology only three body fluids are suitable for routine testing: 
blood, saliva and urine.  
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Blood testing is difficult with regular drug users, partly because the long term injecting 
of street drugs can often lead to damage to veins that makes regular venesection 
difficult and also the high prevalence of blood borne viruses in this population group 
poses an unnecessary risk to clinical and laboratory staff. 
Saliva testing is technically demanding due to the low sample volumes generally 
available, the low levels of drugs present and the fact that saliva is actually a mixture 
of secretions of the parotid, submandibular and sublingual salivary glands. The saliva 
secreted from each of the glands has a different composition, with parotid saliva 
being mainly serous, submandibular saliva being mixed serous and mucoid and the 
sublingual glands being predominantly mucus. Additionally, the composition of saliva 
from a single gland can vary in pH or protein content depending on the rate of saliva 
flow and there is the constant difficulty of food residue in the mouth.  
In contrast, large volumes of urine are easily available with cheap non-invasive 
sample collection procedures. Urine is one of the principal routes of drug elimination 
from the body and the concentration increase caused by the kidney’s reabsorption of 
water increases the levels of drugs to a level that are high enough to permit 
colourimetric testing without the need for mass spectrometry, well within the 
capabilities of the TLC and HPLC methods available when drug testing began. A 
difficulty with using urine as a sample is that the drugs and their metabolites are 
frequently conjugated as part of phase two drug metabolism. Although not normally 
protein bound, this conjugation still requires a hydrolysis step for many methods of 
analysis. As a result, urine has been the main sample type for diagnostic testing and 
routine monitoring of Department of Addictions patients.  
When considering the analysis of drugs, there are two principal differences between 
the matrices available, from urine to waste water in sewage and saliva or hair. These 
are i) the concentration of drugs in the sample and ii) the degree of metabolism or 
degradation from the drug that has been consumed. Beyond these, drug testing is a 
matter of eliminating the effects of the matrix (urine, blood, body tissue and so on) 
and analysing and detecting the drugs. When considering published work, this 
greatly increases the scope of methods that could be considered. In spite of this 
increase in scope, there are still surprisingly few papers that detail methods for 
multiple drugs. There are several possible reasons for this, including commercial 
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sensitivity, a focus on the interpretation of the results or the often simpler approach of 
using methods focussing on a single class of drugs. 
A literature search in October 2009 using the Cambridge Scientific Abstracts Illumina 
database identified 77 papers using HPLC with mass spectrometric detection that 
detailed the methods used, some used for analyses of multiple matrices (see table 
1.1). This list is similar to that in the review (Peters, 2011) of papers published since 
2006, which reported 17 methods in urine, 16 in whole blood, serum or plasma and 
only seven in both oral fluid and hair with a further 5 methods for the identification of 
perinatal drug use.  
Table 1.1 Methods returned from library search using CSA Illumina database October 2009. Search terms 
(“drugs of abuse” or “drug screen” or opiate or cocaine or “drug test”) and (“oral fluid” or urine) and 
(LCMS or “mass spectromet*” or “tandem MS” or “quadrupole or “ion trap”).  
Matrix 
Number of 
papers 
Urine 33 
Blood, serum or plasma 12 
Other body fluids  5 
Saliva or oral fluid 12 
Body tissues 5 
Hair 9 
Sewage and wastewater 8 
Other (e.g. food, particles) 4 
Total papers 77 
 
In recent years the innovations in immunoassay and mass spectrometric techniques 
have allowed saliva testing to become more popular. Saliva testing does not require 
toilet facilities, allows for directly observed collection without embarrassment and 
reduces the risk of adulteration of the sample and, together with several companies 
vying for business, has increased in popularity in nurse led and third sector 
organisations and clinics. However, South London and Maudsley NHS Trust is no 
different from many others and most drug testing performed through Bethlem Royal 
and Maudsley Hospitals uses urine samples.  
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1.2. Drug metabolism and existing practice 
This method was intended to identify users of three principal drugs: heroin, 
methadone and cocaine. To be able to reliably detect these drugs, it is important to 
know the metabolism and interfering factors for these drugs. 
Heroin, or diacetylmorphine, has a very short plasma half-life and is not detected in 
urine. Its primary metabolite is 6-monoacetylmorphine (6MAM), which also has a 
short half-life and is present in urine in low concentrations for up to twenty four hours 
after heroin use (Heroin, 2011). This is further metabolised to morphine, which is 
excreted in urine over the next 3-4 days. Phase 2 drug metabolism prepares the drug 
for elimination from the body by conjugation with glucuronic acid. As a result, most 
morphine is excreted as morphine-3-glucuronide, but around 5-7 % is also excreted 
unchanged, and small amounts may be excreted as morphine-6-glucuronide and 
normorphine (Morphine, 2011). 
Heroin is rarely pure and usually contains around 10% acetylcodeine, produced from 
the acetylation of codeine found in the raw opium (O'Neal, Poklis and Licht, 1998). 
This also has a very short half-life and is primarily metabolised to codeine 
(Brenneisen, Hasler and Würsch, 2002). This can be excreted unchanged, 
conjugated to glucuronic acid or further metabolised to morphine. Heroin use can, 
therefore, be identified by the presence of morphine and codeine and their 
metabolites. However, codeine is a readily available medicine that can be obtained 
over the counter without prescription (Codeine/Paracetamol - Pain Medicines and 
Drugs - NHS Choices). As it then metabolises to morphine, the presence of codeine 
and morphine does not necessarily mean that the urine sample tested is that of a 
heroin user. In this patient group, a limited clinical history is almost always available 
and the presence of morphine and codeine is enough to confirm the use of heroin. In 
other population groups, the presence of 6MAM can prove heroin use, but a 
morphine concentration higher than codeine can also point to heroin use. 
The other principal opiate, dihydrocodeine, is easier to identify as it is metabolically 
distinct from morphine and does not metabolise to either morphine or codeine. As for 
codeine, it is also excreted conjugated to glucuronic acid. 
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Most of the samples tested within this work arose from known heroin users, as the 
main clinical users are the community drug teams and the addictions division of 
South London and Maudsley NHS Trust (SLAM). Most of these patients will be taking 
methadone as a substitution therapy for heroin and detection of this will supplement 
the immunoassay results previously obtained. Methadone is mostly excreted 
unchanged in the urine, but there are also significant amounts of the primary 
metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). 
Another drug in widespread use is cocaine. Cocaine is generally snorted or smoked 
as freebase (crack), but in this population it is often taken mixed with heroin. The 
resulting mixed drug is known as a speedball, and as the two drugs are partially 
metabolised using the same enzymes, the two drugs act synergistically 
(Duvauchelle, Sapoznik and Kornetsky, 1998). Cocaine is partially excreted 
unchanged, but is predominantly excreted as the hydrolysis product, 
benzoylecgonine. There are two other alternative metabolites of cocaine: 
anhydroecgonine is produced in the heat of a crack pipe and cocaethylene is 
produced in the presence of alcohol (Herbst, Harris, Everhart, Mendelson, Jacob and 
Jones, 2011). Neither of these metabolites are detected in the current TLC method. 
As well as replacing the existing TLC method, it would be a benefit if the method 
could replace the existing GC method for amphetamines. This method can identify 
different members of the amphetamine group, including amphetamine, 
methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxy-
methylamphetamine (MDMA), known as ecstasy, methylenedioxyethylamphetamine 
(MDEA) and phentermine. All of these drugs are mostly excreted unchanged, 
although amphetamine is a minor metabolite of methamphetamine and MDA is a 
minor metabolite of ecstasy. Extension of the method to other amphetamine-like 
substances, such as the novel psychoactive substance mephedrone, would also 
benefit the laboratory. 
1.3. Sample extraction 
Sample extraction is the name given to any process where the analytes are removed 
from the original sample matrix and transferred to a matrix that is suitable for 
chromatography. For GC systems that require water free samples for derivatisation, 
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this would mean transferring the analytes into a non-polar organic phase. As well as 
making the sample compatible with the chromatography, extractions can also remove 
interferences and concentrate the sample (Flanagan, Taylor, Watson and Whelpton, 
2007). 
1.3.1. Dilute and shoot sample preparation 
Although not technically an extraction, this is perhaps the simplest sample 
preparation procedure in widespread use. It is generally used for urine samples that 
do not contain significant amounts of proteins and is simply the dilution of the sample 
by a factor of 10-20 or more (Fitzgerald, et al., 2012). Dilute and shoot is not suitable 
for most GC and normal phase HPLC applications, as the polar solvent content 
(usually water) is too high for the chromatographic part of the system. In addition, the 
dilution generally reduces the signal intensity, limiting the technique to analytes at a 
concentration in the low µg/L range and above and with some systems, such as ion 
traps, much higher concentrations. Dilute and shoot is commonly used to reduce ion 
suppression in triple quadrupole instruments when other sample preparation 
techniques (such as protein precipitation or derivatisation) are not required. Ion 
suppression (see section 1.6.7.) may be increased by salts and dilution of the sample 
reduces the salt concentration and therefore reduces the ion suppression. If the 
reduction of ion suppression is greater than the signal reduction caused by the 
dilution, this method produces an increased signal/noise ratio. 
Although dilute and shoot is a common method of sample introduction, the number of 
papers utilising it is quite small, with only five of the papers identified in the literature 
search (see page 5) using the technique, with four of these papers being from the 
Karolinska Institute in Stockholm, the fifth being from the Saskatchewan Disease 
Control Laboratory in Canada. The reason for the limited number of publications in 
this area is unknown, but is most likely to be due to publication bias, rather than 
being a true reflection of the prevalence of the technique. This could occur either 
through the potential authors not considering the methods worthy of publication, and 
therefore not submitting the methods to journals, or by the journals and peer 
reviewers not accepting submitted manuscripts for the same or similar reasons.  
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1.3.2. Liquid-liquid extraction 
This extraction method relies on the fact that polar and non-polar solvents are more 
often than not immiscible. Liquid-liquid extraction (LLE) is perhaps the simplest and 
cheapest extraction technique, requiring no expensive consumables and only a small 
amount of organic solvent (Flanagan, Taylor, Watson and Whelpton, 2007). Proteins 
and salts remain in the aqueous phase and analytes can be extracted into the 
organic solvent.  
The selectivity of LLE can be modified by selection of different solvents and by 
adjusting the pH. Charged analytes will remain in the aqueous phase, as only neutral 
molecules can transfer into the organic layer (Flanagan, Taylor, Watson and 
Whelpton, 2007). Adjusting the analyte pH to around 2 units above the pKa (for basic 
drug extraction) or 2 units below (for acidic analytes) will ensure that almost all of the 
analyte will be extracted. Selectivity can be enhanced further by additional 
extractions, typically a back-extraction into an aqueous phase at a different pH, 
although every extra process reduces the recovery of the target analyte. Evaporation 
and reconstitution of the organic phase can also be used to concentrate the analytes 
into a solvent compatible with the chromatography. 
Liquid-liquid extraction is not easy to automate, as the sample tubes need to be well 
mixed and centrifuged to ensure good analyte transfer and instruments capable of 
this are not in widespread use. A recent development is to use a supported liquid 
extraction (SLE) cartridge, in which the aqueous sample is added to tube containing 
a Fuller’s earth based support (Flanagan, Taylor, Watson and Whelpton, 2007). The 
sample is absorbed and an immiscible organic solvent is added, which drains 
through the support, performing the liquid extraction in the process. As with a liquid-
liquid extraction, the solvent may then be concentrated or further extracted as 
necessary. However, an automated back extraction using SLE is generally carried 
out using a LLE or drying step (Brubaker, n.d.) and consequently SLE is not easy to 
automate when back-extracting. 
There is a little more literature available for liquid-liquid extraction than for dilute and 
shoot, with 10 papers identified using this extraction technique, although only two of 
these (Mueller, Weinmann, Dresen, Schreiber and Gergov, 2005 and Klette,  Horn, 
Stout, Anderson, 2002) use a urine matrix. None of these techniques includes a 
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back-extraction or SLE, most of the authors preferring to dry the organic solvent and 
resuspend in the mobile phase.  
1.3.3. Solid phase extraction 
Solid phase extraction (SPE) uses a silica or polymeric HPLC column packing 
material packed in a syringe barrel. The solvents used are optimised for either 
complete retention or complete elution, rather than the partial retention found in 
HPLC applications. Generally a sample is loaded at an optimal pH for retention and 
then washed with an appropriate solvent (Flanagan, Taylor, Watson and Whelpton, 
2007). This solvent is selected to remove unretained or weakly retained interfering 
substances before a further solvent washes off the analytes into a collection vessel. 
As with LLE, this can then be evaporated and reconstituted as required. One 
disadvantage of SPE is that the extraction columns are disposable, and cost 
significantly more than the solvents required for liquid extractions. However, with no 
organic-aqueous boundary to detect, SPE can be automated with instruments 
capable of sequential addition of solvents and buffers and collection of the final 
extract, either as standalone (offline) instruments or directly connected to the 
chromatographic system, or online SPE. 
Solid phase extraction has become one of the principal techniques in analytical 
toxicology, with 41 published LC-MS methods covering a range of matrices. SPE is 
more robust than standard LLE, with analyte recovery not being dependent on 
efficient solvent mixing or selective removal of the organic phase and this may 
explain the more widespread use of this technique 
1.3.4. Online solid phase extraction 
There are two different on-line SPE methodologies, those that are a simple 
automated SPE with disposable cartridges and those with re-usable SPE cartridges. 
Perhaps one of the best examples of the former is the Gilson ASPEC® automated 
SPE system that can either be operated in off-line or on-line modes. A good example 
of a method using this extraction system is the extraction and analysis of 29 drugs of 
abuse from oral fluid (Badawi, Simonsen, Steentoft, Bernhoft and Linnet, 2009). 
From a technical point of view, this can be seen as a simple automation of an 
existing SPE system, rather than a different method principle. 
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The first applications of re-useable online SPE methods differ very little from 2D-
HPLC methods, with a first HPLC column acting as the SPE cartridge and the 
second column acting as the separation column. One of the difficulties with this 
application is that two HPLC columns connected in series can lead to very high pump 
pressures. To overcome this, online SPE cartridges have a large particle and pore 
size, leading to lower back-pressures. By reducing the size of the column to less than 
10mm, analytes become more concentrated in a band, with little of the band 
broadening that can be found with a standard HPLC column. By combining an online 
SPE cartridge with standard HPLC equipment, extractions may be automated far 
more simply and cheaply than with a dedicated extraction system, although an 
additional HPLC pump is usually needed to allow SPE cartridge regeneration while 
the analytical gradient is running. SPE cartridges are more expensive than 
disposable cartridges used in conventional SPE, but can be cost effective when re-
used. This does of course introduce an extra regeneration step before the cartridge 
can be used for the subsequent sample. 
 
Figure 1.1 Plumbing arrangement of an online SPE system using 6-port valve (Xu, Turner, Meeker, 
Pursley, Arnold and Unger, 2003). a) Sample loading step with analytical column bypassed, b) Sample 
elution step. After sample eution, the valve is reset to position a) for extraction column regeneration 
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Different configurations have been tried with combinations of multi-port valves to suit 
the particular conditions in the laboratory. A six port configuration is shown (see 
Figure 1.1), but a method using an 8 port valve has been published by Callipo, 
Caruso, Foglia, Gubbiotti, Samperi and Laganà (2010) and a method using a 10 port 
valve has been published by Xu, Fan, Kim and El-Shourbagy (2006). 
As a general rule, one HPLC pump is used to load the SPE cartridge while the other 
maintains a flow through the analytical column. The SPE cartridge is then switched to 
be in series with the analytical column for analyte elution and the SPE colmun is then 
regenerated prior to the next sample. Automated SPE is a technique that has not 
been widely published for the analysis of drugs of abuse. It may be that the 
equipment required for automation is not available in research laboratories and larger 
laboratories that have the equipment are less likely to publish their methods, perhaps 
due to commercial confidentiality for example. 
A recent review of online sample extraction techniques covers this well, including 
variations such as stir bar sorptive extraction and the use of novel SPE materials, 
such as molecular imprinted polymers (Pan, Zhang, Zhang, Li, 2014) 
1.3.5. Solid phase micro-extraction 
Solid phase micro-extraction (SPME) works in a similar way to SPE, with a sorbent 
material to adsorb the analyte molecules. In SPME, the solid phase is typically 
coating a fibre contained within a hypodermic needle. The needle allows the septa of 
sample vials to be punctured, after which the fibre can be immersed in the sample. 
The relatively small sorbent size compared to the sample means that the sample 
needs to be agitated to ensure efficient extraction and this can take 20-30 minutes 
(Flanagan, Taylor, Watson and Whelpton, 2007). SPME can produce very clean 
extracts, but is ideally suited to headspace GC applications, where the fibre can 
absorb analytes in the vapour phase and then be placed directly in the GC inlet 
where the analytes can be eluted by thermal desorption (see Figure 1.2). 
Variations of SPME have been tried and published, for example using an organic 
solvent soaked hollow fibre filled with an aqueous acceptor solution. Different pH 
solutions either side of the solvent membrane can help facilitate concentration of 
analytes by ion trapping (Yazdia and Es'haghi, 2005). This particular application is 
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particularly suited to water testing, as the low analyte concentration and long 
immersion time allow a good concentration step to facilitate trace analysis. 
 
Figure 1.2 Diagram of solid phase microextraction with thermal desorption (Barié, Bücking and Rapp, 
2006) 
In the papers identified in the literature search (see p.5), none use SPME. It is most 
likely that the ease of interfacing SPME to gas chromatography strongly favours GC 
as an analysis method and the literature search specifically focussed on LC-MS.  
1.3.6. Turbulent flow chromatography 
Turboflow® is the trade name given to a system of online SPE that combines 
conventional SPE with a size exclusion column, technically known as turbulent flow 
chromatography (Couchman, 2012). The particles forming the solid phase contain 
pores in which analytes can bind to the polymeric or silica stationary phase. Larger 
molecules, such as proteins, have a much smaller surface area with which to interact 
and are retained less than the small molecule analytes for which the method is 
optimised. The extra functionality which makes the method particularly suitable for 
HPLC is that it is designed to operate at high flow rates. 
A Turboflow® column is normally 0.5 mm diameter, much narrower than an HPLC 
column or an online SPE column (typically 2-5 mm). When operated at a flow above 
2 mL/minute, the linear flow rate of the solvent through the column causes turbulence 
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within the spaces between the packing material, which is larger than the packing 
materials of HPLC (50 µm compared with 5-10 µm). This turbulence increases the 
efficiency with which the analytes adsorb to the stationary phase, allowing high 
recoveries compared to standard SPE.  
 
Figure 1.3 Plumbing of a Turboflow® System showing the valve arrangement (Couchman, 2012) 
The Turboflow® system marketed by Thermo can be operated in either quick elute 
(see Figure 1.3) or Focus modes. Quick elute is generally used without an analytical 
column, although with careful solvent matching an analytical column may be used 
(Couchman, 2012). The focus mode is more versatile, with the elution solvent from 
the Turboflow® column being diluted with an aqueous mobile phase before loading 
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onto the analytical column. The relatively low organic strength is designed to be 
insufficient to elute the analytes on the analytical column, which are then focussed 
onto the head of the analytical column for later elution by an increase in the organic 
solvent strength. 
There was little in the published literature about turbulent flow chromatography in 
2009 and even less on its application to drug testing. Several of these were 
published in relation to drug discovery and were published as generic methods, not 
optimised for any particular drug target (e.g. Herman (2002) and Grant, Cameron and 
Mackenzie-McMurter (2002)). Methods have been published for 3 drugs, the 
antimycotic drugs ketoconazole (Ramos, Brignol, Bakhtiar, Ray, Mc Mahon and Tse, 
2000) and terbinafine (Brignol, Bakhtiar, Dou, ajumdar and Tse, 2000) and the 
angiotensin II receptor antagonist telmisartan (Hempena, Gläsle-Schwarz, Kunz, 
Karst, 2006). Additionally a generic dual column method was published in 2002 
(Grant, Cameron and Mackenzie-McMurter). None of these applications consider 
drugs of abuse or multiple classes of drugs. By 2014 there were more toxicology 
papers referring to Turboflow with 58 articles on the analysis of xenobiotics in serum, 
plasma or urine found in March 2014. It was also noted that several of these methods 
have been published on more than one occasion, for example at two different 
conferences (e.g. Duretz, Manchon, Guitton, Cohen and Moreau (2011) and Duretz, 
Cohen, Moreau, Guitton and Manchon (2011)) or as a poster and a journal article 
(e.g. Miles, Couchman, Spicer and Flanagan (2011), Couchman, Birch, Ireland, 
Corrigan, Wickramasinghe, Josephs, Spicer and Flanagan (2012)).  
Of these 58 articles there are only four that relate to drugs of abuse: 
Mueller, Duretz, Espourteille and Rentsch (2011) used a linear ion trap with an APCI 
source and dual Cyclone and C18XL Turboflow® columns to look for 356 drugs and 
metabolites in urine. An almost identical method was also published by this group 
(Mueller and Rentsch) in 2012 for 453 drugs in serum and plasma.  
Yuan, Heideloff, Kozak and Wang (2012) used a triple quadrupole with an ESI 
source and dual Cyclone-MAX® and Cyclone-P® Turboflow® columns. 
In 2013, two Turboflow® methods for drugs of abuse were published in the same 
paper by Schaefer, Peters, Schmidt and Ewald (2013), using a triple quadrupole in 
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MRM mode. One method was intended for opiates, amphetamines, cocaine and 
opioids while the other was intended for benzodiazepines. Both methods used an 
offline hydrolysis step, a Cyclone Max Turboflow column and a Hypersil Gold C18 2.1 
x 50 mm analytical column. Use of a triple quadrupole allowed the method to be 
validated for quantitative analysis at the levels required for detection of drugs in 
apprehended drivers. The first method uses a solvent program very similar to the one 
outlined in the Thermo application note (Rezai, Kozak and Torchlin, 2007).  
The methods of Mueller and Schaefer both use phenyl reversed phase columns, 
either PFP (Mueller) or phenyl/hexyl (Schaefer), and all 3 urine methods use an 
offline hydrolysis process. They also use two separate Turboflow® columns in series 
and the paper by Yuan states that this is the only way they could simultaneously 
extract and detect the cannabis metabolite, 11-nor-∆9-tetrahydrocannabinol-
carboxylic acid.  
Mueller (2011) states that the offline hydrolysis is due to the poor Turboflow® 
retention of glucuronides of benzodiazepines and beta blockers. 
While Turboflow has found some use within toxicology, there appear to be relatively 
few methods using other online extraction systems, although there are some, such 
as the Gilson ASPEC® automated SPE system described by Badawi, Simonsen, 
Steentoft, Bernhoft and Linnet (2009) or the Spark Symbiosis series of automated 
SPE instruments (Robandt, Bui, Scanella and Klette, 2010). There are also a few 
papers from groups using other small SPE cartridges similar to the Phenomenex 
cartridge used in the first part of this project, such as that by de Jager and Bailey 
(2011) using the Thermo Aquasil® C18 cartridge. Possibly the on-going consumable 
costs make these methods too expensive for most laboratories when the emphasis is 
on cost efficiency, especially in taxpayer funded institutions such as universities and 
the NHS. 
1.4. Chromatographic separation 
While it is possible to introduce a sample directly into a mass spectrometer, most 
clinical laboratory systems are hyphenated with a chromatography system. This 
allows the different components within a sample to be introduced sequentially and 
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therefore detected and identified individually. Both gas and liquid chromatography 
have been used for drug testing and each gives a different capability to the analysis. 
1.4.1. Gas chromatography 
Gas chromatography has been around since the 1950s and has been coupled with 
mass spectrometers since the 1960s. Gas chromatographs can be relatively simple 
instruments, comprising a separation column in a temperature controlled oven, a 
sample injection port and (usually) an autosampler.  
The GC column is a tube usually made of glass, brass or steel and up to 3 m long, 
coiled to take up less space and fit in the oven. This column is packed with Fuller’s 
Earth (or similar) that is coated in a liquid or stationary phase. Analytes must normally 
be introduced in a water-free medium, usually either an organic solvent or a vapour 
from a headspace injection vial. The heated injector port vaporises the solvent and 
analytes in gaseous phase are partitioned between the inert gas (usually hydrogen, 
helium or nitrogen) and their retention time is dependent on the partition coefficient of 
the analyte and on the temperature of the column. Often there is a temperature 
program that increases the temperature in a controlled manner, allowing some 
control over the elution times of the analytes. 
1.4.1.1 Capillary gas chromatography 
A most significant breakthrough came with the introduction of commercial capillary 
columns in the 1960’s and 1970’s (Scott, n.d.). These columns are usually between 5 
and 30 meters long and less than 1 mm in internal diameter. The effect of this is that 
there are a very large number of theoretical plates in the column, meaning that 
chromatography peaks can be very pure, with typical peak widths of just a few 
seconds in a 10-20 minute run, sufficient to resolve cis- and trans- isomers of a 
compound. This means that there is a very high peak purity and spectra obtained in 
an electron impact source are highly reproducible, not only between different batches 
but also between different makes of instrument. The mass spectrum produced often 
has little noise and is likely to be very similar to a stored library spectrum. For drugs 
of abuse testing, this means that GC-MS quickly became the gold standard, a 
standard that has only recently been matched by liquid chromatography systems. 
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1.4.1.2 Gas chromatography-mass spectrometry 
GC-MS is not without its disadvantages. As separation is achieved on the basis of 
volatility, GC-MS only works with volatile, heat stable substances. This puts a 
practical limit on the molecular mass of around 500 - 600 amu. Most drugs are of a 
relatively low mass, from 135 amu. (amphetamine) to 468 amu. (buprenorphine), well 
within the separating range of GC. However, some drugs of abuse are unstable at 
high temperatures, rendering them unsuitable for simple GC. Morphine, a very 
significant drug of abuse, has a molecular mass of 285, placing it well within the 
range of GC. However, morphine melts at about 250 °C and decomposes (Morphine, 
sulfate (pentahydrate), 2011), meaning that it cannot normally survive the GC 
separation to be detected. One common solution is to derivatise the morphine to both 
stabilise the structure and increase its volatility. Several of the most common 
derivatising agents add trimethylsilyl (TMS) functional groups in place of the 
hydrogen of the hydroxyl groups of the morphine. Although the mass is increased, 
the removal of hydrogen bonding hydroxyl groups actually increases the volatility of 
the drug. The molecule is also stabilised so that it can survive the temperatures 
encountered in the GC oven.  
1.4.1.3 Gas chromatography equipment 
As has already been mentioned, separation in a GC is mediated by temperature. A 
typical GC will begin with a low temperature of 100-150 °C and increase the 
temperature at 5 - 20 °C per minute until the final temperature is reached, often 300 - 
400 °C. The system then needs to be cooled ready for the next sample. This puts a 
practical limit of around 3 - 6 samples per hour, although if operated isothermally it is 
possible to measure single drugs or single drug groups at a higher rate. 
As shown (see Figure 1.4), the components of a GC system can be fairly simple, 
although autosamplers, column switching devices and cryotraps can all add to the 
complexity of a system. 
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Figure 1.4 Schematic diagram of the main components of a gas chromatography system (Philadelphia 
College of Pharmacy, 2012) 
Most GC systems cannot accept samples in an aqueous medium and the sample 
most commonly used for drug testing, urine, is water based. It is therefore necessary 
to extract the drugs from the aqueous sample into a solvent that is suitable for 
introducing into a GC. In practice the sample preparation procedures for drug testing 
must include an extraction and derivatisation before analysis, with analysis 
proceeding at the rate of a few samples per hour.  
1.4.1.4 Systematic toxicological analysis 
When screening a sample to try to identify whether there are any unexpected drugs 
present, capillary GC-MS with an electron impact source is unrivalled. Any peak 
identified can be compared with a drug library for a tentative identification and 
several different libraries are commercially available. Frequently the basic and acidic 
extracts of a sample are combined and analysed simultaneously. 
This type of work is typically fairly low volume, well within the capability of these 
instruments running at only a few samples per hour, but is less good for clinical drugs 
of abuse testing where fast turnaround times are required and simpler methods are 
becoming increasingly important. One of the solutions to this is to use liquid 
chromatography. 
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1.4.2. High performance liquid chromatography 
High performance (or high pressure) liquid chromatography (HPLC) was developed 
in the 1970s (Waters, n.d.) with ultraviolet or visible light detection (UV-Vis). A 
substantial advantage over GC is that the separation is usually performed at around 
room temperature in an aqueous solvent, meaning that derivatisation and extraction 
are not always required. This considerably simplifies the analytical procedure, but 
does of course come with a price. HPLC columns are much shorter and thicker than 
GC columns, usually being less than 25 cm long and 2-5 mm in diameter. If the 
column is much longer than this, the pressure needed to pump the solvent becomes 
very high, beyond the engineering standards required for simple pumps and 
connectors. These short columns generally have a much lower theoretical plate 
count than GC columns, so that the peaks obtained are not as sharp and defined, 
and separation is not as good. With a long gradient of increasing organic solvent 
composition, it may be possible to get good separation between different peaks, but 
the resolution of the system and the run time limits the number of peaks that can be 
identified with a UV detector. With a mass selective detector, this overlap is much 
less critical and as long as isobaric peaks do not overlap, a very high number of 
compounds may be identified. In an application note produced by Agilent 
(Zweigenbaum, Flanagan, Stone, Glauner and Zhao, 2009) over 600 different 
pesticides may be identified in a single 13 minute analysis. 
1.4.2.1 Components of a high performance liquid chromatograph system 
HPLC systems generally have more components than GC systems and are 
correspondingly more expensive. As well as the autosampler, a pump is required that 
is capable of pumping at the high pressures used in HPLC. Traditional systems had 
upper pressure limits of around 20,000 kPa, but modern systems can achieve 
pressures of 60,000 kPa. This is in contrast to GC systems where a column head 
pressure for a typical GC column may be up to 2,000 kPa and is usually less (Sigma 
Aldrich, 2010) 
Most HPLC systems include a system for mixing two or more mobile phases. With a 
high pressure mixing system (see Figure 1.5), the two mobile phases are mixed on 
the high pressure side of the pumps. This gives a relatively small gradient delay 
volume, but requires a separate pump for each solvent. In contrast, a low pressure 
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mixing system will use a proportioning valve on the low pressure side of a single 
pump to achieve the same mixing of solvents. The gradient delay is generally longer 
than for high pressure mixing, but only a single HPLC pump is required. 
 
Figure 1.5 Diagram of the main components of a typical HPLC system (Flanagan, Taylor, Watson and 
Whelpton, 2007, p. 179) 
Most systems will also have a column oven or column compartment to maintain the 
HPLC column at a set temperature. This increases the reproducibility of retention 
times and is important for any complex analysis. As for GC, there may be many 
additional components to the system, such as an autosampler, column switch or 
solvent degassers. 
Another benefit of using HPLC is that a large number of different column and mobile 
phase combinations is possible, far more than for GC where the mobile phase is a 
non-reactive gas. Changes in column and mobile phase chemistry can change the 
retention characteristics of drugs completely, even allowing a reversal of the eluting 
order if required. 
1.4.2.2 Normal phase chromatography 
The original HPLC methods used pure silica as a stationary phase and had a highly 
organic mobile phase. The mobile phase in normal phase HPLC has a low water 
content and interactions between the analytes and stationary phase are generally 
strongest for polar molecules (Lab-Training.Com, n.d.). A higher aqueous content of 
the mobile phase leads to less interaction between the analyte and column and this 
leads to a shorter retention time. The greater the polarity of the analyte, the greater 
the interactions between the analyte and stationary phase and the greater the 
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retention time, whereas non-polar analytes will elute relatively quickly. Normal phase 
HPLC requires the sample matrix to be largely organic and an extraction is usually 
required to maintain consistent retention times.  Normal phase HPLC is not common 
in drugs of abuse testing. 
In a literature search in 2009, only two papers were identified that used normal phase 
HPLC. Fitzgerald, Rivera and Herold (1999) used a reversed phase column and an 
anion exchange column as an online extraction system, with the normal phase 
column being used for the separation. In this way the high organic strength mobile 
phase used for the elution step does not hinder the separation in the following normal 
phase column. Naidong, Jiang, Newland, Coe, Lin and Lee (2000) used normal 
phase HPLC of hydromorphone following an acetonitrile precipitation of human 
plasma, the normal phase separation eliminating the need to dry or back-extract to 
recover the hydromorphone from the acetonitrile. These papers both represent an 
elegant solution to high organic content sample extracts, although most papers 
viewed use an alternative approach, mainly drying and resuspending the sample 
extract. 
1.4.2.3 Reversed phase chromatography 
The advent of HPLC columns with alkyl groups attached enabled the silica to be 
protected from chemical reaction and allowed predominantly aqueous mobile phases 
to be used. Interactions between the analyte and column are generally through 
hydrophobic interactions, although for phases containing a phenyl moiety pi bonding 
can also play a significant part (Sigma-Aldrich, 2013). Less polar analytes will be 
retained longer on a reversed phase HPLC column than polar analytes and a column 
with an eighteen carbon alkyl chain (C18) will give greater retention than an eight 
carbon chain (C8). For most common HPLC columns, a wide range of solvent 
conditions can be used, including gradients where the organic composition of a 
solvent is increased during the analytical run. Most reversed phase columns cannot 
cope with 100% aqueous solvents, as this may cause the alkyl chains to collapse  
(Przybyciel and Majors, 2002), and gradients typically start with above 10% organic 
component. There are some modern stationary phases that can operate in 100% 
water, such as some phenyl and cross-linked alkyl phases, which further increases 
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the range of conditions available to the chromatographer. Reversed phase columns 
are the most common in use in drug testing. 
Of 72 published methods, two use normal phase and over half (41) of the others use 
a C18 column, the most commonly used reversed phase column. The remaining 
columns in use are predominantly phenyl type (17) or C8 columns (9). 
One of the big advantages of HPLC over GC is the change in selectivity that can be 
achieved by altering the solvent conditions. Once a column is chosen, there are still 
several options that can significantly alter the retention characteristics of the system. 
One of these is the choice of the organic component of the separation, with the two 
most commonly used solvents being acetonitrile and methanol. Acetonitrile is the 
commonest solvent used in the methods identified above, with at least 50 methods 
using this as a solvent. This may be partly because acetonitrile does not strongly 
absorb UV radiation and has therefore become a very common HPLC solvent. 
Acetonitrile is also miscible with water and an increasing percentage of acetonitrile in 
a solvent leads to a lower pressure than water alone. It is not without its problems, as 
acetonitrile can cause polymer build up on HPLC check valves (Dolan, 2008) and is 
produced commercially as a waste product of the plastics industry. During the 
recession of 2008, acetonitrile prices increased by a factor of 10 (Kenward, 2010) 
and acetonitrile became in short supply.  
Methanol has a similar solvent strength to acetonitrile and was used in at least 14 of 
the methods identified above. Although generally cheaper than acetonitrile (even 
before the price of acetonitrile increased in 2008), it is not without its problems, as a 
mixture of water and methanol gives a higher back-pressure than water alone. This 
means that flow rates must be lower when using methanol than when using 
acetonitrile, which can be a limiting factor when high throughput is desirable. 
However, methanol can reduce peak tailing compared to acetonitrile and can give a 
different selectivity, meaning that the choice of solvent must be a balancing act of 
several different factors. 
Most other organic solvents in common use have their own problems when it comes 
to chromatography. Using a stronger solvent can affect the reproducibility of a 
separation, as a small variation in the solvent composition can have a more 
pronounced effect than a similar level of variation with either acetonitrile or methanol. 
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Other solvents are difficult to use due to their immiscibility (e.g. chloroform), toxicity 
(e.g. benzene) or cost (e.g. tax on ethanol) and as a result only acetonitrile and 
methanol are usually used as the principle organic solvents in HPLC. 
1.4.2.4 Ion exchange chromatography 
In addition to hydrophobic, hydrophilic and electrovalent (pi bonding) interactions, 
retention can also be achieved by ionic interactions. Typically the HPLC column has 
a sulphonyl or amine group embedded, which are ionised except at very acidic and 
basic pH values respectively. Retention is achieved through interactions between 
ionic analytes and the stationary phase, with retention generally being dependent on 
the ionic strength (pKa) of the mobile phase and analyte. Ion exchange HPLC can 
produce very selective retention (Morgan, Fisher, Evers and Flanagan, 2011), with 
neutral analytes being unretained. A strong ion exchange resin will be ionised under 
almost any pH condition, making it suitable for a wide range of analyses, and a weak 
ion exchange resin will become neutralised at a given pH, removing any ionic 
interactions and ionic retention. 
Ion exchange chromatography can be combined with a reversed phase to produce a 
mixed mode interaction. This is usually achieved by attaching the ion exchanger to 
an alkyl chain, with retention being based on a mixture of ionic strength and 
hydrophobic interactions. 
Most drugs of abuse are basic, with one or more amine groups that can become 
protonated under basic conditions. This makes cationic exchangers work well for 
many drugs, although some drugs, for example cannabis and ibuprofen, have a low 
pKa and are more suited to anion exchange. However, ion exchange chromatography 
has not proved popular for multi-analyte drugs of abuse testing and ion exchange is 
far more common in the sample preparation steps of an analysis. 
1.4.2.5 Hydrophilic interaction liquid chromatography 
Hydrophilic interaction liquid chromatography (HILIC) is a recent extension to normal 
phase chromatography in which a pure silica stationary phase and an acetonitrile 
based mobile phase are used (Buszewski and Noga, 2012). A small amount of water 
in the mobile phase coats the silica to produce an aqueous stationary phase, similar 
to the waxy stationary phases in gas liquid chromatography. Retention is achieved 
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through differing hydrogen bonding strengths between the analyte and the aqueous 
layer on the stationary phase. It takes time for the water to form a stable layer and 
HILIC is not well suited to gradient chromatography. Since structures of drugs of 
abuse vary considerably, HILIC does not lend itself to multi-drug analysis, although it 
has been used for analysing single classes of drugs (Gheorghe, et al., 2008). 
1.4.2.6 Developments in high performance liquid chromatography 
Instrumentation for liquid chromatography is generally still recognisable from the first 
commercial HPLC systems 40 years ago. The computing power has increased so 
that pumps and autosamplers can generally be controlled from software and modern 
integration software is significantly easier to use than modular integrators. Gradients 
can be formed from high pressure or low pressure mixing with binary and quaternary 
pumps and autosamplers are increasingly sophisticated. However, where there has 
been the greatest effect on the chromatography is in the column. As well as the wide 
range of phases available, the structure of the particles that form the packing material 
has gone through several generations of development and these developments have 
led to a number of other significant changes that affect the separation. 
For many years the only particle size available for an HPLC column was 5 µm 
diameter silica, which was generally available in a 4.6 mm internal diameter column 
that could vary in length between 5 and 25 cm. The van Deemter equation (see 
Equation 2, Appendix C) for resolution in HPLC balances the linear velocity of the 
eluent and the resolution of the separation. Eluent linear velocity itself is governed by 
the mobile phase flow rate and the internal column volume. Use of a narrower bore 
column will increase the eluent linear velocity and lead to increased chromatographic 
resolution. With increased resolution, the length of the column can be reduced, 
reducing the back-pressure on the pump and therefore allowing still higher flow rates. 
As a result, a 2.1 mm internal diameter (i.d.) operating at 0.2 mL/min would have a 
similar linear velocity as a 4.6 mm i.d. column running at 1 mL/min (see Equation 1, 
Appendix C). This has meant that around 75 % of columns used for drugs of abuse 
testing in the literature in the last 10 years are 2.1 mm internal diameter or less, with 
a median flow rate of 0.3 mL/min. Together with short HPLC columns (98 % of these 
are 150 mm long or less) analysis times and solvent usage has been cut dramatically 
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from the typical 20 – 30 minute runs at 1 mL/min or more that were previously 
common. 
Another improvement in column technology is governed by the expanded van 
Deemter equation (see Equation 3, Appendix C) which shows that if the particle size 
is reduced, the plate height is also reduced, which means that the resolution is 
increased. Much of this increase is due to the increased surface area available with 
smaller particles, as the surface area of a sphere reduces with the square of the 
radius but the volume decreases with the cube of the radius. The 5 µm particles in 
common use ten years ago are now often replaced with smaller particles and 3 µm 
particles are common and, in the last few years, particles have become smaller still, 
with 1.8 µm particle columns now easily available commercially. This creates a 
technical challenge, as the spaces between the particles become smaller and the 
mobile phase does not pass though so easily. This leads to increased pressures and 
many modern liquid chromatography pumps are capable of pressures of 600 bar, 
compared to 150 - 200 bar that standard HPLC systems are capable of. These high 
pressures can cause the silica particles that form the stationary phase to be crushed 
and deformed and polymeric particles are now also available. As well as being more 
pressure resistant, polymeric particles can be more carefully controlled at the 
manufacturing stage so that the silanol groups that can affect some reversed phase 
columns are absent. 
Although column size has reduced significantly, the reductions in particle size have 
been less dramatic, with only 40 % of these columns using particle sizes under 5 µm. 
This may be because the true benefit of smaller particles can only be achieved with 
increases in pressure, which necessitates new and expensive hardware. Use of a 5 
µm particle can still give very good resolution without the expense of new HPLC 
pumps and autosamplers, particularly when combined with a narrow bore column. 
An alternative to increasing the pressure capacity of the pump (and therefore the 
column fittings and autosampler) is to use particles that have a highly porous outer 
layer with an impermeable centre. This leads to an increased surface area, and 
therefore resolution, without the corresponding increase in pressure. These fused 
core or porous shell particles are available from several different manufacturers, but 
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are a recent development and have not found their way into the literature for drugs of 
abuse applications. 
It follows that any technique that allows the use of a higher flow rate or analyte mass 
transfer (adsorption rate) can also increase the resolution of an HPLC system. 
Acetonitrile is often chosen as an HPLC solvent because it causes a reduction in 
back-pressure when mixed with an aqueous component in a gradient system, 
whereas a methanolic phase causes an increase in back-pressure. For a given pump 
or column, an acetonitrile gradient can therefore use a higher flow rate than a 
methanolic solvent without reaching the pump or column’s pressure limits. Similarly, 
warming the solvent to above ambient temperature, typically to 40 – 60 °C, will 
reduce the viscosity of the mobile phase components and this will also reduce the 
back-pressure. Mass transfer is also more rapid at a higher temperature and the 
effects of a column oven are therefore more than simply a reduction in mobile phase 
velocity. Temperatures above this can be a hazard due to the flammability of organic 
solvents, so the benefits of the reduced viscosity are limited by safety. Some 
specialised applications use water superheated above 100 °C to improve the 
separation characteristics of a method. The superheated water can even allow 
separations to be performed in 100 % aqueous mobile phases. However, this needs 
specialised equipment and can only rarely be justified.  
Drugs of abuse testing has taken advantage of many of these developments to 
improve the laboratory’s ability to detect drugs. However, the use of a mass 
spectrometer partially negates the need for high quality separations, as the detector 
can be so highly specific. As a result, some of the more expensive or specialised 
options such as the smaller particle size columns have not been widely published. 
Chromatography methods have not changed significantly in the 6 years since the 
project started, with short narrow-bore columns remaining the preferred choice. More 
efficient particles are increasingly available, such as fused core particles (Arbeláez, 
Borrull, Marcé, Pocurull, 2014). Acetonitrile is again readily available and the mobile 
phases used are similar to those found in 2008. 
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1.4.3. Capillary electrophoresis 
Electrophoresis is the separation of ionic species according to their charge and their 
mass or structure. Widely used for the analysis of proteins in serum, modern 
electrophoresis uses a capillary column similar to those used in GC applications, 
although with a liquid mobile phase. A range of different separations can be 
produced based on the pH and composition of the mobile phase, including variations 
such as Capillary Micellar Electrokinetic Chromatography that allow the analysis of 
neutral components (Flanagan, Taylor, Watson and Whelpton, 2007). 
Capillary electrophoresis is not commonly hyphenated with mass spectrometers and 
is not available for use at King’s College Hospital. Although a significant analytical 
method, it will not be discussed further in this work. 
1.4.4. Thin layer chromatography 
Thin layer chromatography, as has been mentioned already, was the method of 
choice in early clinical toxicology laboratories. Modern TLC has changed significantly 
since the days of manually spread plates, and modern high performance TLC 
(HPTLC) systems can use very controlled conditions to produce very reproducible 
separations (Flanagan, Taylor, Watson and Whelpton, 2007). It is possible to then 
place a TLC plate into a mass spectrometer with a MALDI or SELDI source to use 
the mass spectrometer to “visualise” the plate in exactly the same way as a 
proteomics lab will identify the components of a 2D SDS-PAGE gel (Sodium dodecyl 
sulphate – polyacrylamide gel electrophoresis). However, this is not an efficient use 
of one of these expensive systems, which may be better utilised to identify complex 
mixtures of unknowns. As with capillary electrophoresis, discussion of these 
specialised techniques will not continue in this document. 
1.5. Mass spectrometric detection 
A wide variety of detectors can be used with chromatographic systems such as 
HPLC or GC. For HPLC, UV-visible spectroscopy is perhaps the most common 
detector, although specialist detectors such as electrochemical and fluorescent are 
also available. For GC, flame ionisation detectors, nitrogen-phosphate detectors and 
thermal conductivity detectors give either general detection or selective options for 
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detection. However, for toxicology there are few detectors that can beat the mass 
selective detector or mass spectrometer, which can be interfaced to either GC or 
HPLC systems, as well as to electrophoresis or thin layer chromatography if required. 
The first mass spectrometers were standalone systems, with the sample introduced 
at one end and the result being produced subsequently. This technique is fine for the 
analysis of pure materials, mixtures and solids, but is not so useful when it comes to 
the analysis of complex mixtures such as may be found in biological fluids. To 
overcome this, an initial chromatographic separation is performed, followed by mass 
spectrometry of the chromatography product. These systems that consist of two 
different analytical techniques linked together are called hyphenated methods 
(Maurer, 2006). The most common arrangement is to have a chromatographic 
system, whether gas chromatography, liquid chromatography or capillary 
electrophoresis (CE), linked to a detector system, usually a mass spectrometer, 
although nuclear magnetic resonance (NMR) detectors have been used. However, 
the number of possible combinations is huge, with 2 separate chromatographic 
systems running in parallel being another option, for example GC-GC, or 2D-GC 
(Kolbrich, Lowe and Huestis, 2008). 
1.6. Mass spectrometry theory 
Mass spectrometry is the separation and detection of materials based on their 
relative molecular mass. This allows a highly selective method of detecting a 
substance, as the molecular mass will depend on the chemical structure of the 
molecule. Morphine has a molecular mass of 285 (National Center for Biotechnology 
Information, U.S. National Library of Medicine) and codeine has a molecular mass of 
299 (National Center for Biotechnology Information, U.S. National Library of 
Medicine) (both rounded to whole numbers). It follows that a system able to separate 
and detect these two molecular masses can discriminate between the two drugs. 
Conversely, norcodeine, which also has a molecular mass of 285 is indistinguishable 
from morphine in a simple mass spectrometer, as their molecular formulae are 
identical (Fox, Twigger and Allen, 2009). 
Light spectrometry is the measurement of the intensity of light after it has been 
passed through a prism to separate the different wavelengths. Early 20th century 
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spectrometers originally used a photographic plate to record the signal intensity and 
the wavelength would be determined by the position of the signal on the plate. In the 
same way, early mass spectrometers often recorded their output on a photographic 
plate, with the mass determined by the position on the plate and the degree of 
exposure representing signal intensity. This is the origin of the term “mass 
spectrometry” and a graph or plot of the relative signal intensity against the mass is 
still termed a “mass spectrum”. The similarities between light spectroscopy and mass 
spectrometry can be seen (see Figure 1.6), although the ion path in a mass 
spectrometer is generally curved. 
 
Figure 1.6 Comparison of the similarities between light and mass spectroscopy 
DBMS Thesis  F R Evers 
31 
1.6.1. Ions and molecules 
A light spectrometer uses a prism to direct photons towards a photographic plate. 
Photons can pass easily through the glass. However molecules do not show this 
wave-like characteristic and their path would be blocked by any materials in their 
way. Mass spectrometers must therefore manipulate their analytes in a vacuum to 
avoid collisions with air molecules. This means that mass spectrometers need 
another way of manipulating their target analytes and most mass spectrometers use 
either electrostatic or magnetic interactions to control the movements of the materials 
to be detected. A good resource on the history of mass spectrometry and the 
principles behind the various different modes can be found at the Scripps Centre for 
Metabolomics (Scripps Cente for metabolomics, 2013). 
Since most molecules are neutral, they will be unaffected by the electrostatic and 
magnetic forces and cannot be deflected, focussed or separated by the mass 
spectrometer. To avoid this molecules must be given a positive or a negative charge, 
which then allows them to be manipulated by the electrostatic or magnetic forces 
within the mass spectrometer. 
Molecules can gain or lose one or more protons or electrons to become ions and 
these ions can be easily manoeuvred in the mass spectrometer by a series of 
shaped electrostatic or magnetic plates or lenses. The speed or direction of 
movement is determined by the molecular mass of the ion and the number of 
charges it has, a property known as the mass/charge ratio, or m/z. When a molecule 
has gained or lost a proton, the m/z of an ion will differ by one mass unit when singly 
charged. This ion is known as the molecular ion and is often denoted as [M+H] or [M-
H]. The charge on the ion defines one of the basic parameters of a mass 
spectrometry method, either operating in positive mode or negative mode. (Scripps 
Centre for Metabolomics and Mass Spectrometry) 
Most mass spectrometers are unable to tell the difference between a single charged 
ion and an ion that has both twice the mass and twice the number of charges. This is 
particularly problematic for large molecules such as proteins, but is less of an issue 
with small molecules such as drugs of abuse, which usually have a molecular mass 
in the range 100-500 atomic mass units (amu.). Smaller molecules are usually not 
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physically big enough to be stable with many charges and addition of a second 
charge will often cause the molecule to fragment (University of Pittsburgh, 2013).  
1.6.2. Mass selection  
There are a number of different technologies used by mass spectrometers to select 
and isolate the molecules being tested. The early magnetic sector instruments took 
up a large amount of space and were very expensive (Mass Spectrometry Facility, 
2012). The modern sector type systems are smaller, but remain expensive and are 
not often linked to HPLC systems and will not be discussed further here. 
There are four different mass selection technologies that are in widespread current 
use and each has its own benefits and limitations. The choice of mass spectrometer 
will be made largely dependent on the intended use and which of the technologies is 
most suitable. 
1.6.2.1 Quadrupole mass analyser 
In a quadrupole instrument, a set of four metal rods are arranged parallel to each 
other in a square formation (see Figure 1.7). The ions enter the space between the 
rods at one end and are subjected to the electromagnetic forces exerted by the rods. 
Opposite rods are arranged in opposing pairs, with one set having a radio frequency 
potential across them and the other pair a constant voltage. By rapidly varying the 
voltages applied, ions of a given mass or mass range can be made to stay in a stable 
trajectory within the rods and exit at the other end. Ions that do not fit the mass 
selection criteria have unstable trajectories and do not leave the ion channel at the 
exit. 
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Figure 1.7 Schematic arrangement of a quadrupole mass spectrometer lens system (Tissue, 2000) 
The size and geometry of the quadrupole rods defines the mass accuracy of the 
system (Gershman, Block, Rubin, Benna, Mahaffy and Zurbuchen, 2012), which is 
usually between 0.1 and 0.5 amu. Circular rods are common in cheaper systems and 
can provide good unit-mass resolution. More expensive and higher specification 
instruments have hyperbolic rods, which can give greater mass resolution. As ions 
are continually entering and exiting the quadrupole, the data collection rate can be 
quite high, leading to relatively low detection limits (Berger, Langlois, Oehme and 
Kallenborn, 2004). The selected mass can also be varied quickly so that a range of 
masses is scanned to produce a mass spectrum. Simple quadrupoles are also used 
in other instruments as non-selective mass guides, for example allowing all masses 
to be guided from a lens system to a mass filter (Mass Spectrometry Facility, 2012). 
Hexapoles and octopoles made from 6 or 8 rods operate on the same principles and 
are also common in modern instruments, but act only as transfer optics, not a mass 
filter (Pentek, 2011). 
In terms of drugs of abuse testing, quadrupoles are now almost unused in LC-MS, 
although they still find use in GC-MS systems. In the survey of published drugs of 
abuse LC-MS methods (see table 1.1), only 6 of 68 systems identified used single 
quadrupole systems, the most recent being that described by Concheiro, Castro, 
Quintela, López-Rivadulla and Cruz (2006) that was developed and in use in 2004. 
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1.6.2.2 Ion trap 
A three dimensional (3D) or quadrupole ion trap (see Figure 1.8) uses similar 
electrostatic interactions to a quadrupole, but the ions do not transit the length of the 
device as in a quadrupole and are instead trapped in the electromagnetic field. 
Usually the trap consists of two end cap electrodes and a ring electrode and when 
seen in cross section the similarity with a quadrupole cross section is apparent (see 
Figure 1.9). A mass or range of masses can be trapped within the space between the 
end caps and they are then ejected through holes in the end caps to reach the 
detector.  
 
Figure 1.8 Schematic arrangement of the lenses of a quadrupole (3D) ion trap (O'Hair, 2006) 
 
Figure 1.9 Sectional view of a quadrupole ion trap to show the similarity to a quadrupole (Shimadzu, 2014) 
Two dimensional (2D) or linear ion traps (see Figure 1.10) consist of a quadrupole in 
which each rod is split into three sections. Collectively the middle sections act as the 
ring electrode and the end sections act as the endcap electrodes. In some models, 
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the ions are ejected through slits in the quadrupole rods (e.g. Thermo LXQ) and in 
some models the ions are ejected through the end of the quadrupole rods, in the 
same manner as if the trap was a standard quadrupole (e.g. AB SciEx Q-Trap). The 
advantage of a linear ion trap is that the cavity in which the ions are trapped is long 
and narrow, as opposed to a 3D ion trap where the cavity is of equal size in all three 
dimensions. This allows more ions to be confined simultaneously, giving an increase 
in mass resolution and limits of detection when compared to a 3D ion trap. 
 
Figure 1.10 Diagram of a linear (2D) ion trap showing the ion exit slit in the centre section (Shwartz, Senko 
and Syka, 2002) 
Ion traps often have a lower mass resolution than quadrupoles, although they can 
still achieve mass accuracy below unit mass. However, ion traps cannot allow a 
single mass to enter and exit continuously like a quadrupole and must work in 
discrete segments. As a consequence the data capture rate (and therefore limit of 
detection) will be poorer than for the equivalent specification quadrupole (Fitzgerald, 
O'Neal, hart, Poklis and Herold, 1997). However the rate at which ions are scanned 
out of the trap and detected is higher than for a quadrupole and an ion trap is 
therefore faster at producing a mass spectrum. 
Ion traps are not common in toxicology testing and in the 68 methods referred to 
there are only 9 ion traps, all of them being Thermo’s LCQ Deca or LCQ Advantage 
models. This is likely to be a result of the poor limit of detection of these systems 
compared to triple quadrupoles. 
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1.6.2.3 Time of flight 
Time of flight (TOF) instruments (see Figure 1.11) release all ions simultaneously in 
discrete packets and accelerate them with the same energy along an ion path. Since 
the kinetic energy of the ions equals the mass divided by their velocity, the relative 
speeds at which the ions travel will be dependent only on their m/z ratio and they will 
arrive at the detector at different times, with the lighter ions arriving before the 
heavier ions. Often the ion guide will have the emitter and detector at the same end 
of the tube, with a reflector at the other end to reduce the space taken.  
 
Figure 1.11 Schematic representation of the lens system of a time of flight mass spectrometer (Tong, Yu, 
Jin, Hi, Hang and Huang, 2009) 
Mass resolutions can be very high (3 decimal places of mass accuracy) and 
comprehensive mass spectra can be obtained, but like an ion trap, data must be 
collected in discrete segments rather than continuously like a quadrupole. Only a 
single method was found for drugs of abuse using a time of flight detector (Pelander, 
Ristimaa, Rasanen, Vuori, Ojanperä, 2008) 
1.6.2.4 Orbitrap 
The orbitrap (see Figure 1.12) is a development of ion cyclotron resonance mass 
spectrometry that combines the mass separation and detection parts of a mass 
spectrometer in a single component. Most other mass spectrometers use a dynode 
for ion detection, in which the ions strike a target which emits electrons. These 
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electrons strike an electron multiplier, producing a signal that can be detected and 
processed. In the orbitrap, the movement of the ions around a spindle induces tiny 
currents in adjacent electrodes. These currents are amplified and subjected to a 
Fourier transform algorithm from which all masses present can be identified.  
 
Figure 1.12 Diagrammatic representation of the lens system of an orbitrap mass spectrometer (Bateman, 
Kellman, Muenster, Papp and Taylor, 2009) 
The orbitrap operates to better than four decimal places of mass accuracy, but has a 
data collection rate of one scan per second at this accuracy and a scan time of 100 
milliseconds at its lowest resolution, around three decimal places of mass. 
Quadrupoles often have a data window of less than 10 milliseconds. These 
instruments were first marketed in 2005 by Thermo, but in the literature search 
mentioned there were no orbitrap papers listed. A more specific search identified the 
orbitrap as being used in doping control (Virus, Sobolevsky, Rodchenkov, 2008) and 
without the use of an HPLC system (Kauppila, Talaty, Kuuranne, Kotiaho, Kostiainen 
Cooks, 2007) 
1.6.3. Tandem mass spectrometry 
Collectively these techniques are known as mass spectrometry (MS) and they are 
suited to identifying masses of ion species present. Identification of the mass, known 
as the parent mass, is extremely useful and can allow the differentiation of two 
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different drugs, for example morphine (m/z = 286) and codeine (m/z = 300). 
However, parent mass spectra cannot tell the difference between two drugs of the 
same mass, or isobaric compounds, such as morphine and norcodeine (m/z = 286). 
These substances could be separated chromatographically in an LC-MS or GC-MS, 
or they could be split into fragments and these fragments subjected to mass 
spectrometry. This technique is known as tandem mass spectrometry (MS/MS or 
MS2) and can allow a high degree of confidence in the identification of a molecule 
(Madeira and Florêncio, 2012). 
Tandem mass spectrometers usually contain at least two mass selecting 
components, with some form of fragmentation mechanism between them. The 
commonest type of tandem mass spectrometer is the triple quadrupole, where the 
first and third quadrupoles act as mass filters and the second quadrupole is used as 
a collision cell. The collision cell is often a different design, such as a hexapole, but 
the instrument is still referred to as a triple quadrupole as the principle is the same. 
Triple quadrupoles can operate in selected reaction monitoring (SRM) mode where a 
given parent ion is fragmented and a single fragment ion detected (Madeira and 
Florêncio, 2012). Not much spectral information can be obtained, but this mode of 
operation gives one of the most sensitive modes of analysis and is well suited to the 
quantification of known analytes.  
Tandem mass spectrometers will often have a quadrupole as the first mass filter 
(often abbreviated to Q), followed by a collision cell and then a different mass filter, 
either time of flight, an ion trap or an orbitrap. Each of these will give information rich 
spectra of the fragments of the parent ion and therefore very good identification 
criteria. Most combinations of spectrometer types have been tried and there are 
commercial quadrupole-traps, quadrupole-TOF, trap-trap and trap-orbitrap 
instruments.  These hybrid designs are very good for the identification of unknown 
compounds and for identifying a wide range of analytes in a single sample. 
These tandem mass spectrometers have been described as tandem “in space” 
(Madeira and Florêncio, 2012), as the two mass spectrometers are physically 
separated. It is also possible to use the same mass analyser to produce a tandem “in 
time” mass spectrometer (Madeira and Florêncio, 2012). In this case, an ion trap 
performs the initial mass spectrometry, but instead of ejecting the ions it fragments 
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them before detecting the products. The two mass spectrometry events are therefore 
separated in time rather than in space.  
1.6.4. Instrumentation 
Most of the instruments used for drugs of abuse analysis in these papers are triple 
quadrupoles (n = 44), although there are also 9 ion traps and one time-of-flight 
instruments. Quadrupoles are both sensitive and versatile, making them an ideal 
choice for these methods. However 8 of the methods use hybrid Q-trap or Q-TOF 
instruments. Triple quadrupoles are generally better at identifying a relatively small 
number of analytes and this can be seen by the 21 (48%) methods that are optimised 
for a single class of drugs or a only a few selected analytes. Ion traps and hybrid 
instruments are well suited to multi-analyte screening, and 14 (78%) of these 
methods are used for analysing a range of drugs from different classes. 
Very few manufacturers make mass spectrometers for the clinical market and 60 of 
the instruments used are made by just three companies, Waters (including 
Micromass), Thermo (including Finnegan) and Applied Biosystems/SciEx. Bruker 
instruments are more common in inorganic chemistry and only returned a single 
method (Bones, Macka and Paull, 2007) and Shimadzu only produce a single 
quadrupole instrument and also returned a single method (Tatsuno, Nishikawa, 
Katag and Tsuchihashi, 1996). The remaining 7 instruments are all from Agilent. 
Increasing performance and reducing costs in the mass spectrometer market have 
also changed how toxicology laboratories operate, with accurate mass Q-TOF or Q-
Orbitrap (Q-Exactive®) systems becoming increasingly available. One of the principal 
advantages of these systems is that they are capable of storing the mass signal of all 
compounds within a sample. This means that it is easy to either re-analyse the data 
in the future to identify whether a drug or metabolite was present, or to search for a 
large number of poorly characterised substances such as legal highs. The Drug 
Control Centre at King’s College, London, was the UK doping control laboratory for 
the 2012 London Olympics. Athletes have been told that their data may be 
reprocessed in the coming years to identify any user of new performance enhancing 
substances which have not yet been identified by the doping control agencies. In this 
way, the World Anti-Doping Agency hopes to avoid a repeat of the BALCO scandal, 
where the doping agent was unknown to the authorities until a syringe was handed to 
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them by an informant (What is the BALCO scandal?, 2011). By 2014 the hybrid 
instruments such as the Q-Trap or Q-TOF have come to dominate the published 
work, with at least 25 toxicology papers using these instruments. 
There are several relevant reviews that cover the use of LC-MS in clinical and 
forensic toxicology and interested readers would do well to read those by Maurer 
(2004, 2005a, 2005b, 2007) and Peters (2011, 2012) and Maurer and Peters (2005) 
1.6.5. Components of a mass spectrometer 
1.6.5.1 Sources 
The source is the part of the mass spectrometer into which the analyte is introduced 
and in which the analyte is normally ionised. In a standalone system, the sample is 
typically introduced to the mass spectrometer through a vacuum interlock. However, 
this method is not possible with hyphenated techniques, as there is a continual flow 
of carrier gas or HPLC eluent being delivered to the source. The excess liquid or gas 
would quickly destroy the vacuum and must be continually removed. This is a 
relatively minor task when the carrier gas is helium, but becomes more complicated 
when the mobile phase in the HPLC is water based. 
1.6.5.2 Hard and soft ionisation 
Analytes may be ionised in a number of ways, but they are usually separated into two 
classes, hard and soft ionisation. Hard ionisation usually involves the direct ionisation 
of the parent molecule and can cause the molecule to fragment. Often the molecular 
ion is not produced in significant quantities using hard ionisation techniques. 
Conversely soft ionisation techniques generally do not cause fragmentation of the 
molecular ion in the source, enabling the molecular ion mass to be easily identified. 
This is often achieved by the ionisation of the matrix in which the analyte is found, 
with this charge being transferred to the analyte by collisions between the molecules 
and ions (Scripps Cente for metabolomics, 2013). 
1.6.5.3 Electron impact ionisation 
The commonest hard ionisation technique is electron ionisation or electron impact 
(EI) ionisation, often used in GC-MS (Scripps Cente for metabolomics, 2013). The 
GC carrier gas containing the analytes is introduced into the source at high vacuum, 
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usually at right angles to the direction in which ions are to travel. An electron beam 
from a heated wire filament is directed across the source chamber, and the electrons 
strike the analytes, ejecting electrons or protons from the target molecules and 
causing ionisation at functional groups that are particularly prone to ionisation, for 
example phenyl rings and nitrogen atoms. The ions are then attracted to a series of 
lenses that accelerate them into the mass spectrometer (see Figure 1.13) 
The amount of energy delivered by the electron beam is usually standardised at 70 
electron volts (eV) and this is sufficient to fragment the molecule. Since the energy is 
directed at functional groups, the fragmentation patterns will be consistent and, for 
any given substance, the proportions in which the fragments are produced will be 
approximately constant. The masses and proportions of the fragments are constant 
and form the mass spectrum of an analyte. 
 
Figure 1.13 Schematic representation of an electron ionisation source (Gates, 2005) 
1.6.5.4 Chemical ionisation 
With soft ionisation, a carrier or other reagent is directly ionised and this transfers the 
charge to the analyte without causing fragmentation. The parent ion is produced in 
abundance and a mass spectrum produced at this stage will show only the molecular 
ion. In GC-MS this process is usually known as chemical ionisation (CI), typically 
using methane or ammonia as a reagent gas (Gates, 2005). The source 
configuration is very similar to EI, although the volume of the source is generally 
slightly smaller to allow the vacuum to be maintained. The reagent gas is introduced 
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directly into the source and the electron beam ionises the gas in preference to the 
analyte. Random collisions ensure that the charge is transferred to the analyte, which 
can then be accelerated into the mass spectrometer. Generally a GC-MS with CI 
needs a higher efficiency turbo pump to remove the reagent gas added to the 
vacuum chamber. 
1.6.5.5 Electrospray ionisation 
In LC-MS, the hardest form of ionisation commonly used is electrospray ionisation 
(ESI) and the commonest source used in the papers identified, with at least 53 of the 
methods using electrospray ionisation. Electrospray ionisation is usually not hard 
enough to cause fragmentation, but can leave larger molecules with a number of 
charges. Since each extra charge reduces the m/z ratio, a single substance that has 
several charges can have the appearance of being several different substances. 
An ESI source consists of a nebuliser pointing at the entrance to the mass 
spectrometer, although it is usually off-axis so that ions can be directed using 
electrostatic interactions. The HPLC eluent emerges from the tip of the nebuliser 
needle where the nebuliser gas evaporates it. The needle is also held at a high 
voltage, typically 3-4 kV, which causes the eluent droplets to ionise. A combination of 
the nebuliser and a process known as coulomb explosion causes the eluent to 
disperse into very fine, charged droplets before evaporating completely to produce 
gas phase ions which can be drawn into the mass spectrometer (see Figure 1.14). In 
the review by Peters (2011) 16 of the 17 methods for drugs in urine and 13 of 15 
methods for drugs in blood use ESI, showing how this technique is almost the 
standard method for drug testing. 
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Figure 1.14 Image of an electrospray ionisation source showing coulomb explosion (Dahlin, 2008) 
1.6.5.6 Atmospheric pressure chemical ionisation 
The most direct equivalent to chemical ionisation for LC-MS is atmospheric pressure 
chemical ionisation (APCI) in which the HPLC eluent is evaporated by a heated 
nebuliser. Instead of the nebuliser needle being held at a high voltage, a separate 
needle is held near the end of the nebuliser. Instead of a reagent gas, the HPLC 
solvent acts as the reagent and, as for CI, the needle causes the reagent to be 
ionised, leading to soft ionisation (Takada, Sakairi and Koizumi, 1995). With an upper 
mass limit of around 1,000 amu, APCI is not as versatile as ESI and ESI is also 
better at ionising very highly polar substances. These limitations do not affect most of 
the relatively low mass drugs of abuse, yet the relative simplicity of ESI means that it 
dominates and only 8 of the papers identified specify the use of an APCI source. 
1.6.5.7 Other ionisation types 
There are a large number of ionisation types available for mass spectrometers and 
typically these will be optimised for specific analysis types. For example, matrix 
assisted laser desorption ionisation (MALDI) uses a laser to vaporise the substrate 
containing a sample. As for other soft ionisation types, the charge is then passed to 
the analyte (Tanaka, 2003). Similarly surface enhanced laser desorption ionisation 
(SELDI) uses a laser to create ions and both methods are ideally suited to 
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applications where a very small sample amount is available, either following a 2D 
electrophoretic separation or immobilisation by antibodies or other binding systems. 
Fast Atom Bombardment (FAB) is similar to MALDI in that the ionisation is generated 
in the matrix. Instead of using a laser to ionise the matrix in FAB the matrix is ionised 
by bombardment with atoms, generally of argon or xenon. (Barber, Bordoli, Sedgwick 
and Tyler, 1981) 
These techniques are all designed to work with solid or dried substrates and are not 
well suited to hyphenation with HPLC or GC systems. One that can be used is a 
variant on APCI known as atmospheric pressure photoionisation (APPI) which uses 
an intense ultra-violet (UV) light source to ionise the target molecules or the solvent. 
If ionisation efficiency is low, a dopant can be added to the sample. The dopant will 
ionise readily in UV light and therefore improve the ionisation efficiency (National 
High Magnetic Field Laboratory, 2013).  
Although these sources are the main ones used for clinical and forensic biological 
testing, there are a large number of variants using almost any technique available for 
ionising molecules. These are generally optimised for particular applications, for 
example trace element analysis using inductively coupled plasma (ICP) sources, and 
are not generally relevant to drugs of abuse testing. 
1.6.5.8 Vacuum pumps 
The ions in the mass spectrometer have to travel some distance from the source to 
the detector and if this space was at atmospheric pressure the ions would collide with 
the air molecules and never reach the detector. To overcome this, the flight path of 
the ions is kept at a vacuum and the strength of vacuum required depends on the 
length of the flight path. For example, a quadrupole with a path length of 10 cm will 
not need as high a vacuum as a triple quadrupole with a path length of 40 cm, or a 
TOF with a path length of 1 m. If the vacuum is insufficient, the number of ions 
reaching the detector will be reduced and the signal attenuated. (Scripps Cente for 
metabolomics, 2013) 
Most systems will have a combination of pumps, usually consisting of a rough pump 
that is external to the instrument and one or more turbopumps inside the mass 
spectrometer. Turbopumps can produce the very low vacuums of 10-5 torr needed for 
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mass spectrometry, but must have a rough pump to reduce the pressure before they 
can work efficiently. The rough pump can pump down from atmospheric pressure to 
around 10-3 torr (Scripps Cente for metabolomics, 2013). 
The pumping capacity of these vacuum pumps will also determine what type of 
hyphenated techniques are suitable. A capillary GC system will deliver typically a few 
millilitres of helium gas per minute to an EI source and the vacuum pump only needs 
to be sufficient to form and maintain a vacuum at this level. An identical instrument 
set up for CI will need a larger vacuum pump, as the pump will need to remove the 
reagent gas from the source as well as the carrier gas. To operate a similar source 
for an HPLC system would be impractical, as a few millilitres of solvent would expand 
to a litre or more of vapour even at room temperature (18 g of water will expand to 25 
L at Standard temperature and pressure). To allow the use of HPLC, the solvent is 
evaporated at atmospheric pressure in ESI, APCI and APPI sources and the ions are 
formed in this atmospheric pressure region of the source (Scripps Centre for 
Metabolomics and Mass Spectrometry). A series of ion lenses then channels the ions 
into a narrow opening, often known as the capillary, that draws the ions into the low 
vacuum area of the mass spectrometer. A large vacuum pump is still required, but 
this now only needs to remove an atmospheric pressure gas flow, rather than a 
significant solvent vapour flow. 
1.6.5.9 Detectors 
Photographic plates are no longer the method of choice for recording a mass 
spectrum. Instead electronic detectors, more sophisticated than the Faraday Cups 
used on the very early mass spectrographs, are generally used. Often these are 
crystals that will emit an electron when struck by an ion. These electrons are then 
amplified in an electron multiplier tube before striking an anode to generate a current. 
There are a number of different systems in use, for example the electron multiplier 
used in Thermo triple quadrupoles uses a series of dynodes, each held at a higher 
voltage than the last. Electrons therefore cascade from one dynode plate to the next 
until there are sufficient electrons to generate a signal at the anode that can be 
amplified electronically.  
The systems produced by manufacturers such as Agilent use a continuous electron 
multiplier, where there is a single physical electrode that is cone or cup shaped. The 
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material the electrode is made of has a high resistance, so a potential applied at the 
front increases towards the anode, allowing electrons to be multiplied as they pass 
through the electron multiplier. When thought of as a continuous series of circular 
dynodes of increasing voltage, the similarities with a dynode series is easier to 
recognise (see Figure 1.15). 
 
Figure 1.15  Comparison of the structures of discrete and continuous dynode electron multipliers (Gates, 
2004) 
In some systems, a microchannel plate detector (MCP) is used to detect and amplify 
the signal. This sort of detector is a flat plate that contains hundreds of microscopic 
channels running through the plate. Each microchannel is a miniature continuous 
dynode electron multiplier and often two or more microchannel plates are arranged in 
series. This design is particularly suited to applications where spatial resolution of the 
ions is required and in magnetic sector instruments this means that a range of m/z 
values can be recorded simultaneously, making the MCP detector analogous to a 
Diode Array Detector or photographic plate. 
In some instruments, particularly MALDI-TOF systems, the initial dynode material is a 
scintillator that will emit a photon instead of an electron when struck by an ion. This 
photon is then detected in a photomultiplier tube, which is an electron multiplier with 
a scintillation detector ahead of the first dynode. Although the extra stage may 
appear to reduce the efficiency of the detector, this arrangement is several times 
more efficient than the MCP detector (Li, Tsai, Chen, Chen, Lee and Wang, 2007). 
Orbitrap systems and ion cyclotron resonance mass spectrometers both measure the 
ions directly without the need to convert the ion into an electron for detection. In 
these systems, the ions are accelerated around a cavity or spindle and the 
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movement of the ions is analogous to an electric current. This current varies as the 
ion’s energy dissipates and the changing current induces a measureable current in 
adjacent electrodes. This current can then be amplified electronically, although it 
must be subjected to a Fourier Transform algorithm to identify the masses detected 
(Perry, Cook and Noll, 2008). 
1.6.6. Mass spectrometer scan types 
Once the ions are inside the mass spectrometer, the ion may be measured directly 
and a signal recorded. For chemical ionisation and LC-MS, the output will be a 
molecular ion scan, normally referred to as a parent ion scan. For EI and other hard 
ionisation techniques, the output will be a mass spectrum comprising all of the 
fragments produced in the source. A variant of this is where a single ion is recorded, 
known as selected ion monitoring (SIM). For quadrupoles, this increases the 
sensitivity significantly, but for all other mass selectors the sensitivity gain is much 
less (ion traps) or absent (TOF and orbitrap). Several different SIM transitions can be 
monitored sequentially in a scan cycle, but the data obtained is much more limited 
than for full scans (Mellon, Self and Startin, 2000). 
If using tandem mass spectrometry, there are more options depending on the 
settings of the first and second mass spectrometers and the collision cell and the 
type of source. It is easiest to understand using a triple quadrupole, although the 
same types of scan can be done with other systems (de Hoffman, 1996). 
1.6.6.1 Collision cells 
Collision cells are often quadrupoles or hexapoles, although ion traps and other 
designs of collision cell are available. Generally the collision cell is filled with a low 
pressure gas, which varies according to the instrument and manufacturer. This gas is 
frequently helium, argon or nitrogen. Collision induced dissociation (CID) is produced 
by the excitation of ions within the collision cell, giving an increased kinetic energy. 
The ions then hit the collision gas and break into fragments. The degree of 
fragmentation can be controlled by varying the collision gas pressure, the time of the 
excitation cycle or the amplitude of the excitation. Fragmentation is frequently 
optimised for each analyte to try to increase the amount of information obtained. For 
example, an ion trap instrument generally only excites a narrow target mass range. 
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On the Thermo’s LCQ Fleet it is possible to use wideband activation, which increases 
the excitation window from 3 amu. to 20 amu. In this way, ions that preferentially lose 
water or a methyl group will be forced to fragment further, giving additional structural 
information. Similarly in some SciEx instruments the collision energy can be 
increased in stages to produce additional fragments and therefore a more 
characteristic mass spectrum. 
1.6.6.2 Product ion scan 
In a product ion scan, the first quadrupole is operated in SIM mode and the third 
quadrupole is set to scan (see Figure 1.16). This will produce a spectrum similar to 
that produced by EI, but since all of the fragments are derived from the parent ion, 
there will be less interference than in EI. This type of scan is possible with all tandem 
mass spectrometers, although the scan rate of a quadrupole or orbitrap mean that 
the cycle time is relatively long compared with an ion trap or TOF instrument. Product 
ion scans can give very good information about the parent ion, as the parent ion 
mass and all fragment ion masses are known. Since the fragments form an almost 
unique fingerprint of the analyte, this type of scan is very good for identifying 
unknown substances against a library of known spectra.  
 
Figure 1.16 Diagrammatic representation of product ion scan (de Hoffman, 1996) 
1.6.6.3 Parent ion scan 
A parent ion scan is the opposite of the product ion in that the first quadrupole is set 
to scan and the third quadrupole is fixed on a particular mass, usually a lower mass 
than in the scan (see Figure 1.17). This scan is used to identify parent ions where the 
fragment is known, for example where there is a known side chain, adduct or 
derivative but the parent is unknown. Parent ion scans are only possible where the 
first mass analyser is continually scanning (tandem in space), meaning that it is not 
possible to do a parent ion scan in an ion trap or a TOF-TOF instrument. In an 
instrument that uses a full scan second mass analyser, such as an orbitrap, TOF or 
ion trap, the cycle time of the second mass analyser may reduce the scan speed of 
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the first mass analyser. Parent ion scans are therefore best performed with triple 
quadrupoles. 
 
Figure 1.17 Diagrammatic representation of a parent ion scan (de Hoffman, 1996) 
1.6.6.4 Selected reaction monitoring 
One of the most common types of scan on a triple quadrupole is called selected 
reaction monitoring (SRM) where both quadrupoles are set to fixed values (see 
Figure 1.18). If several different SRM transitions are monitored sequentially, this is 
sometimes known as multiple reaction monitoring (MRM). In SRM, a known ion 
enters the collision cell and is fragmented. The fragments then enter the third 
quadrupole which is set to allow only a known fragment mass to pass. This is the 
tandem mass spectrometer equivalent of SIM and offers the greatest sensitivity of 
any hyphenated tandem technique. MALDI-TOF instruments can reach lower 
detection limits, but generally are not hyphenated with chromatographic systems and 
do not generally provide continuous data. 
 
Figure 1.18 Diagrammatic representation of selected reaction monitoring (adapted from de Hoffman, 
1996) 
1.6.6.5 Neutral loss scan 
In a neutral loss scan, the MS is operated in parent ion scan mode, but instead of 
monitoring a fixed fragment, the third quadrupole is also set to scan (see Figure 
1.19). Both quadrupoles scan at the same rate, so that the mass difference between 
them remains constant. This technique only identifies parent ions that produce 
fragments in the same manner, losing the same uncharged mass. This is particularly 
useful in metabolic monitoring, as it allows the identification of known derivatives and 
conjugates: a signal will be generated when a conjugate, such as glucuronic acid, is 
removed from any parent ion in the collision cell. 
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Figure 1.19 Diagrammatic representation of a neutral loss scan (de Hoffman, 1996) 
A continuous neutral loss scan is not possible with an ion trap LC-MS or other 
tandem-in-time instrument (de Hoffman, 1996), although neutral losses may be 
identified by subtracting the mass fragments obtained from the parent ion. An 
advantage of this over a neutral loss scan is that a number of different neutral losses 
may be simultaneously identified. 
1.6.6.6 Multi-level mass spectrometry  
Systems that include an ion trap as one of their mass selectors also have another 
mode that can be used. In multi-level mass spectrometry MSn, the fragments are 
retained in the ion trap after the collision and instead of being scanned out to produce 
a spectrum, most are ejected, retaining a single fragment. This fragment can then be 
fragmented further and its product used to produce an MS3 spectrum (see Figure 
1.20). This method can produce a very high degree of confidence in the identity of 
the initial molecular ion, at the expense of a loss in sensitivity. In some systems, this 
process can be theoretically repeated up to ten times to produce MS10, although this 
is less common and is generally used for structure elucidation studies. 
 
Figure 1.20 Diagrammatic representation of an MS3 scan (adapted from de Hoffman, 1996) 
1.6.7. Ion suppression 
One of the difficulties with mass spectrometry is a phenomenon known as ion 
suppression. As already shown, analytes must be ionised to enter and be detected 
by the mass spectrometer. Anything that reduces the efficiency of the ionisation will 
therefore reduce the number of ions entering the mass spectrometer and therefore 
reduce the signal produced. 
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Ion suppression can happen in a number of ways. Perhaps the easiest to understand 
is the physical process of evaporation. In an LC-MS, the mobile phase must be 
evaporated to leave the analytes as gaseous phase ions. If not all of the mobile 
phase is evaporated, it follows that any analytes that remain in the liquid mobile 
phase will not be able to enter the mass spectrometer (Annesley, 2003). This is 
particularly noticeable when comparing highly aqueous mobile phases with organic 
phases. Water requires more heat to evaporate than, for example, acetonitrile, and 
analytes in an aqueous mobile phase will therefore have lower ionisation efficiencies 
than those in an organic solvent.  
Another common method of ion suppression is found where there are different 
molecules present in the mobile phase. Phosphates are well known as being some of 
the worst salts when it comes to ion suppression and many methods use an 
extraction to remove phosphates (Debets, Mekes, Ritburg and Jacobs, 1995). The 
phosphate ion is very stable and will accept a charge in preference to analytes. Ion 
suppression by phosphates is a major problem with transferring HPLC methods to 
LC-MS, as phosphate buffers are very common with HPLC analysis. 
There are a number of ways of reducing ion suppression and it is common to employ 
a mixture of techniques. Most ion suppressing substances, especially salts, can be 
removed by one of the sample preparation techniques described above, whether 
simple dilute and shoot or on-line SPE systems. Much ion suppression is evident on 
certain sections of a chromatogram, such as following the injection solvent front. 
Good HPLC separation and method development can eliminate this by adjusting the 
relative retention times of the analytes and ion suppression (Annesley, 2003). In 
some systems, an organic solvent is added to the column eluent prior to the MS 
source. This increases the volatility of the mobile phase and therefore the proportion 
of solute ions in the vapour phase. The reduction of ion suppression has been quoted 
as a reason for using APCI or APPI instead of electrospray for an analysis (Keski-
Rahkonen, et al., 2013). 
1.6.8. Data dependent scanning and survey scans 
Until the advent of powerful computers and software for controlling mass 
spectrometers, most mass spectrometer methods used the same acquisition 
parameters throughout a segment of an analytical run. This results in a lot of 
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background data without significant peak information. In complex methods, the 
number of MRM transitions either limit the number of analytes that can be analysed 
simultaneously within the same section of chromatogram or leads to shorter dwell 
times to try to fit more transitions per cycle. As computers became powerful enough 
to process analytical data during the acquisition, this allowed acquisition processes to 
be defined based on the results of a previous scan. Different manufacturers have 
different approaches to this, resulting in triggered MRM (tMRM) (Agilent), Information 
Dependent Acquisition (SciEx) and Data Dependent Scans (Thermo). 
The Agilent tMRM system allows a series of additional MRM transitions to be 
performed if the signal of a specified transition exceeds a threshold. In this way, a 
more complete spectrum can be obtained of an analyte following its detection in a 
single MRM. Instead of acquiring full scan data throughout the run, the additional 
data is only collected when a defined peak is present.  
The Thermo Data Dependent Scanning (DDS) is more flexible than this, allowing any 
defined scan to be triggered following rules in the acquisition software. This has led 
to the use of a “survey scan” where a full scan is performed without any 
fragmentation to identify molecular ions, followed by an MS2 or other scan on any 
identified peaks. Further, the Thermo software can also trigger scan events based on 
the findings of an MS2 or other scan, such as performing an MS3 scan if an MS2 
signal exceeds a defined threshold.  
The Information Dependent Acquisition (IDA) feature of modern SciEx systems 
operates in a similar way to Thermo’s DDS, able to perform a MS survey scan and 
then trigger an MS2 scan based on the results. 
A library search in October 2013 (Web of Science, search terms Topic = toxicology 
AND (“information dependent acquisition” OR “data dependent scan” OR “survey 
scan”) for toxicology papers quoting either Information Dependent Acquisition or Data 
Dependent Scanning or Survey Scan shows a total of only 40 references. Most of 
these papers are reviews and articles on new trends, showing that these new data 
processing methods are entering routine use.  
One of these papers used a desorption electrospray ionisation source without 
chromatography (Nielen, Hooijerink, Claassen, van Engelen and van Beek, 2009) 
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and two papers described methods that were targeting a single drug and its 
metabolites.  A further 14 papers were for multiple drug testing methods, using 
predominantly Information Dependent Acquisition from SciEx, six using the hybrid 
quadrupole-ion trap and five using triple quadrupoles. The remaining three papers 
used a SciEx quadrupole-TOF, an orbitrap and a Thermo LXQ ion trap.  
The power of Data Dependent Scanning is that a relatively large number of analytes 
can be screened with a survey scan, allowing specific MS2 scans to be targeted at 
potential peaks. This reduces the amount of uninformative data collected, allowing 
the instrument to collect more useful data. This can be seen by the fact that most of 
the papers are for at least 20 drugs, with one performing automated library searches 
for over 1000 analytes (Martínez Buenoa, Ulaszewskaa, Gomez, Hernando and 
Fernández-Albaa, 2012). None of these methods use on-line extraction, MS3 scans 
and neutral loss experiments. 
1.7. Previous clinical method 
The previous method was developed by the author in 2002 and consisted of a solid 
phase extraction using Screen C SPE columns from Phenomenex. After an overnight 
hydrolysis with β-glucuronidase, sample (3 mL) was loaded onto an SPE column 
previously wetted with methanol and conditioned with an acetate buffer (pH 5). After 
drawing through under vacuum, the columns were washed with deionised water and 
phosphate buffer (pH 6.8) before being eluted with a 
dichloromethane:isopropanol:ammonia (70:28:2 v/v/v) solvent. The resulting eluent 
was dried down under a stream of air in a hotblock (60 °C)and the residue 
resuspended in methanol before spotting 2 cm from the bottom of a 10 cm TLC plate. 
The developing solvent was ethyl acetate:methanol:ammonia mixture (85:15:2 v/v/v) 
and was equilibrated for at least 30 minutes before the plate was developed. After 
drying the plate was stained with a solution of hexa-chloroplatinate and potassium 
iodide (iodoplatinate stain) and the interpretation of the presence of drugs was made 
by an experienced senior clinical biochemist or biomedical scientist after keeping the 
plate in the dark overnight. An assessment of the sensitivity demonstrated a limit of 
detection of around 1500 ng/mL morphine and benzoylecgonine and around 500 
ng/mL methadone and EDDP (unpublished laboratory data). 
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This method was suitable for use when used to assess the illicit drug use of patients 
from the addictions in-patient unit and community drug teams, but only when 
combined with an immunoassay primary screen. The poor limits of detection made 
this method unsuitable for diagnosis of illicit drug use in an unselected population 
and the three day turnaround is too slow for most acute medicine.  
In addition to taking 3 days to produce a result, the TLC part of the method was 
technically demanding and depended significantly on the skill of the scientist applying 
the samples to the TLC plate. The interpretation was subjective and although 
repeatability was good, results would occasionally differ depending on the person 
reading and interpreting the plate, in particular on the presence or absence of small 
amounts of codeine. 
It was also desirable to reduce the amount of solvents in the laboratory, especially 
the chlorinated solvents (dichloromethane). Dependent on the batch size, this 
method would generate around 50 – 100 mL of chlorinated solvents and 100 mL of 
non-chlorinated solvents each day. The iodoplatinate staining solution is also 
hazardous, with halogenated platinum salts causing skin sensitisation and being on 
the Health and Safety Executive’s EH40 list of maximum exposure limits. 
An advantage of the TLC approach was that any drug extracted by the SPE 
cartridges and reacting to the stain was visible on the plate. This meant that drugs 
such as propoxyphene could be easily identified without requiring additional 
processing or additional standard solutions. However, this also meant that there were 
a large number of unidentified spots on the TLC plate. Occasionally, the intensity and 
positioning of these spots prevented the accurate interpretation of compounds of 
interest, particularly when patients were on a number of antibiotics and 
antidepressants. 
As other laboratories around the country improve their sensitivity, the external quality 
assessment scheme looks to meet their expectations. This includes the lowering of 
the scheme thresholds for the identification of drugs. At the outset of this project, the 
clinical threshold for the detection of morphine was 1500 ng/mL, but the current 
threshold for morphine is 300 ng/mL (LGC Standards Proficiency Testing, 2013). 
Without changing the method to improve its limit of detection, the laboratory would be 
receiving false negative reports for morphine.  
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The TLC part of this method had been in widespread use for many years when the 
laboratory was based at Bethlem Royal Hospital and there was limited scope for 
improvements. Further information could be obtained by the use of sequential 
staining steps and resolution could be improved by the use of an automated TLC 
applicator system and HPTLC. This would have increased either the time taken to 
produce a result, the cost of analysis, or both, and neither of these options are 
desirable in a laboratory that is looking to reduce its costs and improve the service it 
gives to its customers. As a result, it was decided that this method had reached the 
end of its usefulness. 
In 2007, King’s College Hospital acquired the toxicology laboratory at Bethlem and 
transferred it to new premises at KCH in 2008. A new consultant toxicologist was 
appointed and new areas of analysis considered. As part of this, it was decided to 
purchase two LC-MS systems, one for drugs of abuse and one for therapeutic drugs. 
1.8. Aims and objectives 
1.8.1. Aim 
The principal aim of this project was to develop an automated LC-MS method for 
clinical drugs of abuse testing 
1.8.2. Objectives 
The following objectives were defined and agreed with the University of Portsmouth 
at the outset of the project. 
• Develop a Turboflow® liquid chromatography method giving suitable extraction 
and separation of the opiate and amphetamine classes of drugs.  
• Develop an ion trap MS procedure to reliably identify opiate and amphetamine 
class drugs 
• Evaluate the LC-MS method developed for detection of synthetic opioids (e.g. 
methadone, buprenorphine) and cocaine metabolites, with other analytes that 
are required by the laboratory service 
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• Introduce the methodology into routine use within the laboratory, providing 
sufficient training to staff to allow continued operation and understanding 
• Consult with the local drug addiction specialists to provide a drugs of abuse 
service that meets their current and future needs 
In November 2009, a new job opportunity meant that the practical aspects and 
objectives of the project had to be reduced, specifically the final introduction of the 
method, staff training and evaluation in consultation with the local drugs of abuse 
services. The author left KCH in January 2010 before the method had been 
completed and discussions with the course leader and departmental supervisors 
resulted in the scope of the project being extended back to the originally developed 
online SPE method, including the introduction and evaluation of this method. The 
SPE method was an integral part of the development of the final Turboflow® method 
and demonstrates the full method development and improvement program, as well 
as the introduction of the method into routine laboratory processes. 
1.8.3. Clinical justification 
The work involved in a project such as this is significant and unless there is a real 
clinical justification for expenditure of time and resources, the project is a purely 
academic exercise. While this may be a worthy aim, this does not fall within the remit 
of the professional doctorate course, which has as a central aim that the work should 
be of real clinical value. 
There are several reasons why development of these methods is justified for the 
Toxicology Unit at King’s College Hospital: 
• Anticipated reduction in time taken in obtaining a result, leading to more 
efficient use of staff time and resources. This should also lead to a reduction in 
turn-around time, leading to a better laboratory service and one that is more 
able to attract further work from other sources 
• Reduction in the use of hazardous solvents, leading to reduced risk and 
reduced solvent disposal costs 
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• Increased range of analytes available for testing, with an increased accuracy 
and precision. Improvement to laboratory standards elsewhere would lead to 
the Toxicology Unit lagging behind other service providers if no improvements 
were made. 
• Increased availability and use of up-to-date technology such as LC-MS and 
Turboflow® are of particular benefit to a laboratory in a teaching hospital which 
regularly accepts students and placements from other laboratories worldwide. 
1.8.4. Contribution to the knowledge base 
Both online extraction with LC-MS and Turboflow® are methods lacking literature in 
the clinical environment. Many of the published methods are for single drug groups, 
whereas most of the multi-drug methods use either dilute-and-shoot or offline 
extraction. The only Turboflow® methods identified were published after the 
completion of the method development and required an offline hydrolysis step. 
Combination of these two areas would be an important addition to the literature. 
While this method is aimed at clinical drugs of abuse in urine testing, the principles 
also hold true for almost any matrix and the results of the thesis could be of use to 
researchers and routine laboratories looking at tests in matrices such as saliva, 
blood, tissue homogenates and non-clinical matrices. A degree of additional sample 
preparation will be needed for matrices with a solid or particular component (such as 
whole blood or hair samples), but the principles hold true. 
The uniqueness of a project is difficult to assess, partly due to the commercial 
sensitivity that many laboratories are required to observe. Where this project is likely 
to be unique is in the combination of the fully automated sample preparation featuring 
online SPE and Turboflow® extraction to an ion trap LC-MS, giving a very high 
degree of accuracy in the identification of drugs. The project is also likely to be 
unique in the use of neutral loss scans to identify and then produce an MS3 spectrum 
of glucuronide metabolites in urine, an approach that is difficult with the more 
common triple-quadrupole and accurate mass instruments and has not been 
published using Turboflow® sample preparation. 
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2. Reagents and equipment  
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2.1. Hardware 
The mass spectrometer used throughout was an ion trap mass spectrometer (LCQ 
Fleet) from Thermo Fisher Scientific (Hemel Hempstead, UK), with a nitrogen 
generator (Peak, Scotland) supplying the source gases and a helium cylinder (BOC 
Speciality Gases, Guildford, UK) for the ion trap. This is an entry level ion trap system 
with an Ion Max ion source that can be used in both ESI and APCI modes. It is 
controlled by Thermo’s Xcalibur software, which also performs the data analysis and 
integration. An additional option was the ToxID (version 2.0) software from Thermo 
which is intended as an automated drug identification and reporting system.  
Two different HPLC systems were used during the development process. Initially a 
Jasco XLC system was used (Great Dunmow, UK), comprising two high pressure 
pumps (XLC-3185PU), a mixer unit (XLC-2080-32MX), autosampler (XLC-3159AS), 
degasser (XLC-2080-54DG) and column oven (XLC-2067CO). This was controlled by 
EZChrom software (Agilent) running on the same PC as Xcalibur.  
The second HPLC system used was the Turboflow® system from Thermo (Hemel 
Hempstead, UK). This comprised a CTC Combi PAL autosampler system with cooled 
sample trays and dual injector ports, an Agilent G1312A binary HPLC pump (Agilent, 
Wokingham, UK), an Agilent G1311A quaternary HPLC pump,G1379 degasser and 
the Turboflow® valve module. This system was controlled by Aria software (Thermo), 
again running on the same PC as Xcalibur.  
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2.2. Consumables 
Table 2.1 Parts and consumables used during the method development 
Supplier Part Part Number Description 
Thermo Fisher 
Scientific  
HPLC column 25405-052130 50 x 2.1 mm 5 
µm PFP 
 Guard Cartridges 25405-012101 
(Pack of 10) 
Hypersil Gold 
PFP 5 µm 
Phenomenex 
 
Online SPE 
column 
25405-052130 Strata X (50 x 
2.1) online SPE 
column 
 Membrane filters Nylon 66 AFO-
0504 
0.45 µm HPLC 
solvent filters 
Esslab HPLC crimp vials 5181-3375 HPLC crimp vials 
 Crimp caps 5818-1210 Crimp caps 
 
Parts and consumables (see Table 2.1) were purchased from existing suppliers and 
all were paid for without any influence on this project either implied or offered. A 
variety of Turboflow® columns were tested, all from Thermo (see Table 2.2) 
Table 2.2 Turboflow® Column Part Numbers 
Designation Part Number 
C18 953280 
C8 952819 
Phenyl 953278 
Cyclone 953288 
Cyclone-P 952605 
Cyclone MAX 952980 
Cyclone MCX 953287 
MCX: mixed cation exchange, MAX: mixed anion exchange 
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Pipettes and pipette tips were supplied by Esslab (Essex, UK) 
Volumetric flasks, class B, obtained from VWR International (Leicester, UK) 
Mobile phase filtration apparatus (vacuum pump, vacuum flask, sintered funnel) was 
used to filter all solvents and supplied by VWR International (Leicester, UK) 
A glass 500 µL syringe (Hamilton, UK) was used for infusion of standard solutions to 
the LC-MS for tuning purposes. 
2.3. Reagents 
Deionised water was used from an ELIX35 deioniser (Millipore, UK). 
Other reagents (see Table 2.3) were in general use within the laboratory. 
Table 2.3 Reagents and Solvents used During the Method Development 
Supplier Chemical Part number  
Fluka, Sigma-
Aldrich Co. 
(Poole, UK) 
Formic acid 94318  
Ammonium 
formate 
70221  
Rathburn 
(Walkerburn, 
Scotland) 
Acetonitrile RH1016 HPLC Grade 
Methanol RH1019 HPLC Grade 
VWR 
International 
(Leicester, UK) 
Acetic acid  Concentrated 
(Glacial) 
2.3.1. Reagent preparation 
2.3.1.1 Ammonium formate  
Ammonium formate (1 mol/L) was prepared by dissolving of ammonium formate 
(10.61 g) in deionised water (~150 mL) and made up to 200 mL with deionised water 
in a volumetric flask, refrigerated for storage. 
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2.3.1.2 Mobile phase A  
Mobile phase A was prepared by adding of formic acid (1 mL) and ammonium 
formate (10 mL, 1 mol/L) to deionised water (~900 mL), then made up to 1 L with 
deionised water in a 1 L volumetric flask. Formic acid must always be added to water 
to so that the weak dilution releases a small amount of heat which is insufficient to 
vaporise and splatter the acid. The mobile phase was filtered before use using the 
HPLC eluent filtration apparatus. 
2.3.1.3 Mobile phase B  
Mobile phase B was prepared by adding formic acid (1 mL) to acetonitrile (1 L) in a 
volumetric flask (1 L). The mobile phase was filtered before use using the HPLC 
eluent filtration apparatus. 
2.4. Standards and controls 
Reference standards (see Table 2.4) were all purchased from approved commercial 
suppliers. 
Table 2.4 Reference standards and control materials used during method development 
Supplier Material Part 
Number 
LGC Standards 
 (Teddington,  
UK) 
(LGC 
Promochem at  
the time of  
ordering) 
1mL of 6-Acetylmorphine (1.0 mg/mL) in acetonitrile 
6-Acetylcodeine (1.0 mg/mL) in acetonitrile 
Codeine (1.0 mg/mL) in methanol 
Codeine-6-glucuronide (0.1 mg/mL) in 
water/methanol (80:20 v/v) 
Heroin (1.0 mg/mL) in acetonitrile 
Morphine (1.0 mg/mL) in methanol 
Morphine-3β-D-glucuronide (1.0 mg/mL) in methanol 
Morphine D6 (1.0 mg/mL) in methanol 
CERA-009 
CERA-053 
CERC-006 
CERC-08 
 
CERH-038 
CERM-005 
CERM-031 
CERM-086 
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BioRad Urine Toxicology Controls (Negative, C2, C3 and C4) were used throughout 
the project. Drug levels in controls were determined gravimetrically by the supplier 
and quoted in the kit insert (see Table 2.5) 
Table 2.5 Drug concentrations in QC materials 
QC Material  
(Part Number) 
Morphine-3-
glucuronide (ng/mL 
free morphine) 
Codeine 6-mono-
acetylmorphine 
C2 
(442) 
1500 1500 10 
C3 (low opiate) 
(469) 
375 375 10 
C4 
(444) 
4000 4000 20 
 
2.4.1. Preparation of standard solutions 
Standard solutions were prepared by dilution of primary standard solution (1 mL) to 
10 mL in methanol in volumetric glassware. Working standards were then prepared 
by addition of 1 mL of this intermediate standard to a 20 mL volumetric flask and 
filling to the mark with blank urine (BioRad Negative control). Working standards 
were transferred to 25 mL plastic bottles and stored refrigerated for up to 1 month. 
2.5. LCQ Fleet overview 
The LCQ Fleet is an entry level ion trap mass spectrometer, capable of operating in 
ESI or APCI modes. It uses the Ion Max-S source housing, which has an angled 
spray head directing the sample spray towards the ion transfer capillary. This is 
heated to around 300 °C and assists in the desolvation of the ions. The exit of this 
capillary is through the centre of the Tube Lens, which focusses the ions towards the 
skimmer. The capillary is set off-centre to the skimmer, so that any neutral species do 
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not enter the high vacuum area of the mass spectrometer. This area is maintained at 
approximately 1-2 torr and the skimmer is held at approximately 0 V, giving a voltage 
gradient of 3500 – 4000 V from the electrospray needle. Two Quadrupoles and an 
octopole then guide the ions into a Quadrupole Ion Trap, consisting of a ring 
electrode and two endcap electrodes. This is held at around 3 x10-3 torr and -10 V. 
Ions exit the trap through a hole in the centre of the rear endcap electrode and are 
attracted to the dynode, typically held at -15,000 V. 
A schematic diagram of the ion optics (see Figure 2.1) shows the ESI source to the 
left, ion capillary in yellow and the ion trap on the right between the two horizontal 
blue lines. 
 
Figure 2.1 Schematic arrangement of the LCQ Fleet Ion optics (Xcalibur screenshot) 
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3. Method development 
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Development of a method from first principles requires significant time and routine 
working laboratories such as King’s College Hospital often cannot justify this. It is 
therefore simpler to use a published method as a starting point and to modify it where 
it is unsuitable (see Table 3.1). As part of the procurement of the LC-MS, the 
laboratory received a Gold PFP column and a copy of Thermo Application note 409 
(Rezai, Kozak and Torchlin, 2007). This application is intended as an unknown drug 
screen on an ion trap following offline solid phase extraction, using the PFP column 
supplied and an acetonitrile-formate buffer mobile phase. The method focusses 
predominantly on the Thermo LXQ LC-MS system, but also gives some details for 
the LCQ Fleet.  
Table 3.1 HPLC solvent conditions from Thermo Application Note 409 (Rezai, Kozak and Torchlin, 2007) 
Time %A %B Notes 
0 95 5 Sample injection 
0.5 95 5 Gradient start 
5.5 5 95 Gradient end 
8.5 5 95  
8.6 95 5 Re-equilibrate 
13 95 5 End run 
 
The method was tried initially using aqueous standards without sample preparation to 
help validate the method. This worked well when the system had been allowed to 
equilibrate, but the retention times were wildly different from those quoted and when 
sequences of more than one sample were run, the second and subsequent samples 
gave no results. Investigation of the reasons for this identified the mixer as having a 
volume of 2 mL. With a flow rate of 200 µL/minute, this meant that the column was 
still full of acetonitrile when the second injection was made and the retention was 
virtually nil. Changing the mixer volume to 50 µL and ensuring equilibration between 
runs solved the reproducibility problem and produced retention times similar to those 
predicted by the application note. 
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3.1. Sample preparation 
Having identified suitable LC conditions, the next step was to look at sample 
preparation. The simplest sample preparation methods for LC-MS are direct injection 
and dilute and shoot. Both were tried using a high control (BioRad C4) with very poor 
results.  
3.1.1. Direct injection 
Direct injection produced good results for some of the later eluting drugs, such as 
methadone, but was unable to detect even quite high levels (4000 ng/mL) of 
morphine, however much sample was injected up to the maximum 100 µL that the 
autosampler allows. Investigation of this identified ion suppression as having a very 
significant effect, with maximum ion suppression at the same time that morphine was 
expected. Most ion suppression in this matrix is due to salts in the urine, which are 
unretained on a PFP column. The retention of morphine glucuronide is very short and 
overlapped the area of ion suppression. 
Since this method of sample preparation is quickest and cheapest, some effort was 
spent to try to reduce or eliminate the ion suppression. A solution of morphine was 
either injected as a sample or infused into the column outflow using the LCQ Fleet’s 
integrated syringe driver and the ion intensity plotted as blank urine samples were 
injected. This gave a chromatogram trace showing the inverse of the proportion of 
ion suppression i.e. maximum signal at minimal ion suppression. The trace seen 
approximated the trace found when an LC column is overloaded and it was thought 
that by increasing the analyte retention it could be separated from the ion 
suppression. Analyte retention is governed by a number of factors and each of these 
was adjusted to try to remove ion suppression. A 100% aqueous mobile phase, not 
compatible with most reversed phase columns but compatible with the PFP column, 
increased the retention slightly, as did using a slightly lower flow rate. However, the 
greatest effect came from reducing the column temperature to 4 °C, the minimum 
that the column compartment could cool to. Using drug free urine, the morphine 
glucuronide peak was delayed long enough to be mostly resolved from the ion 
suppression. However, further tests with more urine samples showed that the ion 
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suppression varied considerably from sample to sample and reliable reproducible 
results could not be obtained.  
3.1.2. Dilute and shoot technique 
Sample dilution (also known as dilute and shoot) is commonly used in mass 
spectrometry to reduce the effects of ion suppression. Both the signal and the ion 
suppression are reduced by the dilution, but the effect on the ion suppression is 
greater than the loss of signal, leading to an increased signal to noise ratio, and 
therefore increased sensitivity. This works well with triple quadrupole instruments, but 
is less so with ion traps which are less sensitive (see p.34). Although the signal to 
noise ratio is increased, the absolute signal intensity is still below that required for 
reliable detection of drugs near to the required threshold levels. The decision was 
therefore taken that some form of sample preparation was required.  
3.1.3. Liquid-liquid extraction 
Having established that some form of sample preparation is needed, the simplest to 
perform technically is a liquid-liquid extraction, or LLE. Liquid-liquid extraction relies 
on the immiscibility of the matrix (aqueous) with an organic solvent. Salts, proteins 
and ionised molecules are unable to cross from the ionic aqueous phase to the non-
polar organic phase. Usually the organic phase is removed from the tube and 
concentrated, separating the analytes from the matrix. 
Selectivity can be enhanced by adjusting the pH so that the analyte of interest is 
uncharged and therefore crosses into the organic phase. Improved selectivity can 
then be managed by isolating the organic phase in a fresh tube and adding an 
aqueous buffer with a different pH to the original extraction. The newly ionised 
metabolites cross back into the aqueous phase, leaving other non-polar analytes in 
the organic solvent. This back extraction process can give good selectivity, but works 
best when a single analyte group is to be isolated, for example it may extract 
amphetamines but not opiates.  
A simple extraction in either chloroform or dichloromethane was used regularly in the 
laboratory prior to 2003, but there are some drawbacks which make it less suitable 
for regular routine use.  
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Many of the solvents that are immiscible with water are harmful, such as chloroform, 
dichloromethane and hexane. In addition, since they are not miscible with water, they 
cannot be disposed of down the drains and must be collected and disposed of via a 
chemical waste management company. Other suitable solvents, such as methyl tert-
butyl ether (MTBE) are less hazardous than chloroform but may still cause difficulties 
with disposal.  
One of the main reasons that LLE was decided against is that it is frequently difficult 
to automate, which was a significant part of the aim of the project. Automated 
instrumentation cannot easily identify the phase boundary of immiscible liquids, 
which means that pipetting of the organic phase containing the extracted analytes 
must be done manually. If the mobile phase is largely aqueous, the organic phase 
must also be evaporated before analysis, adding an additional step, and if the phase 
boundary is not clear a centrifugation step may be required.  
A recent development has been the introduction of Supported Liquid Extraction (SLE) 
where a syringe barrel contains an absorbent support, such as Fuller’s earth. The 
aqueous sample is completely absorbed on the sorbent and the organic phase is 
added to the top. On elution the analytes cross to the organic phase in the same way 
as in LLE and the organic phase is then collected and the solvent removed. 
However, as for SPE (see below), the aim of reducing hands on time for the analysis 
is not achieved. 
3.1.4. Solid phase extraction 
The logical sample preparation method to use would be off line solid phase 
extraction. This technique was being used for the existing routine method, so would 
have required minimal staff training and would have led to a simpler introduction 
process. However, part of the reason for moving away from the existing method was 
to reduce hands on time, increase automation and reduce the use of chlorinated 
solvents in the laboratory.  
Phenomenex have developed a re-usable SPE cartridge that can be fitted into an 
HPLC system to facilitate online sample extraction. This cartridge contains 20 mg of 
a polymeric sorbent reversed phase with a large particle size of round 50 µm, 
generating very little back-pressure. This reversed phase SPE cartridge can be fitted 
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in series with an HPLC column and a divert valve. During the sample loading cycle, 
the SPE eluent is diverted to waste, removing the salts and proteins causing ion 
suppression. When the divert part of the cycle is complete, the valve can be switched 
and the remaining flow analysed on the mass spectrometer. Alternatively, the 
cartridge can be fitted on a loop in a 6-port 2-way valve in the same way that a 
sample loop is normally connected. As for the in-line arrangement, the sample is 
loaded while the flow is diverted to waste. When this cycle is complete, the valve is 
switched, reversing the flow through the SPE cartridge and onto the HPLC column. 
This arrangement has the advantage that any separation that occurs on the SPE 
cartridge is reversed when the flow direction is reversed. 
3.2. Separation and detection method 
The method supplied by Thermo for use with the application note is designed for the 
identification of unknown substances. The method has an extensive library supplied 
with it, but during testing the method was not able to reliably detect multiple drugs in 
a control sample. The system seemed to be identifying a lot of background noise as 
a signal and the instrument was focussing on this noise instead of the desired signal. 
The decision was therefore made to simplify the method to make it more specific to 
the application for which it was needed, drugs of abuse in urine. 
The principal target ions for the method are the opiate drugs (morphine, codeine and 
dihydrocodeine) and their metabolites, principally the glucuronides. In addition, the 
methods that were to be replaced were capable of identifying cocaine, its principal 
metabolite benzoylecgonine, methadone and its principal metabolite, EDDP, and the 
amphetamine group substances amphetamine, methamphetamine and ecstasy 
(MDMA). It would therefore be desirable to be able to identify these drugs and their 
metabolites. 
3.2.1. Chromatography method 
Each of the required drugs was injected into the system as an aqueous standard or 
urine control, with the LC conditions varied to obtain an optimal separation. Drugs 
that are highly soluble, such as morphine-3-glucuronide (M3G) have very little 
retention, even in very weak mobile phases (low organic content). Conversely, 
methadone is highly retained in weak mobile phases and is also well retained in high 
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strength solvents (i.e. a high percentage of acetonitrile). So that M3G can be 
reasonably retained and the run time kept short for the methadone, a gradient 
separation is a necessity.  
The gradient was developed by using a weak solvent in an isocratic run. Examination 
of the retention times identified a point where a suitable separation had been 
obtained beforehand and the following analytes could be accelerated while 
maintaining a degree of resolution. A variety of gradients were then tested, 
increasing the acetonitrile concentration at different rates to improve the separation 
of the analytes in the later part of the run. No simple solution was found to this, as if 
the gradient was increased too rapidly, the separation would be lost for the next 
analytes in the run (predominantly the amphetamines) but would be ideal for 
methadone and EDDP. Conversely, if the gradient was slow enough to maintain 
separation of the amphetamines, the run time for methadone was too long. A suitable 
compromise was reached by having a multi-step gradient, with an isocratic step after 
an initial gradient, followed by a step change to 100% acetonitrile for the methadone 
(see Table 3.2).  
Table 3.2 Online SPE HPLC method flow parameters 
Time 
(min) 
Flow 
(mL/min) 
%B Divert Valve Comment 
0 0.1 5 To MS Initial conditions to condition 
column 
0.1 0.5 5 To Waste Flush salts and unretained 
components to waste 
1.5 0.2 5 To MS Reverse the SPE cartridge and 
start to stabilise flow to ESI 
nozzle 
12 0.2 40 To MS Gradient to separate and elute 
analytes 
12.5 0.5 100 To MS Ramp to high organic content 
to elute highly retained 
components and regenerate 
SPE column 
15.5 0.5 100 To MS Regenerate SPE column 
15.6 0.1 5 To MS Return to baseline conditions 
17 0.1 5 To MS End equilibration 
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3.2.2. Tuning of the mass spectrometer lenses 
To achieve optimum performance a mass spectrometer often must be tuned to the 
compounds under test. Two forms of tuning are required, the first is compound 
specific and identifies the collision energy required to fragment the ions optimally and 
the second is a common method that guides the ions from the source into the ion 
trap (see Figure 2.1). 
Tuning is achieved by infusion of the drug into the source using the integral syringe 
driver of the LCQ Fleet and the tune program supplied. The parent and daughter ions 
are programmed into the tune program and the voltages of the various lenses and 
the fragmentation energy are varied in sequence to identify either the optimum ion 
focussing conditions or the optimum fragmentation energy. The values obtained can 
be manually transcribed for programming into the MS method, or the tune file can be 
saved for import into the MS control program. 
The optimal collision energies are programmed into the analyte table on which data 
dependent scans are based, although a default collision voltage can be used which 
will be suitable for most analytes. 
Different tune files can be loaded for each segment used in the method (see p.74) 
and the tune files should reflect the types of compounds under test. Small molecules 
such as most drugs do not require a very high voltage on the tube lens of the source 
to focus the ions into the first quadrupole. However, this voltage would be too low to 
focus larger molecules such as proteins and the signal obtained would be relatively 
weak. Conversely, the higher voltage required to focus the larger ions of proteins 
would create too much of a repulsive force which would dissipate small ions. Most 
drugs of abuse are in the 200 - 400 amu. range and use of the tune file created with 
morphine provides a suitable mid-range molecular mass for drug analysis. 
3.2.3. Online solid phase extraction mass spectrometer acquisition method 
Having decided on an LC method, the mass spectrometer method could be created. 
While the simplest method would be to test for every analyte at all stages of the 
analysis, this does not play to the strengths of an ion trap and the cycle time to test 
for every drug would be too long. This is because the time for a spectrum to be 
produced (an MS2 scan) is up to 150 ms, and with at least fifteen analytes in the 
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initial method, the scan cycle time would be over 2 seconds. With peaks only 10-15 
seconds wide, there would be insufficient data points for reliable peak identification. 
Xcalibur software has a very powerful feature called data dependent scanning. This 
allows the results of one scan event to dictate the parameters of following scans. By 
using data dependent scanning it is possible to perform an initial survey scan using a 
full scan (i.e. no fragmentation) and use the results of this scan to decide which MS2 
scan or scans should be performed next. Various rules can be written that decide 
which scan should be performed next, based on the retention times, ions detected, 
ion intensity or previously detected ions. 
A simple approach to an MS method would be to use the data from the Thermo 
Application note 409. Unfortunately this application does not give sufficient data to 
recreate the analysis. The retention times and parent ion masses are easy enough to 
identify by infusing pure drug solutions, but the details of the data dependent 
detection parameters are not given, reducing the usefulness of the application note. 
The first MS method produced was a survey scan followed by a data dependent MS2 
scan on the most intense peak in the survey scan. However, this consistently missed 
most of the drugs on test, as there were frequently other species present, probably 
from the mobile phase, which were more intense. The solution was to define the ions 
that would be examined in the survey scan and to define the time windows in which 
they would be tested. In this way, all of the analytes should be detected in the survey 
scan and MS2 scans performed.  
This procedure works and peaks can be identified based on their MS2 fragmentation 
patterns. However, not all peaks in a control material are identified and the peak for 
methadone is bisected by the EDDP peak, giving a significant proportion of missing 
data. The reason for this is that only the most intense peak in a time window is 
identified and weaker peaks that are not completely resolved will be masked by the 
more intense peaks.  
While it is possible to define rules that prevent the same MS2 scan from being 
performed in consecutive cycles, a simpler option is to perform several consecutive 
scans on not just the first but the second, third and fourth most intense peaks. In this 
way, all overlapping peaks in the defined analysis windows can be detected. 
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As an outline method, this works well for most drugs, but was shown to give poor 
results for two drugs in particular. Morphine, and its primary metabolite morphine-3-
glucuronide, were frequently poorly identified in the survey scan, leading to 
inadequate peaks for reliable analysis. Part of the reason for this is that the ionisation 
efficiency of a metabolite is largely dependent on the environment in the source. In 
the highly aqueous environment at the start of the analytical run, the ionisation 
efficiency of morphine and morphine-3-glucuronide is poor and the extensive 
fragmentation of morphine gives a relatively low MS2 signal. 
The other problem analyte is 6-acetylmorphine (6MAM) which is present at 
significantly lower concentrations than any other drug or metabolite tested. The 
United Kingdom National External Quality Assessment Scheme (NEQAS) guidelines 
for clinical drugs of abuse testing specify 300 ng/mL as the cut off point for 
methadone and cocaine and 1500 ng/mL (Heathcontrol Drugs of Abuse in Urine 
Scheme Information) for opiates. Monoacetylmorphine is present in much lower 
concentrations and the threshold is 10 ng/mL, more than an order of magnitude 
lower. As 6MAM is unlikely to be one of the most intense ions present, defining this 
as a dependent scan is likely to result in missed results. 
In the case of all three analytes, it was decided to dedicate a scan event to testing for 
these drugs in every set of scans. This ensured that these drugs are always tested, 
even in the absence of good survey scan data. The use of a survey scan, three 
dedicated MS2 scans and several data dependent scans increased the scan cycle 
time considerably and also created a large amount of redundant data. Segmenting 
the run into two separate scan cycles allows dedicated MS2 scans appropriate to the 
morphine and M3G in the first segment, from 1.5 minutes after sample injection to 
2.5 minutes, and for 6MAM in the second segment. 
One of the strengths of an ion trap compared to a triple quadrupole is the ability to 
perform MS3 scans. This is particularly valuable in the case of the glucuronide 
metabolites. Part of the reason for this is that in an ion trap, all of the fragmentation 
energy is focussed on the parent ion mass. Smaller and larger masses are not 
affected by this fragmentation energy. This gives efficient fragmentation of the parent 
mass, but in the case of glucuronide metabolites, the only chemical bond broken is 
the link between the drug (or metabolite) and the glucuronic acid. All of the energy of 
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the fragmentation is absorbed by the weaker glucuronide linking bond and energy in 
the glucuronic acid or drug is dissipated. This means that there is a single fragment 
ion, which does not give reliable library search matches. Library searching works 
better when there are several fragments to match. 
For the glucuronide metabolites, it is possible to isolate the fragment corresponding 
to the drug or metabolite, having lost the glucuronide moiety in the fragmentation 
process. By further fragmenting this ion, an MS3 spectrum is obtained, which 
corresponds to the MS2 spectrum of the parent drug. An extra dedicated scan event 
was defined for the morphine-3-glucuronide in the first segment, further improving the 
ability of the method to reliably detect morphine and its primary metabolite. 
3.2.3.1 Optimisation of mass spectrometer acquisition parameters 
There are a number of other MS settings which were not adjusted from the default 
settings at this time (see Table 3.3). They will produce perfectly adequate spectra 
and will not adversely affect the detection characteristics, but may be optimised. This 
optimisation is done for the Turboflow® method described later. 
Table 3.3 Parameters not optimised at this time 
Parameter Function 
Isolation width The width of the mass window that the 
collision energy is applied to 
Wideband Activation Spreads the collision energy to cover ±20 
mass units.  
Default Charge State Setting allows identification of multiply 
charged ions 
Activation Q The “Q value” offset at which the collision 
energy is applied 
Activation Time The time in milliseconds that the collision 
energy is applied 
Collision energy The amount of energy applied to induce 
fragmentation 
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3.2.4. Final online solid phase extraction mass spectrometer method 
The final SPE method that was introduced into the laboratory was also published at 
the conference of The International Association of Forensic Toxicologists (TIAFT) in 
Geneva in 2009. It consisted of two segments (see Figure 3.1 and Figure 3.2). 
Segment 1 consists of a survey scan followed by two data dependent scans and two 
dedicated scans to search for morphine glucuronide, which was also used to tune the 
lens system. The dependent scans looked for the most intense ions present in a list 
of ions, which can be found in the SPE method file (see Appendix F.3) 
 
Figure 3.1 SPE Method Segment 1 scan parameters 
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Figure 3.2  SPE Method Segment 2 scan parameters 
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Segment 2 used a total of 5 data dependent scans to search for up to five analytes, 
followed by two dedicated scans for 6-acetylmorphine and acetylcodeine. Morphine 
was used as a tune compound and the dependent scans looked for the most intense 
ions present in a list of ions (see Appendix F.3) 
3.2.5. Data processing 
ToxID® is an automated reporting system for use with Thermo mass spectrometers. 
A parameter file specifies some critical information, such as the parent ion mass, 
retention time, principal fragment ion mass and minimum library search scores. It 
also includes the report header information, such as the laboratory name and a link 
to the laboratory logo in bitmap format.  
Following this is a list of all analytes that will be examined for reporting. Each analyte 
is listed with the molecular ion mass, the expected retention time and the minimum 
library match criteria to assign an analyte as positive.  
This list of analytes needs to be maintained and updated as the method evolves, but 
the retention time can be taken from the expected retention time in the MS method. 
Two formats of report are available, a short format and a long format. 
The short format report (see Figure 3.3) lists each identified analyte in a table with 
the library match results, retention time and peak intensity value and an image of the 
MS trace of each analyte 
This report shows a large amount of information which allows closer examination of 
the data if necessary.  
• The header shows the file name and path, the acquisition date and the sample 
ID 
• Every trace lists the acquisition conditions in the description to the right, 
including the maximum signal intensity (shown as NL:), the m/z range scanned 
and the MS conditions (e.g. “ITMS + c ESI d w” shows an Ion Trap Mass 
Spectrometer operating in positive mode collecting centroid data with an 
electrospray source, with the data coming from a data dependent scan using 
wideband activation) 
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• Each trace shows every scan event that registered a signal matching the scan 
conditions and the principal product ion specified in the configuration file 
• The table shows whether the analyte is a parent drug or metabolite (p or m), 
the MS order of the scan, the library search scores (search index(SI) and 
reverse search index (RSI)) and parent mass, expected and actual retention 
times and peak intensity, together with the library that the peak was matched 
with. 
 
 
 
Figure 3.3 Example of a ToxID short format report (traces 4-8 cropped) 
All of this information is also given at the top of the ToxID long report, although in this 
case each analyte is listed on a separate page as shown for benzoylecgonine (see 
Figure 3.4). Each page includes the mass spectrum of the most intense scan in the 
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chromatogram laid alongside the matching library spectrum. There is also a “delta 
spectrum” displayed, which shows the library spectrum subtracted from the acquired 
spectrum. If the two spectra match well, the result will be a series of small peaks 
either side of the axis, representing the daily variability of fragmentation intensities. If 
there is a peak in either spectrum that is significantly different in relative intensity, this 
will show as a prominent peak in the delta spectrum. Examination of the delta 
spectrum gives a quick visual way to demonstrate that two spectra are equivalent. 
 
 
Figure 3.4 ToxID long format report for benzoylecgonine in a QC sample 
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Also on the long report is the chemical structure of the analyte (if this has been 
uploaded to the library), including the molecular formula, Chemical Abstracts Service 
number and the molecular weight. 
Several different spectral libraries were supplied with the system, including the 
National Institute of Standards and Technology (NIST) and Maurer/Pfleger/Webber 
and ToxLib supplied by Thermo libraries. Since the spectrum acquired by each type 
of mass spectrometer and at different collision energies can vary, every analyte 
detected on this instrument was also saved as an in-house library. 
By default, ToxID searches through all libraries in the system and consequently there 
may be several library hits for every analyte. To reduce this, only the in-house library 
was searched. Each analyte could therefore only be detected once. 
A separate library is required for MS3 spectra and this can be handled a little 
differently. Since the MS3 spectrum of a glucuronide conjugate following loss of the 
glucuronide moiety is exactly the same as the MS2 spectrum of the unconjugated 
drug, this was used as a simple way of adding MS3 spectra. For each glucuronide or 
sulphate conjugate found, the MS2 spectrum acquired on the LC-MS was saved in 
the MS3 library under the name of the conjugate. If this analyte is present in sufficient 
quantity, this will cause it to be identified twice in the ToxID report, firstly as the MS2 
conjugate and secondly as the MS3 spectrum. 
3.2.6. Method validation 
Method validation for this stage of the project consisted of several elements: 
• Within and between batch precision (repeatability) for the principal analytes 
previously analysed by TLC and Gas chromatography (ie morphine, codeine, 
dihydrocodeine, amphetamine, methadone, EDDP and ecstasy) and also 6-
monoacetylmorphine. 
• Comparison of results of 100 patient samples with previously analysed data, 
and evaluation of any differences, and 9 external quality assessment (EQA) 
results 
• Assessment of carryover and ion suppression. 
• Identification of limits of detection of the principal drugs 
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A validation document was prepared following the laboratory policy for validations 
and submitted to laboratory management for authorisation. 
Also prepared at this time and submitted as part of the validation was a framework 
for the robust identification of new analytes to the LC-MS method, an assessment of 
the costs of the method, staff training requirements, continued quality control of the 
method and changes required to the laboratory computer system prior to introduction 
of the method, this validation document is reproduced (see Appendix E.2). 
3.3. Turboflow® method 
After routine operation of the method for several months, a Turboflow® HPLC system 
became available for use. This was considered as possibly more reliable than the 
original SPE method and would solve several difficulties in the laboratory. The first 
difficulty that was regularly encountered was that some urine samples would block 
the SPE cartridge, even with its larger 50 µm particles. Sometimes this would happen 
with as few as 100 injections, less than 25% the normal lifetime of the SPE 
cartridges. Secondly, the detection limit for morphine and morphine glucuronide were 
around 1000 ng/mL, which was perfectly reasonable for clinical testing at the time. 
However, the EQA scheme for drugs of abuse was shortly going to move to a 400 
ng/mL cutoff and the existing method would suddenly become unsuitable. Finally the 
expected benefits of the Turboflow® system had not been realised in another area of 
the laboratory and demonstrating successful operation was politically desirable. Work 
on developing a Turboflow® method started in September 2009. 
3.3.1. Turboflow® column selection 
There are a number of different Turboflow® columns available (see Table 3.4), similar 
in performance to the types of HPLC columns in common use. An application note 
produced by Thermo uses an anion exchange column for opiates, but there is no 
consensus about which column is most suitable for drugs of abuse. 
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Table 3.4 Turboflow® column phases 
Designation Solid Phase 
C18 Silica reversed phase 
C8 Silica reversed phase 
Phenyl Silica reversed phenyl phase 
Cyclone Polymeric reversed phase 
Cyclone-P Polymeric reversed phenyl phase 
Cyclone MAX Mixed reversed phase and anion 
exchange 
Cyclone MCX Mixed reversed phase and cation 
exchange 
 
3.3.1.1 Turboflow® development method 
To evaluate a Turboflow® column, the outflow was connected directly to the mass 
spectrometer, bypassing the analytical column. Sample was loaded in a solvent that 
enables maximum retention using the phase under test (normally 100% aqueous) 
and then eluted in the recommended elution solvent and followed with a strong 
elution solvent. This pattern of use should produce peaks in three areas of the MS 
trace: 
1 Unretained analytes. Unretained analytes should elute at or shortly after 
the solvent front 
2 Retained analytes. Retained analytes stick well to the Turboflow® column 
but are eluted easily from the column 
3 Strongly retained analytes. These analytes stick well to the Turboflow® 
column, but are difficult to elute  
The general method for testing the Turboflow® columns is shown (see Table 3.5). 
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Table 3.5 Gradient used for evaluating Turboflow® columns 
Step Time (s) Flow 
(mL/min) 
Solvent Comment 
1 0 – 60 0.5 Load Retention solvent 
2 60 – 90 0.5 Aqueous Elute Elution with aqueous solvent 
only 
3 90 – 120 0.5 Organic elute Elution with weak organic 
solvent 
4 120 – 150  0.5 Organic clean Strong organic solvent 
5 150 – 260 0.5 Regenerate 100% aqueous solvent 
 
The flow was kept at 0.5 mL/min to ensure that turbulent flow was not happening and 
any retention effect was attributable to the column and solvent combination only. 
Acetonitrile was used as the organic solvent, as this gives lower back-pressure than 
methanol, and this is a very common mobile phase, allowing comparison with other 
methods. 
 
Figure 3.5 Optimisation of Turboflow® Cyclone MAX column retention: morphine retained on Turboflow® 
column for 3.03 minutes, demonstrating excessive retention 
Morphine is strongly retained on an anion exchange column (see Figure 3.5). The 
sample was loaded in basic conditions and the loop elute step used an acidic mobile 
phase to attempt to elute the analytes. In this case, morphine was only eluted after 
the 100% organic elute step, meaning that the morphine was retained too strongly to 
wash off in normal analytical conditions. 
All available Turboflow® columns except the C8 column were tested to see which 
gave the best performance. It was expected that since all of these drugs are basic 
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drugs, the MCX column would give the best performance and that reversed phase 
columns would allow moderate retention. While the reversed phase and MCX 
columns did give a high degree of retention, this was sometimes too strong to be 
eluted in 200µL of 100% acetonitrile.  
The column selected for further development was the Cyclone MAX polymeric anion 
exchange column (see Table 3.6). This is counter-intuitive, since most of the drugs 
being tested do not easily form anions. Comparison of the elution profiles of the 
Cyclone MAX and Cyclone columns shows that they have very similar retention 
characteristics, but the Cyclone MAX allows a cleaner and fuller elution than the 
Cyclone column. The reason for this is probably that when eluting in acidic 
conditions, the stationary phase functional groups and analytes both become 
positively charged. This causes a repulsive force between the stationary phase and 
the analyte which is stronger than the reversed phase retention and the positively 
charged analytes enter the mobile phase. This is particularly advantageous for 
methadone, which is relatively non-polar and has a strong reversed phase retention 
and is not normally eluted in 200 µL of acetonitrile. 
Table 3.6 Initial Turboflow® extraction method HPLC parameters 
Start 
Time 
(s) 
End 
Time 
(s) 
pH Elution 
pump 
solvent 
%B 
Loading 
Pump Flow 
Rate 
(mL/min) 
Elution 
Pump Flow 
Rate 
(mL/min) 
Comment 
0 60 9.5 0 2.0 
 
0.2 Sample loading in 
turbulent flow 
conditions. Eluting 
pump maintains 
column flow 
60 120 3.5 1 0.2 0 Elution from the 
Turboflow® column 
with the loop 
contents 
120 360 3.5 50 1.0 0.2 Regeneration of the 
Turboflow® column  
360 420 3.5 1 0.2 0.2 Filling the loop with 
elution solvent 
420 600 9.5 0 0.2 0.2 Re-equilibrate 
Turboflow® column 
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As all samples are extracted through the same column, it is important to ensure that 
there is no carryover from one sample to the next. A sequence of four injections was 
performed with 5 analytes to assess carryover (see Table 3.7). 
Table 3.7 Sample injection protocol for the assessment of carryover 
Injection 
number 
Injection type Reason 
1 Deionised Water Prime sample loop, ensure there is no 
carryover from previous samples 
2 Test sample Urine sample spiked with analyte 
3 Deionised water in 
Laminar flow 
Laminar flow bypasses Turboflow® 
column, so any carryover identified is 
likely to come from the syringe or from the 
guard or analytical columns 
4 Deionised water in 
Turboflow® injector 
Any carryover identified must come from 
the injection port, Turboflow® column or 
the transfer valve 
 
Carryover was assessed for amphetamine, morphine, morphine-3-glucuronide, 
cocaine and methadone. These were used to demonstrate carryover in the most 
clinically significant polar and non-polar analytes. 
Carryover for methadone was estimated to be 1.47% at a level of 200,000 ng/mL in 
the Turboflow® injector system and the other analytes there was no carryover 
detected. In the formal validation document, carryover was assessed for 
amphetamine and benzoylecgonine and found to be not significant. 
3.3.2. Recovery 
Recovery can be defined as the amount of an analyte that is available for detection 
after the extraction. With a Turboflow® system, this is easy to estimate by injecting a 
sample first using the laminar flow injector and then with the Turboflow® injector. The 
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peak height or area of the Turboflow® injection as a percentage of the laminar 
injection gives the recovery.  
Table 3.8 Assessment of recovery from the Turboflow® column 
Analyte Laminar Injection 
peak height 
Turboflow® injection 
peak height 
Recovery 
(%) 
Morphine 6893 4495 65.2 
Cocaine 122271 82630 71 
Methadone 5359864 328227 73 
Amphetamine 26550 24200 91 
Morphine-3-
glucuronide 
44007 850 21 
 
Poor recovery of morphine glucuronide (see Table 3.8) is likely to be due to the poor 
retention of this analyte on reversed phase columns. Calibration of the method 
should therefore be made using the Turboflow® injector, as calibration using the 
laminar flow injector is likely to give results only 65 – 90 % of actual for most analytes 
and only around 20 % of actual for morphine glucuronide. 
3.3.3. Analytical column method 
Experience with the SPE method suggested that a phenyl column was suitable, 
giving enhanced retention of drugs containing phenyl rings, which includes all of the 
drugs of interest. No change was therefore made to the analytical column, although a 
variety of different types of gradient were tested. The gradient was initially developed 
using laminar flow injection (LX). For conversion to the final Turboflow® injection (TX), 
the Turboflow® loading time (1 minute) needed to be added to the gradient and the 
loading pump flow during the transfer step needed to be made up from the eluting 
pump. Aqueous standards were used to develop the analytical method, as the 
Turboflow® sample preparation step was omitted. 
As before, a gradient separation is required to enable sufficient retention of 
morphine-3-glucuronide and elution of methadone in a reasonable time. The 
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analytical gradient effectively starts at 60 seconds when the Turboflow® column is 
switched into the analytical system, as the morphine-3-glucuronide elutes in the 1% 
organic solvent at about 2 minutes.  
A maximum run time of 20 minutes was chosen to try to ensure sufficient sample 
throughput. This leaves around 18 minutes to perform the separation before returning 
the analytical column to the starting conditions. Simple gradients that allowed 
methadone to elute in around 15 minutes did not give a good separation of 
amphetamine and cocaine and shallow gradients that allowed good separation of 
these left methadone being eluted far too late. Fortunately there is a big time gap 
between the main group of drugs (including all the amphetamine derivatives and 
cocainics) and methadone, allowing a gradient change to occur away from any peaks 
of interest. The relevance of this is that if the retention times change between runs, 
for example with decreasing column performance or slightly different mobile phase 
strength, this would have a disproportionate effect on the retention times of these 
peaks.  
Table 3.9 Final Turboflow® extraction and HPLC Parameters 
Step Start Time 
(min) 
Flow 
(mL/min) 
%A %B Comment 
1 0 0.2 100 0 Equilibration and 
Turboflow® loading 
2 1 0 100 0 Flow of 0.2mL/min 
from Loading Pump 
3 3 0.2 100 0 Morphine-
glucuronide elution 
4 4 0.2 85 15 Start of gradient 
5 11 0.2 70 30 End of gradient 
6 11.01 0.2 0 100 Step to elute 
methadone 
7 16 0.2 0 100 Late eluting peaks 
8 16.01 0.2 100 0 Return to Initial 
conditions 
9 20 0.2 100 0 End of run 
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The optimum gradient starts after the elution of morphine glucuronide (which is 
eluted in 100% aqueous eluent) and after a step change to 15% organic rises 
gradually to 30% organic (see Table 3.9). At 11 minutes, the gradient conditions were 
changed to allow faster elution of methadone, with methadone being eluted in close 
to 100% acetonitrile. Although a range of gradient rates were tested to elute 
methadone, there was no degradation if the organic content was immediately 
increased to 100%.  
3.3.4. Mass spectrometer method 
Experience with SPE methodology and additional training on the capabilities of the 
ion trap system allowed a more comprehensive and targeted approach to developing 
the mass spectrometer method. This facilitated detection of a greater number of 
analytes at lower concentrations and also better quantitation and reduced target 
analyte list maintenance. 
3.3.4.1 Scan parameters 
With an ion trap it is possible to keep the trap “open” for varying lengths of time and 
therefore to change the number of ions entering the trap. However, this has two 
adverse effects: 
1 The increased collection time reduces the number of scan events and 
therefore reduces the number of data points across a peak. For confident 
analysis and quantitation, more data points are desirable. 
2 As more ions enter the trap, the charge within the trap increases. Ions in 
the centre of the trap will be shielded from the full voltage of the trap by the 
ions around them and the practical effect of this is a decreased mass 
resolution. 
To resolve this, the LCQ Fleet has a setting called the Analyser Gain Control (AGC). 
This defines a maximum time for the trap to acquire ions and monitors the number of 
ions entering the trap and closes the trap when a preset maximum is reached. It 
achieves this by performing a short scan event and counting the ions and then 
calculating the trap open time for the main scan event. This combination prevents 
trap overloading and also ensures that the scan time is not too long. 
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The ion count settings of the trap were maintained at the default settings, as any 
increase in the number of ions would reduce the resolution and any decrease could 
affect sensitivity or spectrum quality. However the maximum trap times were 
examined to see if there could be any performance improvement. 
In practice, where a full scan was performed, the time that the trap was open was 
always limited by the maximum scan time, rather than the maximum ion limit. This 
was tested at 5, 10 and 15 ms and the signal intensity was similar for all times (see 
Table 3.10). For MS2 scan events, the times tested were 50, 100 and 150 ms and the 
shorter ion time gave better results. This is partly because a shorter ion time leads to 
more consistent filling of the ion trap. 
Table 3.10 Analyser gain control evaluation using 3 time settings using butalbital (m/z 312 at 6.5 minutes) 
AGC Setting MS response Total scan time 
50 ms 7.32 x102 50 ms 
100 ms 6.32 x102 100 ms 
150 ms 6.49 x102 106 ms 
 
As can be seen (Table 3.10), the greatest signal intensity was obtained with the 
shortest AGC setting. As a result, this setting was retained for all subsequent method 
development and for the final analytical method. 
Another default setting of the MS is to use 3 microscans. The LCQ Fleet performs 
three separate scans within each scan event. These are then aggregated to give a 
single data point, the intention being to average the spectra to obtain a more 
reproducible mass spectrum. For a single scan event lasting 155 ms there will be four 
component scans (see Table 3.11). All 3 microscans use the same AGC settings 
defined by the AGC pre-scan. This uses up precious scan time and the number of 
microscans used and their contribution to spectrum quality were assessed.  
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Table 3.11 Typical scan component timings 
AGC 
Scan 
1st Microscan 2nd Microscan 3rd Microscan 
5 ms 50 ms 50 ms 50 ms 
 
All fragmentation in a mass spectrometer has a degree of variability. When looking at 
the ratio of intensities of 2 fragment ions, the European Union Guidelines on the 
interpretation of analytical results (The Commission of the European Communities, 
2002) specify that 2 ions should have a ratio that varies by no more than 20% where 
the ions have similar intensities. By aggregating several microscans, the LCQ Fleet 
averages out this variability and the spectrum obtained should be more similar to 
stored library spectra.  
A selection of analytes were tested using 1, 2 or 3 microscans and the performance 
evaluated.  
Since the total response is the average of the responses of the microscans, the 
recorded response was similar for each of the drugs tested (amphetamine, ecstasy, 
benzoylecgonine, codeine, methadone, 6MAM and morphine-3-glucuronide). 
The use of microscans is intended to improve spectrum quality, so the forward and 
reverse library match scores were also compared for the above drugs, and again 
there was no significant decrease in spectrum quality. A Search Index (SI) score of 
>600 and reverse search (RSI) of >700 was considered acceptable and this was 
obtained easily whenever there was a sufficient ion intensity to obtain a reasonable 
quality spectrum. This suggests that for this application, the use of a single 
microscan will not lead to a decrease in performance. However, unless an 
improvement can be demonstrated, there is no reason to reduce the number of 
microscans.  
Additional microscans reduce the number of data points available, so an increased 
number of data points across a peak may be sufficient reason to reduce the number 
of microscans. Chromatograms were examined and the number of scan events 
across a peak were identified to see if there is an increase in data points. 
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Table 3.12 Assessment of number of data points for 3 analytes with 3 different microscan settings 
Analyte 1 microscan 2 microscans 3 microscans 
Amphetamine 5 data points 3 data points 3 data points 
Morphine-3-
glucuronide 
9 data points 4 data points 3 data points 
EDDP 18 data points 9 data points 5 data points 
 
The reduced number of microscans does significantly increase the number of data 
points (see Table 3.12). For all subsequent analyses, a single microscan was used, 
meaning that more scan events can be included in the method, allowing a greater 
degree of analyte identification. 
3.3.4.2 Survey scans used for the Turboflow® method 
Experience of using survey scans during the SPE method development and 
operation allowed additional improvements to be made when it came to further MS 
method development. One of these improvements was to use the Turbo Scan feature 
of the ion trap to perform the survey scan faster. Turboscans reduce the time taken 
to perform the scan by increasing the rate at which ions are scanned out of the trap. 
While this is very much quicker than a normal scan, the overall effect is limited due to 
the trap filling time. However, the use of the turboscan does reduce the total analysis 
time, allowing more data points across a peak. On its own, this may not be a 
significant improvement, but the combined effect of several different improvements in 
the MS method reduce the total cycle time, allowing more drugs to be detected in a 
single analytical run. 
The survey scans ran from m/z 125 to m/z 800 in all segments, covering the full 
range of expected parent ion masses. 
3.3.4.3 Scan segments used in the Turboflow® method 
In order to minimise unnecessary data acquisition, the MS method was split into 3 
segments. Each segment can contain different scan events and be tuned using a 
different analyte. 
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Segment 1 lasted from the start of data acquisition for 6.6 minutes. Segment two 
lasts for only 1.45 minutes and segment 3 lasted for 8.45 minutes from 8.05 minutes 
until the end of the run. All three segments use the same parent mass and reject 
mass lists and the scan structures are the same across all segments. This means 
that the only practical difference between the segments is the dedicated scan event, 
set for morphine glucuronide in segment 1, 6-monoacetylmorphine in segment 2 and 
acetylcodeine in segment 3. 
3.3.4.4 MS2 data dependent scans used in the Turboflow® method 
Experience with the initial SPE method allowed simplification of the data dependent 
scans for the Turboflow® MS method. The initial SPE method used a series of up to 
five MS2 scans after the initial survey scan. Streamlining the technique allowed this to 
be reduced to a total of 5 scan events.  
Following the survey scan, the most intense ion from the parent ion list was 
subjected to an MS2 scan if the ion intensity was greater than 500 counts. This is the 
primary scan event in each segment, designed to detect any known drugs present. 
Following this, a second data dependent scan was performed on the most intense 
ion present in the survey scan, excluding any masses listed in the reject mass list. 
While this scan event may be able to detect a wide variety of substances, this would 
require manual processing and manual library searching. The principal reason for 
this scan was to use the data acquired to search for neutral losses. If the most 
intense ion in the original survey scan is that of a glucuronide or sulphate conjugate, 
the MS2 scan should allow the identification of the parent drug or metabolite using the 
principle of a neutral loss. For example, codeine (m/z 300) has a glucuronide 
metabolite with an m/z of 476. If codeine-glucuronide is identified as the most intense 
ion in the survey scan, the MS2 scan should show a significant peak at m/z 476 – 176 
= 300. This peak is then selected for an MS3 scan in the fourth scan event of the 
cycle.  
As previously discussed, using the most intense peak in a range for data dependent 
scans can lead to significant drugs being missed. A target compound list was 
therefore developed that lists all target analytes by their expected retention windows. 
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A full list of analytes and their target retention time windows can be found in 
Appendix F.4 
Analytes and retention times were found by injection of aqueous standards of the 
drugs onto the analytical column and examining the survey scan data for the 
molecular ion peak. Once identified, the analyte was added to the mass list and the 
standard was re-injected to verify that the correct mass spectrum could be obtained. 
At this time, the mass spectrum of the analyte was acquired (if not already done so) 
and copied to the in-house mass spectrum library for library spectrum matching (see 
page 97 for ToxID spectrum matching). 
Examination of the mass list shows that it is unlikely that more than 5 analytes will co-
elute and this approach should not lead to any analytes being missed. However, the 
list should be periodically examined to ensure that any new drugs added to the list do 
not risk false negative results. A peak intensity threshold was also added so that 
dependent scans would not be triggered by background noise. The threshold was set 
at a level that was consistently above the baseline level, as assessed by a series of 
sample injections. 
3.3.4.5 Dedicated scans used in the Turboflow® method 
As for the SPE method, a series of dedicated scans was set for critical analytes that 
may otherwise be missed.  
The parameters were the same as for the SPE method, with dedicated scans for 
morphine and morphine glucuronide in the first segment, 6-monoacetyl morphine in 
the second segment and acetyl codeine in the 3rd segment.  
Unlike for the SPE method, the 6-monoacetylmorphine scan was restricted to an 
isolation width of 1 mass unit. This was implemented to improve the mass spectra 
produced during these scans and therefore increase the specificity of the scan. Apart 
from this modification, no other parameters were modified during the method 
development stage, although following implementation it is understood that the 6-
monoacetylmorphine parameters were amended slightly. 
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3.3.4.6 Neutral loss scan in the Turboflow® method 
The reason for the second survey scan is that this enables neutral loss processing of 
data in subsequent MS2 and MS3 scans. Without defining the mass to be searched, a 
data dependent MS2 scan is performed on the most intense peak within the mass 
range. The MS2 scan is not intended to directly identify any drugs, but to look for any 
peak which loses 176 amu., corresponding to the loss of glucuronic acid. An MS3 
scan of this peak is then performed to try to identify the drug that formed the 
conjugate. Some of the advantages of operating in this fashion are that specific 
scans do not need performing for every different glucuronide and glucuronides of 
unspecified drugs can be identified. This leads to a simplification of the mass list in 
the analytical method, although for automatic reporting they would still need to be 
defined in ToxID. 
Since an MS3 scan would only be performed when a tentative glucuronide was 
identified, it is fairly quick and easy to look through all MS3 scan events on Xcalibur 
software, although this is still a manual process, and library searches would need to 
be performed manually. If substances identified in this fashion are then added to the 
ToxID configuration file, this represents a powerful way of increasing the capabilities 
of the method. 
Tramadol is found in urine conjugated to both glucuronic acid and also sulphate. 
Looking for glucuronic acid conjugates alone might lead to tramadol being missed 
and so a second mass was added to the neutral loss mass list, corresponding to the 
sulphate conjugate. In this way, the neutral loss scan looked for the most intense 
sulphate or glucuronide conjugate to perform an MS3 scan on. The ToxID mass list 
needed to be updated and the library spectrum for the MS3 sulphate conjugate 
added, but this change allows a further improvement in the capability of the 
developed method. 
3.3.4.7 Dynamic exclusion of masses in the Turboflow® method 
By specifying that an MS2 scan needs to be done on the most intense peak in a scan, 
this leads to additional difficulties. Firstly, there may be peaks or a constant 
background of a scan that produce a large amount of unwanted data. These peaks 
may be from LC components (such as bleeding stationary phase) or plasticizers and 
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other substances that can enter the system. These were minimised by running some 
blank samples without drug. Any ion that had a significant background intensity was 
added to the reject mass list, so that this would never trigger an MS2 scan. Also the 
general background signal was examined and the threshold for the MS2 scan was set 
so that background signal would not trigger MS2 scans. 
Secondly, the presence of a large peak of one drug could be the most intense peak 
in the survey scan for some time and this could swamp the signal of any co-eluting 
drug, especially if the co-eluting drug is present in a lower amount.  
To avoid this, a feature called dynamic exclusion was enabled. Dynamic exclusion 
causes a detected mass to be temporarily included in the reject mass list, so that 
subsequent scans do not look for the same substance continuously. After a defined 
time, the mass is removed from the dynamic exclusion list so that it may again be 
detected and subject to an MS2 scan if it is still the most intense ion present. 
There are two main settings for dynamic exclusion, the number of repeats and the 
exclusion time. The number of repeats defines how many times an ion must be 
detected before it can be added to the reject list and the exclusion time defines how 
long the ion remains on the reject list. 
Initially the repeats was set to 5 and the exclusion time to 10 seconds. However, this 
typically leads to 5 consecutive MS2 scans of the same mass, followed by a break of 
10 seconds and then another 5 MS2 scans. Chromatographic performance is poor, 
as a peak is identified just as the peak front arrives at the detector and is then either 
not detected again or is detected in 2 or 3 further blocks of data, as can be seen (see 
Figure 3.6). 
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Figure 3.6 Chromatogram demonstrating the effect of poor Dynamic Exclusion settings (Upper trace: EDDP, 
lower trace: Methadone) 
 As well as making the chromatogram harder to read visually, this may mean that a 
peak is only detected at its start and any concentration information is not gathered. 
To rectify this, the repeats setting was changed to 1 and the duration to 2 seconds. 
This means that every time an MS2 scan is performed, the same scan is disabled for 
a further 2 seconds. The chromatogram would show a data point every 2-3 seconds 
across the peak, allowing peak shape and intensity to be assessed, and would allow 
other substances to be identified in the intervening 2 seconds. The total cycle time 
varies depending on what else is being examined at any particular point of the run, 
but normally this allows at least 2-3 co-eluting peaks to be identified. 
Dynamic exclusion can be set as a global setting and in this way the dynamic 
exclusion settings apply to the ions in the parent mass list, the neutral loss mass list 
and in all three MS segments. 
3.3.5. ToxID configuration for the Turboflow® method 
ToxID was set up in almost exactly the same way for the Turboflow® method as for 
the SPE method. The mass lists were different because the retention times were 
different, but otherwise there were no significant differences.  
A number of additional drugs, principally benzodiazepines, were added to the 
configuration file to begin the process of identifying these drugs. The illicit heroin 
markers noscapine, desmethyl-papaverine, desmethyl-papaverine-glucuronide and 
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meconine were also added to the configuration file, following the work carried out by 
Tracey Gous (Gous, Sherwood, Evers and Blackburn, 2011). 
The configuration file for ToxID can be found in Appendix F.2  
3.3.6. Automated addition of internal standards 
In the final phase of the project, experiments were performed to automatically add 
the deuterated internal standard to samples using the autosampler. A vial of internal 
standard was loaded into the autosampler tray and the needle programmed to draw 
up the internal standard before the sample. Drawing in this order reduces any risk of 
patient samples contaminating the stock of internal standard. The reverse is less 
likely to happen due to the much lower concentration of internal standard in most 
samples and that the needle will only visit a sample vial once on a normal run, rather 
than repeatedly as happens with the internal standard. 
The method was set up to sample 40 µL of the internal standard, followed by a 
needle wash and a 10 µL air gap to further reduce the chances of contamination. The 
needle then visited the sample vial and drew 50 µL of sample before injecting all into 
the loading port of the HPLC.  
This was demonstrated to work in theory, but the reduction in sample volume 
reduces the sensitivity of the method by 50 % and the normal sample volume of 100 
µL was considered necessary. A 250 µL syringe and carrier were therefore ordered 
to finalise this part of the method development, but budget restraints in the National 
Health Service (NHS) in January 2010 meant that this could not be ordered in time to 
validate prior to leaving the Trust. 
3.3.7. Method validation of the Turboflow® method 
Method validation was performed as for the SPE method. As previously stated, the 
method was not complete at the time the author left the laboratory at King’s College 
Hospital and the validation had to be completed by remaining staff. The validation 
document produced at this time can be found in Appendix E.7 
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4. Results and discussion 
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4.1. Final online solid phase extraction method used for the routine 
analysis of samples 
The SPE method operated between December 2008 and August 2009 produced 
reliable results for the opiates, amphetamines, cocaine, methadone (see Figure 4.1) 
and was extended to several other analytes. It suffered a little from not having 
accurate quantitation, meaning that presence of an analyte could only be reported as 
present or absent, but the added certainty of the identity of a drug was a significant 
improvement over the TLC method. It was possible to compare results approximately 
by examining the ion intensity and score as +, ++ or +++ (or weak positive, positive, 
strong positive), but this was not often reported.  
4.1.1. Sensitivity and specificity 
Patient sample results from the SPE method were compared with results from 
samples analysed by TLC for Opiates or GC for amphetamines during October and 
November 2008, as well as a selection of methadone and cocaine positive samples 
(see table 4.1). 
All results are qualitative by LCMS, TLC and GC and so cannot be processed using a 
Deming regression. 
Table 4.1 Results of 100 samples analysed by both TLC, GC or immunoassay and LCMS 
 
Morphine EDDP Codeine Methadone Cocaine Amphetamine DHC 
True POS 56 83 2 80 50 3 2 
True NEG 39 17 93 20 48 97 98 
False POS 4 0 5 0 2 0 0 
False NEG 1 0 0 0 0 0 0 
SENSITIVITY 98.2% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
SPECIFICITY 90.7% 100.0% 94.9% 100.0% 96.0% 100.0% 100.0% 
 
The results of the TLC or GC are taken as “TRUE” and LCMS results are compared 
to these.  
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Sensitivity = LCMS POSITIVES  or True Positives         .  
  TLC POSITIVES       (True POS + False NEG) 
 
Specificity = LCMS NEGATIVES  or True Negatives         .  
  TLC NEGATIVES       (True NEG + False POS) 
Sensitivity and specificity relate the method being tested to the existing method, 
which is assumed to be correct. In this case the new method is more accurate than 
the existing method, as can be seen when the anomalous results are investigated. 
4.1.1.1 False positive cocaine results 
These 2 samples had cocaine results of 204 and 238 ng/mL by immunoassay. 
Cocaine was present at levels detectable by the LCMS. This would be reported as 
negative by immunoassay, which uses a cutoff of 300 ng/mL to differentiate positive 
and negative results. 
4.1.1.2 False positive codeine results 
Codeine is a common contaminant of heroin and the presence of codeine should not 
be unexpected in urine samples from heroin users. The limit of detection by LCMS is 
much lower than by TLC and in four of these samples, morphine (from heroin) was 
present. In the fifth sample, opiates were detected by immunoassay, but neither 
morphine nor codeine were detected by TLC. 
4.1.1.3 False positive morphine results 
Three of these samples were opiate immunoassay positive, but no morphine was 
detected by TLC. The detection limit for morphine is slightly less for LCMS than TLC, 
but the level of interference is lower, enabling more certain identification of morphine.  
The fourth sample was codeine positive, with only a weak morphine concentration. In 
most of the UK population, codeine can be metabolised to morphine, and this 
probably represents codeine use rather than heroin. 
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4.1.1.4 False negative morphine result 
One sample found to be positive for morphine by LCMS was re-analysed by TLC and 
found to have no morphine. There was significant interference covering the morphine 
area on the plate and the original identification of a weak positive morphine was 
uncertain and made in conjunction with the patient history. This shows how the 
added certainty of identification by spectral library matching gives improved results 
compared to the existing method. 
4.1.2. Precision 
Precision was assessed by the analysis of quality control materials five times on the 
same batch (intra-batch precision) and on five consecutive batches (inter-batch 
precision) and determination of the coefficient of variation (%CV) (also known as 
residual standard deviation) of the response. 
Five drugs from four drug groups were assessed at three levels to determine 
precision (see table 4.2). 
Table 4.2 Reproducibility of analysis for the online solid phase extraction method 
Drug Level 
(ng/mL) 
Intra-batch 
precision (%CV) 
Inter-batch 
precision (%CV) 
95% confidence 
limits (± ng/mL) 
 1500 8.9 5.0 300 
Morphine 225 24.7 5.0 111 
 4000 17.7 15.6 1850 
 1500 6.6 4.3 232 
Codeine 225 15.7 14.0 93 
 4000 12.7 18.7 1466 
 375 2.5 15.5 114 
Amphetamine 675 11.9 6.7 181 
 1500 5.0 8.4 247 
Cocaine 
metabolite 
115 12.0 9.2 34 
185 6.7 5.9 32 
1000 4.5 10.4 204 
 225 2.3 6.2 27 
Methadone 375 3.9 6.0 44 
 1000 1.9 14.9 292 
The 95% confidence limits are 1.96 times the inter batch precision. Where the intra-
batch precision is higher than the inter-batch precision, the precision values have 
been combined as the square root of the sum of the squares of the intra- and inter-
batch precision values. 
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During routine operation, it also became evident that the online SPE cartridge 
sometimes became blocked, usually in the middle of an analytical batch and often 
overnight. Investigations suggested that this blocking was caused by precipitation of 
proteins in the SPE cartridge when exposed to acetonitrile. The life of SPE 
cartridges, intended to be around 500 – 1000 samples, was sometimes reduced to 
less than 100 samples, an unacceptable increase in costs and disruption to 
scheduled laboratory work. The aqueous equilibration step at the end of the run was 
therefore increased by one minute and after this was done there were no significant 
problems with SPE cartridge lifetime. 
 
Figure 4.1 Results of a patient sample showing extracted ion chromatograms. (Black: morphine glucuronide, 
Green: morphine, Blue: codeine glucuronide, Olive: codeine, Purple: 6-MAM, Grey: benzoylecgonine, Light Blue: 
EDDP, Red: methadone) 
Internal day-to-day performance of the method was monitored by the recording on 
worksheets of the results of the quality control samples (see Figure 4.2). Internal 
quality control results were very good and the method was able to give consistent 
qualitative results on a daily basis, during a working week. 
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Figure 4.2 Quality control result printout, (1: Amphetamine, 2: Ecstasy, 3: MDEA, 4: EDDP, 5: Benzoylecgonine, 
6: Codeine, 7: Methadone, 8: Propoxyphene) 
Performance in the EQA (proficiency testing) scheme through the analysis of 12 
separate samples throughout the year for all drugs within the laboratory’s repertoire. 
In the first year of operation, the online SPE method did not result in any false 
positive or false negative results for the amphetamine group, benzoylecgonine, 
methadone or EDDP. There was 1 false negative result for 6-monoacetylmorphine 
and morphine (below the limit of quantification). 
Several other modifications were made to the method during the first year of 
operation. A research trial that was underway in the Toxicology Unit was the 
identification of noscapine and papaverine metabolites. Noscapine and papaverine 
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are two alkaloids found in poppy seeds that survive the manufacture of heroin and 
can be detected in the urine of heroin users. They were being used in the 
Randomised Injectable Opioid Treatment Trial (RIOTT) to differentiate drug users 
prescribed diamorphine from those using heroin. The previous method in the 
laboratory was a GC-MS method and these analytes were added to the LC-MS 
method as part of an in house MSc project by Tracey Gous supervised by the author 
and the results of the trial were published (Strang, et al., 2010). The initial 
identification of the spectrum of desmethyl-papaverine was made using the MSn 
capability of the ion trap and published as a poster at the conference of The 
International Association of Forensic Toxicologists (TIAFT) in Geneva in 2009 (Evers, 
Marsh and Gous, 2009). 
The other significant adjustment to the method was the addition of ketamine and its 
metabolite norketamine to the mass list. Ketamine is a sedative used by the 
ambulance service instead of opiates, as it does not depress the respiratory system 
in the way that opiates do. However, the reason for it being added to the LC-MS 
method was that it is in use as a recreational drug, particularly in the clubs of south 
London. The midwives in the obstetrics department at KCH were interested in 
knowing whether some of their mothers were taking ketamine. A ketamine standard 
was therefore obtained and the retention time and spectrum of these metabolites 
identified. Ketamine was therefore added to the repertoire of the Toxicology Unit, 
starting the expansion of the service from covering only the addictions department at 
SLAM to other service areas.  
Another observation during the first year was that in most samples from heroin users 
the morphine glucuronide peak was adequate to produce an MS3 library match in 
ToxID. However, in weaker samples, below around 2000 ng/mL, the glucuronide 
peak was present in the MS2 spectrum but not in the MS3 with sufficient peak 
intensity to provide a good library match. Given that these samples were from opiate 
users and had tested positive for opiates by immunoassay, this level of identification 
is sufficient to report a morphine positive result. However, the level of confidence is 
lower if the sample comes from a patient not known to be on opiates, as 
demonstrated by Bayesian probability. 
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Bayes theorem takes the pre-test probability and adjusts it based on the sensitivity 
and specificity of a test. If a known heroin user tests positive for opiates by 
immunoassay (with a specificity of around 85% in this population, Synergy Health 
unpublished data), it is highly likely that this is due to morphine, even without the 
confirmatory LC-MS test. However, in an unselected population, the specificity of the 
opiates immunoassay for morphine is only around 10% (due to the far higher 
prevalence of codeine). With a pre-test probability of only 10% (corresponding to the 
prevalence of morphine in the unselected population), the specificity of the 
confirmatory test must be much higher to report morphine as being positive. 
As a result, the SPE method is more limited in its application and any identification of 
the presence of morphine should not be made solely on the MS2 identification of 
morphine glucuronide, but must include either morphine (MS2), morphine glucuronide 
(MS3), a more intense codeine or codeine glucuronide peak or clinical details 
showing the expected presence of morphine. It was hoped that the improved results 
of the Turboflow® extraction would increase the MS3 signal intensity sufficiently to 
allow the more widespread application of the LC-MS opiates method. 
4.2. Final Turboflow® method used for the routine analysis of samples 
The Turboflow® instrument methods are reproduced (see Appendix F.4 (Mass 
spectrometer acquisition method) and Appendix F.5 (Turboflow® HPLC method)). 
The final protocol for drugs of abuse by Turboflow® was introduced into the laboratory 
on August 2nd 2010. The drugs included on this method were as shown (see Table 
4.3). 
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Table 4.3 Analytes validated for analysis by Turboflow® 2010 
Morphine Dihydrocodeine glucuronide 
Morphine glucuronide Codeine 
Codeine glucuronide Methadone 
6-Monoacetylmorphine EDDP 
Dihydrocodeine Amphetamine 
Benzoylecgonine Methamphetamine 
Acetylcodeine Hydroxypapaverine glucuronide 
Ketamine Dihydroxypapaverine glucuronide 
MDMA (Ecstasy) Pholcodine 
Hydroxypapaverine Nortriptyline 
Dihydroxypapaverine Noscapine 
 
Precision was formally recorded for only three analytes, morphine glucuronide, 
codeine and benzoylecgonine and is shown (see table 4.4). 
Table 4.4 Reproducibility of analysis for Turboflow® method for three selected analytes 
 Codeine Morphine 
glucuronide 
Benzoylecgonine 
Within day 
reproducibility 
12.34% 9.56% 15.59% 
Between Day 
reproducibility 
12.12% 16.33% 13.50% 
95% confidence 
interval 
±23.6% ±32.0% ±26.5% 
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In addition to reproducibility, around 100 samples were also analysed by the existing 
SPE method and the new Turboflow® method (see Table 4.5).  
Table 4.5 Comparison of patient results using SPE and Turboflow® extraction 
 
Morphine 
glucuronide Codeine Methadone Benzoylecgonine Amphetamine 
True POS 80 23 71 39 1 
True NEG 20 77 29 61 99 
False POS 1 11 9 1 1 
False NEG 3 0 1 5 0 
SENSITIVITY 96.39 % 100 % 98.61 % 88.64 % 50 % 
SPECIFICITY 95.24 % 87.50 % 76.32 % 98.39 % 99 % 
 
The anomalous results were investigated to identify why they differed from the 
original method (Birch and Marsh, 2010). 
• The high number of false positives for codeine and methadone are caused by the fact 
that the SPE method was not very sensitive for these analytes. Therefore whilst it shows 
as a false positive, in fact they were all genuine positives that the SPE method did not 
detect. 
• The few false negatives that have been found were likely caused by the analytes being 
present at such low concentrations that they were below the cutoff and would not have 
been reported as positives even with the SPE method. 
These false negatives occurred where the drugs are identified as present, but below 
the reporting threshold. Even though the SPE method was able to identify the 
presence of the drug, the final report would have been negative and as such the 
Turboflow® method did not result in any false negative reports. 
Limits of detection and linearity were not formally assessed at this time, contrary to 
the method validation plan that had been left with the laboratory (see Appendix E.6). 
Both authors of the validation document have left the Toxicology Unit and it is not 
recorded why the precision of other analytes was not assessed formally in the 
method validation. 
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4.3. Introduction into the laboratory 
The Clinical Pathology Accreditation (CPA) Standards for the Medical Laboratory  
(Clinical Pathology Accreditation (UK) Ltd, 2010) were introduced in 1992  to set 
minimum standards for pathology laboratories and to improve patient safety. The 
standards include the requirements that methods are validated before introduction 
(Standard F1), that they are fully documented in Standard Operating Procedures 
(SOP) (Standard F2), that records are kept to enable the reconstruction of the assay 
conditions (Standard A9.4) and that staff performing the assays are trained in their 
performance (Standard F3.1). Documentary evidence is required for all of these 
activities and these shall also be assessed by an audit program to ensure that these 
standards are being adhered to (Standard H1.1). A series of documents therefore 
needs to be prepared to fulfil these standards for the LC-MS drugs of abuse assay, 
as well as formal procedures for the acceptance and introduction of the assay. 
4.3.1. Documentation for the online solid phase extraction method 
Initially the method was developed to replace the TLC opiate confirmation assay and 
the amphetamine GC-FID assay and also the confirmation of methadone and 
cocaine if required. As a first step in the process, a validation document was 
produced (see Appendix E.2) with an updated SOP (version 3.0 see Appendix E.1). 
The SOP was electronically authorised through the department’s computerised 
document control system, QPulse, and the validation was submitted to the 
department’s executive committee. The first live patient samples were analysed on 
December 1st 2008. 
There are also a number of other documents that needed to be created or updated to 
maintain compliance with the CPA standards. The department’s training scheme 
needed to be amended with the updated method (see Appendix E.3) and staff trained 
and a maintenance log needed to be prepared. Most analytical equipment performs 
best with a planned preventative maintenance schedule. In the case of the LC-MS 
this includes daily, weekly and monthly maintenance, as well as the manufacturer’s 
annual service visit and any unscheduled maintenance. This maintenance log serves 
two purposes, firstly as a prompt that the operator to perform the maintenance, but 
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also as a record that the maintenance has been performed so that this activity can be 
audited. 
The newly developed method is different to that in use prior to the change and as 
such the laboratory computer system requirements are different. These changes 
were first made in a backup copy of the laboratory computer system known as CERT 
and tested before introduction into the live database. There were four principal 
changes to the system at this time: 
• Removal of the GC test code, a non-reportable free-text line to record the 
details of the GC analysis 
• Renaming of the TLC test code to LCMS.  
• For amphetamine screening sample positive results, the LCMS code replaced 
the GC test code.  
• The worksheet for confirmation tests was amended to include all LCMS tests 
on one worksheet instead of requiring a TLC worksheet and a GC worksheet. 
The SOP was updated in May 2009 when the Jasco HPLC was replaced with the 
Agilent and Turboflow® equipment, although at this stage the method was still the 
SPE method. This SOP is also reproduced (Appendix E.5) as SOP version 4. 
4.3.2. Interfacing the hardware system to the laboratory computer system 
Further modification to the validated SPE method during 2009 was the introduction of 
an analyser interface. Interfacing an analyser to the laboratory computer system can 
offer a number of benefits, including lower risk of transcription error and reduced 
level of data entry. While it is possible to set up a quantitation method on the LC-MS, 
which will produce numerical results that can be output to through an interface to the 
laboratory computer system, the reports produced by ToxID are in a PDF format and 
it is not as easy to import from these. However, it is possible to import the worksheet, 
which can save at least 5 – 10 minutes for every batch, representing at least 40 
hours per year.  
A data import method to allow simple data entry into the LC-MS was devised. This 
was based on a simple text file export from the LIMS system followed by some 
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formatting in Microsoft Excel (v.2003), which included addition of controls, worklist 
numbering and selection of the correct HPLC and MS method files. Screenshots of 
the Excel file can be found (see Appendix F.7 (EZChrom and Xcalibur) and Appendix 
F.8 (Aria)) together with the macros written in Excel.  
4.3.3. Operation of the interface between the laboratory computer 
system and the LC-MS 
The automation consisted of a formatted spreadsheet with 3 buttons at the top of a 
sheet formatted for printing. The first button (Full Worklist) runs a macro to import a 
text file previously exported from the Pathnet system. Lab numbers are inserted 
automatically into the correct positions on the worklist, together with the date of the 
worklist, operator and controls at the beginning and end of the worklist and after 
every 10 samples. The sheet is designed to be printed as a working record of 
samples to be prepared and to write results onto prior to transfer to the Pathnet 
laboratory computer system.  
The second button (Edit Worklist) is used where the full list of outstanding samples is 
not to be included on the worklist, for example if there are additional samples to add 
or if the worklist is to be split into two. This works in exactly the same way as the first 
button except that the process is paused after the text file is imported from Pathnet to 
allow editing. A third button is used to resume the import process. 
The final button is labelled Export Sequence and this copies the formatted export 
sheet onto a named text file that can be saved to a USB memory stick for transfer to 
the LC-MS computer for import into EZChrom and Xcalibur software. 
When the Aria software was introduced, the import sequence became easier, as the 
Aria software passes sequence information automatically to the Xcalibur software. 
The sequence template was modified to match the Aria format, for example the 
sample vial identification and injection parameters, and the EXPORT macro edited to 
export a single .csv file. 
The OPEN_WORKLIST macro was also simplified to remove the option of editing the 
worklist and also improve QC handling. 
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4.3.4. Maintaining the quality of laboratory results 
In a modern clinical chemistry or toxicology laboratory, quality is an important and 
integral part of laboratory operations. One of the ultimate markers of laboratory 
quality is the accreditation that is awarded by the United Kingdom Accreditation 
Service (UKAS) under the banner of the CPA standards (Clinical Pathology 
Accreditation (UK) Ltd, 2010).  
Among the required quality requirements that need to be implemented prior to 
introduction of a method are risk and control of substances hazardous to health 
(COSHH) assessments, a validation document and written Standard Operating 
Procedures. Copies of these documents can be found (see Appendix B and 
Appendix E). Ongoing assurance of the quality of results is monitored in a number of 
ways, with each activity assessing a different aspect of the testing. 
The principal way in which quality is maintained is by the use of Quality Control (QC) 
samples. These are standards that are analysed as unknown samples on every 
batch and compared with previously established target ranges. Typically these 
ranges are based on the mean and 2 standard deviations of previous batches and 
the results are usually plotted as Levy-Jennings plots. However, with qualitative 
results this plot would be meaningless and results are recorded on the worksheet to 
demonstrate that they have been examined and assessed, but formal trending of the 
results does not occur. Batches are rejected if the QC sample results are unsuitable, 
with samples being rerun. 
All results produced during the procedure are entered into the laboratory’s computer 
system, initially Pathnet but later Clinisys. An additional step within the computer 
system is clinical authorisation. Authorisation involves a senior scientist examining 
the results in conjunction with other data available, often a set of previous results and 
a request form with clinical information. The purpose of this is to reduce the chances 
of incorrect results being released, but also to alert medical staff to any clinically 
relevant results, either by telephoning the ward or clinic or by the addition of a 
comment to the results. 
Having established that an assay is performing consistently within the laboratory, 
additional samples are analysed and compared with the results of other laboratories. 
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Three of these proficiency testing or EQA samples are distributed by the scheme 
organiser every 3 months and analysed. Consensus results are only obtained after 
the results submission deadline. In this way, quality can be independently assessed 
and scored. Both QC and EQA results are needed to assure the laboratory that the 
results of every batch are accurate.  
4.4. Introduction of the Turboflow® method to routine use within the 
laboratory 
The author left King’s College Hospital in January 2010 before the final details of the 
method were finalised. A list of outstanding work was given to the Toxicology Unit 
manager, with instructions for the completion of the validation (Appendix E.6). 
Work in progress at this time included an assessment of the feasibility of 
automatically adding the internal standard as part of the autosampler program. 
Validation of the method was scheduled to occur after this assessment had been 
concluded. This assessment required a 250 µL autosampler syringe in place of the 
100 µL syringe supplied with the system and delivery of this part was delayed. When 
delivered it was determined that an additional syringe holder was also required to 
enable the syringe to be held in place on the autosampler. An order for this part was 
placed as one of the last activities the author did in the laboratory. Laboratory 
financial constraints meant that the requisition for the larger syringe holder was 
rejected by laboratory management. As a result, the final project validation was 
completed by Toxicology Unit staff in June and July 2010, with some minor 
modifications to the author’s intended protocol, particularly the offline addition of 
internal standard to the urine sample. The validation was completed in July 2010 and 
the method implemented in August 2010. This validation document and 
corresponding SOP are reproduced (see Appendix E.7 and Appendix E.8 
respectively). 
As for the SPE method, QC has been recorded simply as the presence or absence of 
the appropriate analytes in the QC samples. It was hoped that the peak intensity 
values would either be able to produce semi-quantitative numerical results, or at the 
very least would allow the peak intensity to be recorded and plotted. It has not been 
determined whether the analyte peak intensities are directly proportional to analyte 
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concentration. Should this be the case a semi-quantitative result may be obtained, 
allowing an assessment of between batch reproducibility and improving the ongoing 
assurance of the quality of the analysis. 
4.5. Evidence based medicine 
For centuries people have used naturally occurring substances to change the way 
that they perceive the world. Often this would be for spiritual reasons and the use of 
these substances would be generally small scale or low intensity. As these 
substances became more purified and more available, they were able to exert a 
greater effect on the users and would be taken for the enjoyment of the effects 
produced, rather than for the original spiritual reasons. As the strength of these drugs 
increased, they induced dependence in heavier users and led to addiction. The scale 
of use means that addiction psychiatry has become a branch of the medical 
profession that can be found in all areas of the country and community drugs teams 
can be found throughout the UK. As with all other areas of medicine, psychiatry has 
become increasingly evidence based and this evidence includes the use of 
laboratory diagnostic tests.  
In order to assist a patient to overcome their addiction, there are several steps that 
need to be followed. Firstly the psychiatrist needs to identify the drug that the patient 
is addicted to and to quantify how much is being consumed. In most branches of 
medicine, this is fairly easy to achieve and at South London and Maudsley NHS Trust 
this is done by interviewing the patient. It is quite easy to interview a heroin user and 
determine that they inject daily, but the differing purity and combination of opiate 
drugs consumed can be difficult to convert to a single usage figure. For convenience, 
the addictions team often convert the amount of opiate drugs consumed into a 
common score based on the amount of money spent on drugs. Market forces mean 
that a lower grade heroin will be worth less on the street and will therefore contribute 
less to the overall cost of drugs.  
Where addiction can suffer compared to other branches of medicine is that the 
addiction changes the user’s perception of the world and users will often be 
inaccurate in their answers as they attempt to take advantage of the health services 
or to avoid their influence. For example, many users will enter treatment not because 
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they wish to cure their addiction but because this is the aim of somebody else, such 
as the legal system or a friend or relative. It is also common for users to seek 
treatment for reasons other than to give up their drug addiction. This is often for 
financial reasons, as drug addiction, particularly heroin addiction, can be expensive. 
Addicted patients will use the healthcare system to obtain free methadone, thereby 
reducing their spend on heroin and allowing them a degree of normal social 
functioning. In some cases, the aim is not to use the methadone to reduce the effects 
of addiction, but to sell to the supplier.  
In order for a user to enter treatment, it is therefore necessary for the psychiatrist to 
have evidence that the patient in front of them is a heroin user. This is easily 
accomplished with the use of a laboratory test. The results of this test can be used in 
conjunction with the users stated drug consumption to help determine what 
prescription is appropriate. 
Later on in treatment, laboratory tests will have a different focus. Detection of heroin 
metabolites can show the clinician that the patient is still using heroin (and may 
therefore need an increased methadone dose) and detection of methadone or 
buprenorphine can confirm that they are at least partially compliant with their 
prescribed treatment. In some cases, the addiction may cause the patient to deny, 
either to themself or to the psychiatrist, that they are still taking the drugs or that they 
have a drug problem. 
When a patient is compliant with treatment or is abstaining, the urine drugs test 
allows this to be evidenced to the clinical team, allowing continued support and 
encouragement. Current trends in psychiatry include an increased use of 
contingency management, a process where users are given small rewards for the 
achievement of goals. This may include incentives such as cinema tickets for a given 
number of negative drug tests, or even a “gold star” for attending the clinic at the 
correct time and date. These rewards do not need to be expensive to help encourage 
a user with their treatment. Effective laboratory support is therefore a necessity for 
the implementation of some forms of contingency management. 
As an inpatient on a detoxification and rehabilitation ward, it is important to medical 
services that the ward does stay drug free. It is hard enough to give up drugs with 
support and doubly so if there is somebody continuing to use drugs, the “bad apple” 
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in the barrel. Regular testing of the inpatients can provide the evidence that this is so 
and allow the early removal of patients who are breaking the rules and putting the 
rehabilitation of others at risk. The laboratory report can provide evidence of this to 
the ward staff and to the continuing user. 
Of course there are other health effects of illicit drugs, such as the effect on the 
family or unborn child and all of these can benefit, at least in part, by the use of a 
urine drugs test in a clinical setting. 
4.6. Toxicology testing at King’s College Hospital 
The method for testing for drugs of abuse, especially opiates, at Bethlem and 
Maudsley hospitals and then at King’s College Hospital until 2008 was a thin layer 
chromatography method largely unchanged for 20 years. As the pattern of drug use 
changed and the expectations of the customers rose, especially with respect to 
turnaround times, the TLC method became out-dated and inadequate. Of the 
available technologies, LC-MS has proven itself to be fast and reliable and applicable 
to a wide range of situations and drugs. However, without a standardised method or 
equipment it is up to individual laboratories to determine the best conditions to use 
based in their own particular circumstances. 
As time and cost pressures increase, there are several key areas where a laboratory 
can make improvements and the methods developed here were designed to take 
advantage of these improvements. Firstly, the degree of operator intervention 
required for the SPE method is significantly below that required for the original 
manual method, saving upwards of an hour a day of skilled operator’s time. 
Secondly, the cost of consumables is reduced markedly, with the single SPE 
cartridge being re-used several hundred times instead of individual disposable 
cartridges. Thirdly, the elimination of the hydrolysis step has allowed typical 
turnaround times to be reduced from 3 days to 2 days. This improvement in result 
availability may not have any measureable effect in the laboratory, although the 
faster turnaround time may assist in gaining future work, but could lead to a 
measureable reduction in costs for the addictions services who use the laboratory, 
for example the faster response could lead to user being admitted to treatment 
quicker or removed from the ward earlier. 
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Other benefits not identified at the outset of the project include the identification by 
maternity services of mothers who are using ketamine, allowing intervention to 
improve infant survival or prognosis and the identification of “red heroin” as 
alprazolam, allowing better information to service users. The extension of the method 
has also allowed a colleague to obtain her master’s degree and has produced the 
results for a major trial into the use of injectable opioids. 
The improvements due to the Turboflow® system are not as significant as those 
already achieved by the on-line SPE, but were still worth the time and effort spent on 
method development. The Turboflow® method further reduces staff hands-on time, 
although by a smaller margin and has improved the quality of results produced. It has 
also produced a framework that allows a wider range of drugs to be identified and 
allows a greater degree of quantification than the SPE method.  
It could be argued that a simpler system could produce results that are as good or 
better than those produced by the methods developed here. For example, there are 
several manufacturer defined methods for the identification of drugs of abuse using a 
triple quadrupole that are less complicated than the method employed here. 
However, a triple quadrupole is generally significantly more expensive than an ion 
trap and does not allow the benefits of MS3 identification of drugs and metabolites. 
Turboflow® and SPE sample extraction are both more expensive than the dilute-and-
shoot methods that can be used with a triple quadrupole, but the sample clean up 
steps reduce the level of source contamination compared with dilute and shoot 
methods and are more extendible to other matrices. 
Without the LC-MS, the drug testing element of the Toxicology Unit would have 
lagged behind the standards achieved in other NHS laboratories and could have 
compromised the long term future of this element of testing. Other LC-MS systems 
are available for use at King’s College Hospital, but all are used for other purposes 
and it would be difficult or impossible to guarantee access on a daily basis to allow 
timely reporting of drugs of abuse samples. 
The procedure developed in 2010 remains in operation in the Toxicology Unit in May 
2014, albeit with a few minor modifications, for example additional drugs, modified 
conditions for the detection of 6-monoacetylmorphine and a modification to improve 
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the limit of detection for morphine when the EQA scheme lowered the clinical cut-off 
to 300 ng/mL. 
4.7. Transferability to other laboratories and applications 
Ion trap LC-MS systems are uncommon in drugs of abuse testing laboratories and 
triple quadrupoles are much more common. The reason for this is that a triple 
quadrupole is more sensitive, allowing it to be used for a variety of other quantitative 
methods. For laboratories that need to search for unknown substances, a GC-MS is 
generally more popular because of the wide availability of mass spectral libraries and 
the historical widespread use of these systems, with off-the-shelf methods generally 
available from the manufacturers. Other more expensive LC-MS combinations such 
as the Q-Trap from Sciex or Q-TOF hybrids and Thermo’s Orbitrap can perform as 
well in most areas and even remove the need for any sample preparation. 
There are several advantages that this newly developed method gives compared to 
most other LC-MS systems: 
1 Good quality mass spectra are obtained from all analytes. To obtain this 
type of data from a triple quadrupole requires fairly extensive parameter 
settings (e.g. tMRM from Agilent). Quadrupole-TOF instruments, 
quadrupole-traps and Orbitraps can acquire this data easily, but these 
instruments are generally more expensive than ion traps  
2 Minimal sample preparation is required. Most methods require a sample 
dilution (dilute and shoot) or offline extraction, with or without a hydrolysis 
step. Hydrolysis typically adds at least an hour of incubation time prior to 
analysis 
3 The use of MS3 scans triggered from a neutral-loss scan allows the simple 
identification of glucuronide and sulphate conjugates, followed by library 
searching 
While these advantages make this system well suited to the intended application, the 
rarity of this combination of Turboflow® and Ion Trap suggest that it is unlikely that 
this method will be employed exactly elsewhere. However, there are several 
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elements of the method that are readily transferrable to other laboratories using LC-
MS. 
The Turboflow® extraction and LC-MS method can be readily adapted for any mass 
spectrometer coupled to a Turboflow® system, whether this is an ion trap, triple 
quadrupole or an accurate mass system 
The method files, consisting of the retention times and parent masses of the 
analytes, can be easily transferred to any other LC-MS system using the same 
column and solvent combination. Slight changes may need to be made, for example 
depending on the gradient delay volume for a particular system, but this change is 
easily within the capability of any experienced HPLC method developer. 
Use of a CTC® autosampler for internal standard addition is unusual and presents a 
simple way of automating this analytical step, whether for drugs of abuse or any 
other similar type of application using internal standards. This can also be used to 
perform the dilution step of dilute-and-shoot methods used on triple quadrupoles and 
similar instruments. It is slightly more limiting in methods that require offline 
hydrolysis, as this will necessitate the accurate measurement of the sample volume 
and addition of a known volume of hydrolysis reagent.  
The use of a neutral loss scan to identify glucuronide or sulphate metabolites is also 
unusual. It is not likely to be widely used in routine work as it is generally simpler to 
hydrolyse the conjugate and look for the parent drug. However, the use of a neutral 
loss scan could assist in the addition of new analytes to other LC-MS methods, or to 
improve the power of general unknown screens.  
4.8. Further work 
As a result of this work, a number of further items of research and development have 
been identified. These include significant whole pieces of work and also incremental 
method development actions that are essential for any laboratory to remain up to 
date. 
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4.8.1. Benzodiazepines 
The benzodiazepine class of drugs contains around 30 common members and 
metabolites. In the SLAM addictions clinics diazepam and Librium® 
(chlordiazepoxide) are the most commonly prescribed benzodiazepines. However, 
other benzodiazepines are also available and in 2009 alprazolam was reported as 
being found as a component of illicit heroin. One sample of this was received at the 
laboratory and the mass spectrum obtained from an infusion of a solution of the 
substance demonstrated that this was alprazolam. Addition of the benzodiazepines 
and their metabolites to the method would allow this information to be communicated 
back to the community drugs teams on a patient level basis, allowing improved 
patient care. 
This would also allow the addictions psychiatrists to start prescribing alternative 
benzodiazepines, such as nitrazepam or clonazepam, which have different metabolic 
pathways and are less prevalent through illicit channels. This would allow dose 
optimisation based on illicit benzodiazepine use as the metabolites of diazepam 
would be readily identifiable. A Turboflow® benzodiazepine method has been 
developed for use at King’s College Hospital, but this has been developed on a triple 
quadrupole instrument separate from the general drugs of abuse confirmation 
method developed here. 
4.8.2. Repertoire 
As new drugs are detected using the described method, especially through the 
identification of glucuronide or sulphate metabolites, these drugs should be added to 
the mass list of the LC-MS method and also of ToxID, including addition to the in-
house spectrum library. 
The easiest way to advance with this is to constantly monitor a defined screen on the 
Xcalibur software that shows any MS3 transitions. The trace is likely to be largely 
blank, with a few short areas where an MS3 signal is detected, with this signal 
sometimes being only a few scan events long. Selection of the acquired MS3 
spectrum in these areas is easily achievable on the Xcalibur software and this can 
then be used to search any available MS spectral libraries. Any good library matches 
that have a parent ion mass that corresponds with the MS2 product are then good 
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candidates for addition to the library. Additional confirmation may also be possible by 
searching the survey scan for a peak corresponding to the free drug parent ion. As 
already discussed, a drug needs to be present at an appreciable concentration to 
produce an MS3 spectrum and it is therefore likely that such a drug will be 
identifiable, at least in low concentrations, in the survey scan.  
It would also be prudent at this point to examine the metabolism of the identified drug 
and to examine the literature. If a potential glucuronide conjugate of a target is found 
using the above method, but the drug identified in the library does not form 
conjugates, it is then clear that the match is incorrect. Similarly if the drug is 
extensively and completely metabolised and not found in the urine, this would also 
suggest that the tentative match is incorrect. The literature search should also 
identify if there are any other metabolites that may be searched for in the survey scan 
to further increase confidence in the identification of the candidate drug. 
Addition of the newly identified candidate parent ion into the MS2 mass list, followed 
by a reinjection of the sample should then confirm the presence of the unconjugated 
drug by checking the resultant MS2 trace against the spectral library. The increased 
signal intensity compared to the MS3 signal is likely to lead to a more reproducible 
spectrum than that obtained in the original MS3 trace and this can then be added to 
the in-house MS2 and MS3 libraries. In addition, the MS2 trace of the conjugate can 
also be added to the in-house MS2 library. Finally, the free and conjugated peaks 
need to be added to the ToxID configuration file to allow reporting. 
In this way, it is possible to identify and save to the method new drugs and 
metabolites without necessarily having to obtain reference materials from a supplier. 
However, if there is no reference material and the sample in which the drug or 
metabolite is identified is not from a patient known to be taking the drug, this peak 
should always be treated with caution until an independent source of data can 
corroborate the candidate drug. 
4.8.3. Cannabis 
The Toxicology Unit at King’ College Hospital does not have a validated method for 
the unequivocal identification of cannabis metabolites. An immunoassay method in 
use is very good (positive predictive value of the immunoassay is over 95% (SHLS 
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unpublished data)), but there are occasions where the immunoassay fails, for 
example in patients with HIV who are prescribed efavirenz (Atripla®, Sustiva®). A 
confirmation method for cannabis would be beneficial to KCH and would assist in the 
transferability of the method to other laboratories. 
Cannabis is different from most of the other drugs of abuse in that the main urinary 
metabolite is acidic, whereas all the opiates, amphetamines, benzodiazepines and 
cocainics are basic drugs. This means that the retention characteristics on the 
Turboflow® column are likely to be different for cannabis. Cannabis metabolites 
should be investigated to determine whether they are retained on the Turboflow® 
column and what the elution and detection conditions are. Even if the described 
Turboflow® method does not allow the identification of cannabis metabolites, it should 
be possible to produce a method that is capable of performing this identification using 
an alternate Turboflow® column or solvent combination. It is likely that the level of 
cannabis metabolites normally found in urine is too low for this method to be suitable 
using the LCQ Fleet and this work has not been carried out. 
4.8.4. Other matrices 
An alternative matrix becoming popular, particularly with community drug teams, is 
saliva (also known as oral fluid or oral mucosal transudate). Currently no 
investigations into salivary drugs have been made using the described method. This 
would increase the repertoire of the laboratory and allow increased revenue, 
particularly as some of the local community drug teams have already switched to this 
testing strategy. 
Similarly there is an increased interest in testing for drugs in hair, particularly from the 
family law sector. While this is outside the current remit of KCH, this is an area for 
examination. The Addictions Department of the Institute of Psychiatry have already 
expressed an interest in this area of research, as it allows a longer term picture of 
drug use to be built up. Currently the Addictions Department of SLAM continues to 
use urine as a primary drug testing sample and there has been no call for saliva 
methods to be developed. However, as with cannabis the levels of drugs normally 
found in saliva are generally too low for reliable detection with this ion trap method. 
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4.8.5. User feedback 
One of the original aims of this project was to evaluate how this change in the service 
affected the treatment and prescribing habits of the community drug teams. Informal 
meetings with some of the key staff have given positive feedback to the better quality 
results obtained using the SPE method, but no formal assessment of these benefits 
has been made. There are two reasons why this element of the original project was 
not completed to the depth that would have been preferred: 
• The author’s decision to leave South London, preventing effective liaison with 
the users of the toxicology laboratory 
• The transfer of the pathology division of King’s College Hospital to a partially 
privately owned organisation meant that the focus of the toxicology unit 
manager and the laboratory manager was on internal organisational transition, 
rather than on obtaining formal feedback on a small aspect of the laboratory’s 
repertoire 
User satisfaction is still assessed as part of the laboratory’s quality and accreditation 
requirements, but this is intended to examine the whole service rather than this 
particular aspect. As a result, there is no information available to allow the 
assessment of user satisfaction of this part of the pathology service in isolation. 
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5. Conclusion 
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The original stated aim of this project was to develop a Turboflow® method to detect 
drugs of abuse in a clinical population. This aim has been achieved and by reading 
through the pages of this thesis it is possible to understand some of the parameters 
that have been set or modified to enable a highly efficient method. The method 
developed is capable of detecting a wide range of drugs and metabolites with library 
spectrum matching for reliable identification. The lack of any hydrolysis step ensures 
simple sample preparation, and the combination of MS2, MS3 and neutral loss scans 
with data dependent scanning allow many drugs to be detected in the same sample. 
This combination of features has not been published by any other authors. 
However, this method is not the end result but just the beginning. Without training for 
the staff operating the method routinely, without the ongoing quality control and 
ongoing method development, this method would have ceased operation when the 
author left the Toxicology Unit. Over four years later the basic method is still in 
operation, although as should be expected for routine methods, there have been 
some modifications along the way. 
Turbulent flow chromatography is a powerful technique for simplifying sample 
preparation and ion trap mass spectrometers are able to give a very high degree of 
confidence in the identity of a substance. The combination of the two techniques has 
created a versatile method able to expand as the library data becomes more 
comprehensive without any need to alter the method details. This is particularly 
useful as laboratory methods come under close scrutiny from accreditation assessors 
and changes to methods come under increasing control. 
Beyond the details of the method, the professional doctorate course has had a 
definite positive impact on the author and the completion of this course and thesis 
have changed the author’s outlook from that of a laboratory technician to one of a 
healthcare scientist, looking beyond the walls of the laboratory and considering the 
impact and effects of his actions on the wider health economy.  
DBMS Thesis  F R Evers 
126 
6. Reflection 
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An important element of the Professional Doctorate at the University of Portsmouth is 
that it improves the professional development of the students. Part of this 
development is the use of educational techniques to assist the students to become 
experts in their chosen fields and to operate at a level expected from somebody with 
a doctoral qualification. Much has been made in the educational literature about 
reflective practice and a variety of different approaches and models have been 
discussed and tried. The professional doctorate will not have achieved its aim if the 
results of the course and the results of this thesis are shelved on completion and they 
do not lead to a change of behaviour. The following sections, written in the first 
person, demonstrate how the author has learned from the process, has changed his 
approach to work and has developed into a scientist able to perform to the very high 
standards expected from a doctoral candidate. 
6.1. Personal reflection 
I have been interested in “science” since before starting secondary school and it will 
have come as no surprise to those who knew me at school that I went on to work in a 
laboratory, study for an MSc and eventually start on this Professional Doctorate 
course. Perhaps some of the people who knew me would be surprised at the time 
between my first degree (completed in 1992) and registering for the doctorate (2005). 
Part of the reason for the delay was in finding the specific subject that I am 
passionate about. In 2001 I began working in toxicology and quickly knew that this 
was where I wanted to specialise. The 2004 course was already full when I enquired, 
so I began in October 2005. 
One of the reasons for choosing this particular professional doctorate course was the 
politics of the NHS. In a laboratory there are 4 different groups of staff:  
• the laboratory assistants who perform the more basic tasks and are often not 
qualified to degree level 
• Biomedical scientists (such as myself) who typically perform complex 
analyses, are responsible for the implementation of quality within the 
laboratory and are generally responsible for the results produced 
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• Clinical Scientists who focus more on the interpretation of laboratory results, 
method development and communication of results to medical staff 
• The medically qualified doctors who are generally in charge of the clinical 
governance of the laboratory, who will see their own patients and take 
ownership of more complex cases 
Since the professionalisation of biomedical science over the last 20 years or so, the 
boundaries between clinical and biomedical science have become increasingly 
blurred. It is no longer gross misconduct for a biomedical scientist to authorise a 
result and biomedical scientists are now permitted to join the Royal College of 
Pathologists. Clinical scientists (who are relatively few in number) have strongly 
defended their position from biomedical scientists and it is not easy for a biomedical 
scientist to reach the top of their profession unless it is through management.  
The professional doctorate course has allowed me to become an associate member 
of the Royal College of Pathologists, to be involved in research and to work at a level 
previously restricted to clinical scientists. 
The course itself is open to medical professionals from the fields of nursing, 
pharmacy, physiotherapy and imaging and this crossover between professions has 
helped to break down the barriers often faced by laboratory staff, who too often do 
not fully consider the hospital outside the pathology department. The discussions 
between students have sometimes been lively and have helped me to obtain a fuller 
grasp of the wider NHS. 
Two of the modules were what I considered typical doctoral level courses, namely 
the advanced research techniques and the publication and dissemination modules. 
They helped focus on the difference between a master’s degree and a doctorate and 
have clearly been designed to assist in the completion of a thesis. However it is the 
first module that has perhaps had the greatest impact on my professional 
development. 
6.2. Professional review and development 
The module essentially asked “what is an expert” and “how do you get there” and 
asked students to develop a map of how this would be achieved. The Personal 
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Development Plan that I developed in 2006 gave a blueprint for my development that 
I broadly followed and this was revised towards the end of the taught element of the 
course in 2007. 
I have had difficulty with the formal structure of some of the reflective practice models 
and work better with an unstructured approach. I have a good memory when it 
comes to toxicology and drugs of abuse and the notes I take of lectures, cases and 
from reading papers are very limited. As a result, when I am reviewing my notes it is 
not the detail that I focus on but the circumstances and application of the data, 
allowing me to extrapolate to other situations. An example of this is the combination 
of data from two papers, one on the differences in cocaine concentrations in the hair 
of light, moderate and heavy users and one on the differences in cocaine levels in 
hair from different parts of the body. When asked for an estimation of the level of 
cocaine use from body hair samples, I was able to assimilate these pieces of 
information to give an estimation of the cocaine use of an individual. 
A colleague and I now compile a short document each month to review significant 
cases and to review articles and papers read. This document is circulated among all 
of the laboratory’s senior staff for learning and comments and also saved to the 
department’s document library for further learning opportunities. A similar document 
is also prepared when we attend conferences, so that all staff can receive the benefit 
of this company expenditure. 
At the outset of the module I knew little about educational theory and we were 
encouraged to think about how we learn and therefore how we should teach different 
elements of our working practice. This has tied in well with two courses that I have 
attended since, the first on the role and responsibilities of a team leader and the 
second the Institute of Leadership and Management certificate in leadership and 
management. Both courses included self evaluations very similar to those done 
during the professional development module and I have been able to use all of these 
evaluations to further assist my personal development and understand how to get the 
best out of myself. Perhaps the biggest revelation was a statement in one of the 
evaluations that said that I am “disinterested in purely scholastic pursuits”. At first I 
misread this as “not interested in knowledge”, which is far from the truth – I enjoy 
reading New Scientist about subjects as diverse as particle physics and astronomy 
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as well as medical laboratory testing and I enjoy any science and nature based 
program on television such as Horizon. However, the real meaning of the statement 
was that I am not interested in knowledge for the sake of education. This simple 
phrase explains to me some of the reasons that it has taken over three years to 
complete the writing up of this thesis after leaving King’s College Hospital. In my 
mind, the work for the project was complete, except for a few items that I could not 
achieve as I was no longer an employee, and the completion of the thesis was a 
purely scholastic pursuit. Even since this understanding, it has taken some time to 
really start writing properly, but as I write, the thesis is nearly complete and I am 
feeling satisfaction for a piece of work that I can be proud of. Writing this has also 
rekindled my interest in the work that I did and I have found the background reading 
interesting and informative. Perhaps the thesis has developed beyond a “purely 
scholastic pursuit” which is why I am now interested? 
One of the principal aims of starting on the route of the professional doctorate was to 
enable me to reach the top of my profession and ultimately to allow me to achieve 
the status of consultant toxicologist. In pathology, the highest qualification that can be 
achieved is the Fellowship of the Royal College of Pathologists (FRCPath). Other 
titles and qualifications are either academic titles, such as “professor”, or are of an 
equal but different standing as the FRCPath, such as FRCS (Fellowship of the Royal 
College of Surgeons), or are job titles, such as Consultant. As a result of this course I 
am now an associate of the Royal College of Pathologists and for acceptance to the 
fellowship I need to complete a doctoral level thesis and sit an oral exam with the 
college. It is intended that this thesis is the next step on the route to the fellowship. 
6.3. Advanced research techniques 
This module looked in some detail at the types of techniques generally found in 
doctoral level projects. Split into Quantitative methods and Qualitative methods, the 
two parts of the course were aimed at very different types of research. I am much 
more comfortable with quantitative research, the use of numbers to reach a 
conclusion. I find this intuitive and easy to understand and I received a high score for 
this part of the assignment. Although some of the specific techniques were new to 
me, such as the use of the SPSS® software, each part followed on simply from my 
previous knowledge. 
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It was different with the qualitative part of the module. Qualitative research remains a 
foreign language to me and while I may understand some of the background and 
general principles, the actual interpretation and analysis give me difficulty. The poor 
quality assignment I wrote was clearly a numerical persons attempt at qualitative 
research, with each individual phrase processed in excel almost as if it was a piece 
of numerical data. In trying to use a phenomenological approach to the data, one of 
the markers commented that I did not really pick out the meanings from the 
interviews. A personality assessment carried out through work has identified that I 
am not really sensitive to others feelings and the poor mark I received for this 
assignment reflects this.  
However, this part of the unit has taught me about qualitative research and when 
discussing work with a social science researcher I was able to hold sensible 
conversations about the work without having to ask the most basic questions. I know 
that this area is not for me, but at least I understand that and know somebody I can 
refer to if this sort of data analysis is ever required. 
6.4. Publication and dissemination 
This module was one of the most enjoyable of the whole course and helped to give 
me the background to publication, for example an understanding of the whole 
process, and also of the effects of a journal’s impact factor. 
One of the main factors to come from the course was a realisation that much of the 
published work available is of relatively poor quality. While the aims and objectives of 
papers are frequently clearly stated, the completeness of the information is often 
lacking. When recently asked to interpret the results of a cocaine test done in leg hair 
of an Asian donor, I needed to assimilate data from several papers to reach a 
reasonable interpretation. Part of the reason for this was that there was one paper 
commenting on the difference between African and Caucasian hair (which 
incorporate cocaine differently), a second paper comparing cocaine levels in hair 
samples from different parts of the body and a third comparing relative levels of 
cocaine in hair according to the amount of drug used. While each paper was 
complete in itself, they were limited by the populations and therefore the subject data.  
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I have not written any papers since the start of this course, although I have made 
significant contributions to two papers and I have published 2 posters where I have 
been wholly or mainly responsible for the content and  2 posters where I have 
contributed. I want to publish more work and am awaiting a positive opportunity. A 
change of role within the laboratory has recently changed this and I have several 
papers or short communications that I aim to publish within the next 12 months. 
Without the understanding given during the lectures and particularly the assignment, 
I would not be contemplating publication. The assignment walked us through the 
publication process for two separate papers, one written by ourselves and one 
written by another student. By writing and commenting on other student’s papers, 
and responding to the comments, it was possible to see the whole process from 
beginning to end. Although much work (and extensive printing) I believe that this 
assignment is a good introduction to publication and would recommend to the course 
leader that this element of the course is retained. 
Although I have not published much written peer reviewed material I have written an 
article for Occupational Health magazine and have made a large number of oral 
presentations, both to scientific and non-scientific audiences. I really enjoy this 
aspect of my work and would like to do more of this. At the outset of the professional 
doctorate course, my public speaking skills were poor. I volunteered to give the first 
presentation in the second or third week of the course, not because I was confident 
but because I wanted to get it over and done with. I was then able to relax and watch 
how others performed and to learn from them. In the space of around 18 months, I 
went from a person reading from cue cards and gripping the table for support to 
somebody who can ad-lib a presentation to 100 people without nerves, walking 
around near the lectern and without any cues other than the contents of Powerpoint® 
slides. While presentation skills was not a directly taught element of the course, the 
presentations that were required and the way that this part of the course was 
structured made a very big difference to my improvement in presentation ability. The 
lecture I am required to give at the end of this course has, for me, been a very big 
target: I will perform well in this lecture. 
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6.5. Project proposal 
The final part of the taught component of the course was the project proposal. Unlike 
others, my project was unencumbered by ethics. However, it was not always the 
case.  
The original project that I wanted to pursue was a comparison of the results obtained, 
including clinical outcome, of drug users in treatment using either traditional 
laboratory drug testing or point of care drug tests. I worked on this project proposal 
for around a year before switching to this method development and this year taught 
me a lot. As well as some of the structure of community addiction services, I did learn 
about some of the ethics committee submission procedures and how to structure a 
project. It was more complex because the aim was to demonstrate equivalence, 
which is always much harder than to prove a difference. The reason that the project 
was finally dropped was that after promising initial discussions, the consultant with 
whom I was planning to work stopped returning my calls and e-mails. In consultation 
with my supervisors, my project was altered. Perhaps this taught me as much about 
the research and development process as if everything had worked right first time. As 
I write this, I am hoping again to work with the local addiction services and am 
coming up against some of the same problems. With what I learned last time and 
how I have developed professionally since, I am confident that I can make some 
progress here. 
This perhaps summarises the whole course for me. It is not what I learned in the 
lectures that has hopefully earned me the title of Doctor. It is the process that I have 
gone through, the discussions that I have had along the way and how I have applied 
my knowledge that has made the difference. This thesis on its own is not a doctorate, 
it is simply one measureable objective along the pathway of professional 
development. 
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